HIV Infections
Conditions
Brief summary
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and antiviral activity of combinations of monoclonal antibodies PGT121, PGDM1400, 10-1074, and VRC07-523LS administered via intravenous infusion in healthy, HIV-uninfected adults.
Detailed description
This study will evaluate the safety, tolerability, pharmacokinetics, and antiviral activity of combinations of monoclonal antibodies PGT121, PGDM1400, 10-1074, and VRC07-523LS administered via intravenous infusion in healthy, HIV-uninfected adults. Participants will initially be enrolled into one of three groups. At Day 0, Groups 1, 2, and 3 will receive dual combinations of mAbs administered sequentially via IV. Group 1 will receive a combination of PGT121 and VRC07-523LS, Group 2 will receive PGDM1400 and VRC07-523LS, and Group 3 will receive 10-1074 and VRC07-523LS. Study staff will review study data from Groups 1, 2, and 3 and determine if Group 4 may begin to enroll. Participants in Group 4 will receive PGDM1400, PGT121, and VRC07-523LS administered in sequence via IV on Day 0 and at Month 4. Study duration will be 12 months for participants in Groups 1, 2, and 3, and 16 months for participants in Group 4. Participants will attend several study visits, which may include physical examinations, blood and urine collection, HIV testing and pretest counseling, risk reduction counseling, and questionnaires.
Interventions
BIOLOGICALPGT121
20 mg/kg administered intravenously
BIOLOGICALPGDM1400
20 mg/kg administered intravenously
BIOLOGICAL10-1074
20 mg/kg administered intravenously
BIOLOGICALVRC07-523LS
20 mg/kg administered intravenously
Sponsors
National Institute of Allergy and Infectious Diseases (NIAID)
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 50 Years
Healthy volunteers
Yes
Inclusion criteria
General and Demographic Criteria * Age of 18 to 50 years * Access to a participating clinical research site (CRS) and willingness to be followed for the planned duration of the study * Ability and willingness to provide informed consent * Assessment of understanding: volunteer demonstrates understanding of this study and completes a questionnaire prior to first study product administration with verbal demonstration of understanding of all questionnaire items answered incorrectly * Agrees not to enroll in another study of an investigational research agent until completion of the last required protocol clinic visit * Good general health as shown by medical history, physical exam, and screening laboratory tests HIV-Related Criteria: * Willingness to receive HIV test results * Willingness to discuss HIV infection risks and amenable to HIV risk reduction counseling * Assessed by the clinic staff as being at low risk for HIV infection and committed to maintaining behavior consistent with low risk of HIV exposure through the last required protocol clinic visit (see the protocol for more information) Laboratory Inclusion Values Hemogram/Complete Blood Count * Hemoglobin greater than or equal to 11.0 g/dL for volunteers who were assigned female sex at birth, greater than or equal to 13.0 g/dL for volunteers who were assigned male sex at birth. For transgender participants who have been on feminizing hormone therapy for more than 6 consecutive months, determine hemoglobin eligibility based on the gender with which they identify (ie, a transgender female who has been on hormone therapy for more than 6 consecutive months should be assessed for eligibility using the hemoglobin parameters for persons assigned female sex at birth). * White blood cell count equal to 2,500 to 12,000 cells/mm\^3 * White blood cell (WBC) differential either within institutional normal range or with site clinician approval * Platelets equal to 125,000 to 550,000/mm\^3 Chemistry * Chemistry panel: Alanine aminotransferase (ALT) less than 1.25 times the institutional upper limit of normal; creatinine less than or equal to institutional upper limit of normal Virology * Negative HIV-1 and -2 blood test: US volunteers must have a negative Food and Drug Administration (FDA)-approved enzyme immunoassay (EIA) or chemiluminescent microparticle immunoassay (CMIA). * Negative Hepatitis B surface antigen (HBsAg) * Negative anti-Hepatitis C virus antibodies (anti-HCV), or negative HCV polymerase chain reaction (PCR) if the anti-HCV is positive Urine * Negative or trace urine protein Reproductive Status * Volunteers who were assigned female sex at birth: negative serum or urine beta human chorionic gonadotropin (β-HCG) pregnancy test performed prior to study product administration on the day of initial study product administration. Persons who are NOT of reproductive potential due to having undergone total hysterectomy or bilateral oophorectomy (verified by medical records), are not required to undergo pregnancy testing. * Reproductive status: A volunteer who was assigned female sex at birth must: * Agree to use effective contraception for sexual activity that could lead to pregnancy from at least 21 days prior to enrollment through the last required protocol clinic visit. Effective contraception is defined as using one of the following methods: * Condoms (male or female) with or without a spermicide, * Diaphragm or cervical cap with spermicide, * Intrauterine device (IUD), * Hormonal contraception, * Tubal ligation, * Any other contraceptive method approved by the HVTN 130/HPTN 089 Protocol Safety Review Team (PSRT) * Successful vasectomy in any partner assigned male sex at birth (considered successful if a volunteer reports that a male partner has \[1\] documentation of azoospermia by microscopy, or \[2\] a vasectomy more than 2 years ago with no resultant pregnancy despite sexual activity postvasectomy); * Or not be of reproductive potential, such as having reached menopause (no menses for 1 year) or having undergone hysterectomy or bilateral oophorectomy; * Or be sexually abstinent. * Volunteers who were assigned female sex at birth must also agree not to seek pregnancy through alternative methods, such as artificial insemination or in vitro fertilization until after the last required protocol clinic visit.
Exclusion criteria
General * Weight greater than 115 kg * Blood products received within 120 days before first study product administration, unless eligibility for earlier enrollment is determined by the HVTN 130/HPTN 089 PSRT * Investigational research agents received within 30 days before first study product administration * Intent to participate in another study of an investigational research agent or any other study that requires non-Network HIV antibody testing during the planned duration of the HVTN 130/HPTN 089 study * Pregnant or breastfeeding Vaccines and other Injections * HIV vaccine(s) received in a prior HIV vaccine trial. For volunteers who have received control/placebo in an HIV vaccine trial, the HVTN 130/HPTN 089 PSRT will determine eligibility on a case-by-case basis. * Previous receipt of humanized or human mAbs, whether licensed or investigational; the HVTN 130/HPTN 089 PSRT will determine eligibility on a case-by-case basis. * Previous receipt of monoclonal antibodies VRC01, VRC01LS, VRC07-523LS, PGT121, PGDM1400, or 10-1074 Immune System * Immunosuppressive medications received within 30 days before first study product administration (Not exclusionary: \[1\] corticosteroid nasal spray; \[2\] inhaled corticosteroids; \[3\] topical corticosteroids for mild, uncomplicated dermatological condition; or \[4\] a single course of oral/parenteral prednisone or equivalent at doses less than 20 mg/day and length of therapy less than 14 days.) * Serious adverse reactions to VRC07-523LS, PGT121, PGDM1400, or 10-1074 formulation components (acetate, sucrose, polysorbate 80, histidine, and sorbitol; see the protocol for more information), including history of anaphylaxis and related symptoms such as hives, respiratory difficulty, angioedema, and/or abdominal pain * Immunoglobulin received within 90 days before first study product administration, unless eligibility for earlier enrollment is determined by the HVTN 130/HPTN 089 PSRT (for mAb see criterion above) * Autoimmune disease (Not excluded from participation: Volunteer with mild, stable and uncomplicated autoimmune disease that does not require immunosuppressive medication and that, in the judgment of the site investigator, is likely not subject to exacerbation and likely not to complicate Solicited and Unsolicited AE assessments) * Immunodeficiency Clinically significant medical conditions * Clinically significant medical condition, physical examination findings, clinically significant abnormal laboratory results, or past medical history with clinically significant implications for current health. A clinically significant condition or process includes but is not limited to: * A process that would affect the immune response, * A process that would require medication that affects the immune response, * Any contraindication to repeated infusions, or blood draws, including inability to establish venous or sub-cutaneous access. * A condition that requires active medical intervention or monitoring to avert grave danger to the volunteer's health or well-being during the study period, * A condition or process (eg, chronic urticaria or recent injection or infusion with evidence of residual inflammation) for which signs or symptoms could be confused with reactions to the study product, or * Any condition specifically listed among the
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants With Early Discontinuation of Vaccinations and Reason for Discontinuation | Measured through Month 4 | The number (percentage) of participants with early discontinuation of vaccinations and reason for discontinuation was summarized by arm. The three participants discontinued treatment in T4 were due to the COVID-19 pandemic lockdown. |
| Chemistry and Hematology Laboratory Measures - Creatinine in mg/dL | Measured during Screening, Days 0, 14, 56, 84*, 112, 140*, 168, 224, 280, 336, 392*, and 448*. Days with * are only available for T4 | For each local laboratory measure, summary statistics were presented by treatment group and timepoint for the overall population. |
| Chemistry and Hematology Laboratory Measures - Hemoglobin in g/dL | Measured during Screening, Days 0, 14, 56, 84*, 112, 140*, 168, 224, 280, 336, 392*, and 448*. Days with * are only available for T4 | For each local laboratory measure, summary statistics were presented by treatment group and timepoint for the overall population. |
| Chemistry and Hematology Laboratory Measures - Lymphocyte Count, Neutrophil Count in 1000 Cells/Cubic mm | Measured during Screening, Days 0, 14, 56, 84*, 112, 140*, 168, 224, 280, 336, 392*, and 448*. Days with * are only available for T4 | For each local laboratory measure, summary statistics were presented by treatment group and timepoint for the overall population. |
| Chemistry and Hematology Laboratory Measures - Platelets, WBC in 1000 Cells/Cubic mm | Measured during Screening, Days 0, 14, 56, 84*, 112, 140*, 168, 224, 280, 336, 392*, and 448*. Days with * are only available for T4 | For each local laboratory measure, summary statistics were presented by treatment group and timepoint for the overall population. |
| The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Measured during Screening, Days 0, 14, 56, 84*, 112, 140*, 168, 224, 280, 336, 392*, 448*, and 504* Days with * are only available for T4 | The number (percentage) of participants with lab grade \> 1 for alanine aminotransferase (ALT), creatinine, hemoglobin, lymphocyte count, neutrophil count, platelets, white blood cells (WBC) was summarized by arm |
| Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Pain and/or Tenderness | Measured through 3 days after each vaccine dose at T1-T3: Day 0 and T4: Days 0, 112 | Graded according to the Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events, Version 2.1 \[July 2017\]. The maximum grade observed for each symptom over the time frame is presented. |
| Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Measured through 3 days after each vaccine dose at T1-T3: Day 0 and T4: Days 0, 112 | Graded according to the Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events, Version 2.1 \[July 2017\]. The maximum grade observed for each symptom over the time frame is presented. |
| Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Measured through 3 days after each vaccine dose at T1-T3: Day 0 and T4: Days 0, 112 | Graded according to the Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events, Version 2.1 \[July 2017\]. The following symptoms are considered as systemic reactogenicity if the onset date was within the periods of assessment specified in the protocol: malaise and/or fatigue, myalgia, headache, nausea, vomiting, chills, arthralgia, and body temperature. The item Max. Systemic Symptoms is the maximum of the individual systemic reactogenicities excluding body temperature for a participant. |
| Chemistry and Hematology Laboratory Measures - Alanine Aminotransferase (ALT) in U/L | Measured during Screening, Days 0, 14, 56, 84*, 112, 140*, 168, 224, 280, 336, 392*, and 448*. Days with * are only available for T4 | For each local laboratory measure, summary statistics were presented by treatment group and timepoint for the overall population. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Magnitudes of TZM-bl Cells Responses Against mAb-specific Env-pseudotyped Viruses Among Participants Who Received All Scheduled Product Administrations | Measured during Screening, Days 0, 3, 28, 56, 112, 140*, 168*, 224* Days with * are only available for T4 | Neutralizing antibodies against HIV-1 were measured as a function of reductions in Tat-regulated luciferase (Luc) reporter gene expression in TZM-bl cells. The assay performed in TZM-bl cells measured neutralization titers against the Env-pseudotyped viruses sensitive to the bnAbs (i.e., bnAb-specific viruses) in each infusion group. |
| Serum Concentrations of PGT121, PGDM1400, 10-1074, and VRC07-523LS for All Participants | Measured during Screening, Days 0, 3, 6, 14, 28, 56, 84*, 112, 140*, 168, 224, 280, 336, 392*, and 448* Days with * are only available for T4 | Serum PGDM1400, PGT121, and VRC07-523LS IgG levels were measured on a Bio-Plex instrument (Bio-Rad) using a validated assay designed to simultaneously measure infused PGDM1400, PGT121, and VRC07-523LS by its ability to bind anti-idiotype antibody captured on fluorescent magnetic beads. This assay was derived from a standardized custom HIV-1 Luminex assay. PGDM1400, PGT121 and VRC07-523LS were titrated and combined to create a standard curve that was used to determine concentration of the diluted samples. The negative controls were CH58 (an irrelevant mAb) and blank beads.Serum 10-1074 level was measured by anti-idotypic ELISA. Participant serum sample was incubated in anti-ID coated micro-plate well. A conjugated secondary antibody was used to detect bound 10-1074. Samples were titrated to ensure positive optical density (O.D.) readouts fall within the linear range of the assay for monoclonal antibody concentration calculations |
| Magnitudes of TZM-bl Cells Responses Against a Panel of Env Pseudotyped Viruses for All Participants | Measured during Screening, Days 0, 3, 28, 56, 112, 140*, 168*, 224* Days with * are only available for T4 | Neutralizing antibodies against HIV-1 were measured as a function of reductions in Tat-regulated luciferase (Luc) reporter gene expression in TZM-bl cells. The assay performed in TZM-bl cells measured neutralization titers against the Env-pseudotyped viruses sensitive to the bnAbs (i.e., bnAb-specific viruses) in each infusion group. |
| Magnitude of Neutralizing Activity Against a Panel of Env Pseudotyped Reference Viruses in TZM-bl Cells for All Participants | Measured during Screening, Days 0*, 3, 28, 56*, 112, 140*, 224* Days with * are only available for T4 | Neutralizing antibodies against HIV-1 were measured as a function of reductions in Tat-regulated luciferase (Luc) reporter gene expression in TZM-bl cells. The assay performed in TZM-bl cells measured neutralization titers against the Env-pseudotyped viruses sensitive to the bnAbs (i.e., bnAb-specific viruses) in each infusion group. |
| Serum Concentration Levels of PGT121, PGDM1400, and VRC07-523LS Among Participants Who Received All Scheduled Product Administrations | Measured during Screening, Days 0, 3, 6, 14, 28, 56, 84*, 112, 140*, 168, 224, 280, 336, 392*, and 448* Days with * are only available for T4 | Serum PGDM1400, PGT121, and VRC07-523LS IgG levels were measured on a Bio-Plex instrument (Bio-Rad) using a validated assay designed to simultaneously measure infused PGDM1400, PGT121, and VRC07-523LS by its ability to bind anti-idiotype antibody captured on fluorescent magnetic beads. This assay was derived from a standardized custom HIV-1 Luminex assay. PGDM1400, PGT121 and VRC07-523LS were titrated and combined to create a standard curve that was used to determine concentration of the diluted samples. The negative controls were CH58 (an irrelevant mAb) and blank beads.Serum 10-1074 level was measured by anti-idotypic ELISA. Participant serum sample was incubated in anti-ID coated micro-plate well. A conjugated secondary antibody was used to detect bound 10-1074. Samples were titrated to ensure positive optical density (O.D.) readouts fall within the linear range of the assay for monoclonal antibody concentration calculations. |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| T1: PGT121 + VRC07-523LS mo 0 PGT121 20 mg/kg AND VRC07-523LS 20 mg/kg to be administered IV sequentially in this order at Month 0. | 6 |
| T2: PGDM1400 + VRC07-523LS mo 0 PGDM1400 20 mg/kg AND VRC07-523LS 20 mg/kg to be administered IV sequentially in this order at Month 0. | 6 |
| T3: 10-1074 + VRC07-523LS 10-1074 20 mg/kg AND VRC07-523LS 20 mg/kg to be administered IV sequentially in this order at Month 0. | 6 |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) PGDM1400 20 mg/kg AND PGT121 20 mg/kg AND VRC07-523LS 20 mg/kg to be administered IV sequentially in this order at Month 0 and Month 4. | 9 |
| Total | 27 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 | FG003 |
|---|---|---|---|---|---|
| Overall Study | Death | 0 | 1 | 0 | 0 |
| Overall Study | Lost to Follow-up | 0 | 2 | 3 | 0 |
| Overall Study | Participant Unable to Adhere to Visit Schedule | 0 | 0 | 0 | 1 |
Baseline characteristics
| Characteristic | Total | T1: PGT121 + VRC07-523LS mo 0 | T2: PGDM1400 + VRC07-523LS mo 0 | T3: 10-1074 + VRC07-523LS | T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) |
|---|---|---|---|---|---|
| Age, Continuous | 26 years | 25 years | 29 years | 28 years | 30 years |
| Age, Customized 18 - 20 years | 1 Participants | 0 Participants | 0 Participants | 0 Participants | 1 Participants |
| Age, Customized 21 - 30 years | 17 Participants | 6 Participants | 3 Participants | 4 Participants | 4 Participants |
| Age, Customized 31 - 40 years | 4 Participants | 0 Participants | 2 Participants | 0 Participants | 2 Participants |
| Age, Customized 41 - 50 years | 5 Participants | 0 Participants | 1 Participants | 2 Participants | 2 Participants |
| Age, Customized Above 50 years | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Age, Customized Less than 18 years | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Age, Customized Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Ethnicity (NIH/OMB) Hispanic or Latino | 3 Participants | 0 Participants | 1 Participants | 0 Participants | 2 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 24 Participants | 6 Participants | 5 Participants | 6 Participants | 7 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race/Ethnicity, Customized American Indian or Alaska Native | 1 Participants | 0 Participants | 0 Participants | 0 Participants | 1 Participants |
| Race/Ethnicity, Customized Asian | 3 Participants | 1 Participants | 1 Participants | 0 Participants | 1 Participants |
| Race/Ethnicity, Customized Black or African American | 2 Participants | 0 Participants | 0 Participants | 2 Participants | 0 Participants |
| Race/Ethnicity, Customized More than one race | 1 Participants | 0 Participants | 1 Participants | 0 Participants | 0 Participants |
| Race/Ethnicity, Customized Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race/Ethnicity, Customized Other | 1 Participants | 0 Participants | 1 Participants | 0 Participants | 0 Participants |
| Race/Ethnicity, Customized White | 19 Participants | 5 Participants | 3 Participants | 4 Participants | 7 Participants |
| Region of Enrollment United States | 27 Participants | 6 Participants | 6 Participants | 6 Participants | 9 Participants |
| Sex: Female, Male Female | 16 Participants | 5 Participants | 3 Participants | 3 Participants | 5 Participants |
| Sex: Female, Male Male | 11 Participants | 1 Participants | 3 Participants | 3 Participants | 4 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk |
|---|---|---|---|---|
| deaths Total, all-cause mortality | 0 / 6 | 1 / 6 | 0 / 6 | 0 / 9 |
| other Total, other adverse events | 5 / 6 | 6 / 6 | 4 / 6 | 4 / 9 |
| serious Total, serious adverse events | 0 / 6 | 1 / 6 | 0 / 6 | 0 / 9 |
Outcome results
Primary
Chemistry and Hematology Laboratory Measures - Alanine Aminotransferase (ALT) in U/L
For each local laboratory measure, summary statistics were presented by treatment group and timepoint for the overall population.
Time frame: Measured during Screening, Days 0, 14, 56, 84*, 112, 140*, 168, 224, 280, 336, 392*, and 448*. Days with * are only available for T4
Population: Overall Number of Participants Analyzed represents participants enrolled and eligible for laboratory assessment. Participants do not have laboratory assessments if they attended the visit but laboratory specimens were not collected, missed the scheduled visit, or terminated participation in the study prior to the scheduled visit.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| T1: PGT121 + VRC07-523LS mo 0 | Chemistry and Hematology Laboratory Measures - Alanine Aminotransferase (ALT) in U/L | Alanine Aminotransferase (U/L)-Day 224 | 24 U/L |
| T1: PGT121 + VRC07-523LS mo 0 | Chemistry and Hematology Laboratory Measures - Alanine Aminotransferase (ALT) in U/L | Alanine Aminotransferase (U/L)-Baseline | 15 U/L |
| T1: PGT121 + VRC07-523LS mo 0 | Chemistry and Hematology Laboratory Measures - Alanine Aminotransferase (ALT) in U/L | Alanine Aminotransferase (U/L)-Day 168 | 14 U/L |
| T1: PGT121 + VRC07-523LS mo 0 | Chemistry and Hematology Laboratory Measures - Alanine Aminotransferase (ALT) in U/L | Alanine Aminotransferase (U/L)-Day 0 | 14 U/L |
| T1: PGT121 + VRC07-523LS mo 0 | Chemistry and Hematology Laboratory Measures - Alanine Aminotransferase (ALT) in U/L | Alanine Aminotransferase (U/L)-Day 14 | 14 U/L |
| T1: PGT121 + VRC07-523LS mo 0 | Chemistry and Hematology Laboratory Measures - Alanine Aminotransferase (ALT) in U/L | Alanine Aminotransferase (U/L)-Day 336 | 18 U/L |
| T1: PGT121 + VRC07-523LS mo 0 | Chemistry and Hematology Laboratory Measures - Alanine Aminotransferase (ALT) in U/L | Alanine Aminotransferase (U/L)-Day 56 | 13 U/L |
| T1: PGT121 + VRC07-523LS mo 0 | Chemistry and Hematology Laboratory Measures - Alanine Aminotransferase (ALT) in U/L | Alanine Aminotransferase (U/L)-Day 112 | 17 U/L |
| T2: PGDM1400 + VRC07-523LS mo 0 | Chemistry and Hematology Laboratory Measures - Alanine Aminotransferase (ALT) in U/L | Alanine Aminotransferase (U/L)-Day 336 | 8 U/L |
| T2: PGDM1400 + VRC07-523LS mo 0 | Chemistry and Hematology Laboratory Measures - Alanine Aminotransferase (ALT) in U/L | Alanine Aminotransferase (U/L)-Day 280 | 12 U/L |
| T2: PGDM1400 + VRC07-523LS mo 0 | Chemistry and Hematology Laboratory Measures - Alanine Aminotransferase (ALT) in U/L | Alanine Aminotransferase (U/L)-Day 112 | 9 U/L |
| T2: PGDM1400 + VRC07-523LS mo 0 | Chemistry and Hematology Laboratory Measures - Alanine Aminotransferase (ALT) in U/L | Alanine Aminotransferase (U/L)-Day 224 | 12 U/L |
| T2: PGDM1400 + VRC07-523LS mo 0 | Chemistry and Hematology Laboratory Measures - Alanine Aminotransferase (ALT) in U/L | Alanine Aminotransferase (U/L)-Day 168 | 11 U/L |
| T2: PGDM1400 + VRC07-523LS mo 0 | Chemistry and Hematology Laboratory Measures - Alanine Aminotransferase (ALT) in U/L | Alanine Aminotransferase (U/L)-Day 14 | 16 U/L |
| T2: PGDM1400 + VRC07-523LS mo 0 | Chemistry and Hematology Laboratory Measures - Alanine Aminotransferase (ALT) in U/L | Alanine Aminotransferase (U/L)-Baseline | 14 U/L |
| T2: PGDM1400 + VRC07-523LS mo 0 | Chemistry and Hematology Laboratory Measures - Alanine Aminotransferase (ALT) in U/L | Alanine Aminotransferase (U/L)-Day 56 | 15 U/L |
| T2: PGDM1400 + VRC07-523LS mo 0 | Chemistry and Hematology Laboratory Measures - Alanine Aminotransferase (ALT) in U/L | Alanine Aminotransferase (U/L)-Day 0 | 12 U/L |
| T3: 10-1074 + VRC07-523LS | Chemistry and Hematology Laboratory Measures - Alanine Aminotransferase (ALT) in U/L | Alanine Aminotransferase (U/L)-Baseline | 13 U/L |
| T3: 10-1074 + VRC07-523LS | Chemistry and Hematology Laboratory Measures - Alanine Aminotransferase (ALT) in U/L | Alanine Aminotransferase (U/L)-Day 0 | 13 U/L |
| T3: 10-1074 + VRC07-523LS | Chemistry and Hematology Laboratory Measures - Alanine Aminotransferase (ALT) in U/L | Alanine Aminotransferase (U/L)-Day 14 | 11 U/L |
| T3: 10-1074 + VRC07-523LS | Chemistry and Hematology Laboratory Measures - Alanine Aminotransferase (ALT) in U/L | Alanine Aminotransferase (U/L)-Day 56 | 20 U/L |
| T3: 10-1074 + VRC07-523LS | Chemistry and Hematology Laboratory Measures - Alanine Aminotransferase (ALT) in U/L | Alanine Aminotransferase (U/L)-Day 112 | 16 U/L |
| T3: 10-1074 + VRC07-523LS | Chemistry and Hematology Laboratory Measures - Alanine Aminotransferase (ALT) in U/L | Alanine Aminotransferase (U/L)-Day 168 | 17 U/L |
| T3: 10-1074 + VRC07-523LS | Chemistry and Hematology Laboratory Measures - Alanine Aminotransferase (ALT) in U/L | Alanine Aminotransferase (U/L)-Day 280 | 13 U/L |
| T3: 10-1074 + VRC07-523LS | Chemistry and Hematology Laboratory Measures - Alanine Aminotransferase (ALT) in U/L | Alanine Aminotransferase (U/L)-Day 336 | 14 U/L |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Chemistry and Hematology Laboratory Measures - Alanine Aminotransferase (ALT) in U/L | Alanine Aminotransferase (U/L)-Day 168 | 17 U/L |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Chemistry and Hematology Laboratory Measures - Alanine Aminotransferase (ALT) in U/L | Alanine Aminotransferase (U/L)-Day 56 | 16 U/L |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Chemistry and Hematology Laboratory Measures - Alanine Aminotransferase (ALT) in U/L | Alanine Aminotransferase (U/L)-Day 14 | 12 U/L |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Chemistry and Hematology Laboratory Measures - Alanine Aminotransferase (ALT) in U/L | Alanine Aminotransferase (U/L)-Day 224 | 14 U/L |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Chemistry and Hematology Laboratory Measures - Alanine Aminotransferase (ALT) in U/L | Alanine Aminotransferase (U/L)-Day 0 | 14 U/L |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Chemistry and Hematology Laboratory Measures - Alanine Aminotransferase (ALT) in U/L | Alanine Aminotransferase (U/L)-Day 392 | 15 U/L |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Chemistry and Hematology Laboratory Measures - Alanine Aminotransferase (ALT) in U/L | Alanine Aminotransferase (U/L)-Day 280 | 14 U/L |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Chemistry and Hematology Laboratory Measures - Alanine Aminotransferase (ALT) in U/L | Alanine Aminotransferase (U/L)-Day 84 | 13 U/L |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Chemistry and Hematology Laboratory Measures - Alanine Aminotransferase (ALT) in U/L | Alanine Aminotransferase (U/L)-Baseline | 14 U/L |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Chemistry and Hematology Laboratory Measures - Alanine Aminotransferase (ALT) in U/L | Alanine Aminotransferase (U/L)-Day 448 | 14 U/L |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Chemistry and Hematology Laboratory Measures - Alanine Aminotransferase (ALT) in U/L | Alanine Aminotransferase (U/L)-Day 140 | 18 U/L |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Chemistry and Hematology Laboratory Measures - Alanine Aminotransferase (ALT) in U/L | Alanine Aminotransferase (U/L)-Day 112 | 15 U/L |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Chemistry and Hematology Laboratory Measures - Alanine Aminotransferase (ALT) in U/L | Alanine Aminotransferase (U/L)-Day 336 | 16 U/L |
Primary
Chemistry and Hematology Laboratory Measures - Creatinine in mg/dL
For each local laboratory measure, summary statistics were presented by treatment group and timepoint for the overall population.
Time frame: Measured during Screening, Days 0, 14, 56, 84*, 112, 140*, 168, 224, 280, 336, 392*, and 448*. Days with * are only available for T4
Population: Overall Number of Participants Analyzed represents participants enrolled and eligible for laboratory assessment. Participants do not have laboratory assessments if they attended the visit but laboratory specimens were not collected, missed the scheduled visit, or terminated participation in the study prior to the scheduled visit.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| T1: PGT121 + VRC07-523LS mo 0 | Chemistry and Hematology Laboratory Measures - Creatinine in mg/dL | Creatinine (mg/dL)-Day 224 | 1 mg/dL |
| T1: PGT121 + VRC07-523LS mo 0 | Chemistry and Hematology Laboratory Measures - Creatinine in mg/dL | Creatinine (mg/dL)-Day 168 | 1 mg/dL |
| T1: PGT121 + VRC07-523LS mo 0 | Chemistry and Hematology Laboratory Measures - Creatinine in mg/dL | Creatinine (mg/dL)-Baseline | 1 mg/dL |
| T1: PGT121 + VRC07-523LS mo 0 | Chemistry and Hematology Laboratory Measures - Creatinine in mg/dL | Creatinine (mg/dL)-Day 336 | 1 mg/dL |
| T1: PGT121 + VRC07-523LS mo 0 | Chemistry and Hematology Laboratory Measures - Creatinine in mg/dL | Creatinine (mg/dL)-Day 14 | 1 mg/dL |
| T1: PGT121 + VRC07-523LS mo 0 | Chemistry and Hematology Laboratory Measures - Creatinine in mg/dL | Creatinine (mg/dL)-Day 56 | 1 mg/dL |
| T1: PGT121 + VRC07-523LS mo 0 | Chemistry and Hematology Laboratory Measures - Creatinine in mg/dL | Creatinine (mg/dL)-Day 0 | 1 mg/dL |
| T1: PGT121 + VRC07-523LS mo 0 | Chemistry and Hematology Laboratory Measures - Creatinine in mg/dL | Creatinine (mg/dL)-Day 112 | 1 mg/dL |
| T2: PGDM1400 + VRC07-523LS mo 0 | Chemistry and Hematology Laboratory Measures - Creatinine in mg/dL | Creatinine (mg/dL)-Day 56 | 1 mg/dL |
| T2: PGDM1400 + VRC07-523LS mo 0 | Chemistry and Hematology Laboratory Measures - Creatinine in mg/dL | Creatinine (mg/dL)-Day 14 | 1 mg/dL |
| T2: PGDM1400 + VRC07-523LS mo 0 | Chemistry and Hematology Laboratory Measures - Creatinine in mg/dL | Creatinine (mg/dL)-Day 112 | 1 mg/dL |
| T2: PGDM1400 + VRC07-523LS mo 0 | Chemistry and Hematology Laboratory Measures - Creatinine in mg/dL | Creatinine (mg/dL)-Baseline | 1 mg/dL |
| T2: PGDM1400 + VRC07-523LS mo 0 | Chemistry and Hematology Laboratory Measures - Creatinine in mg/dL | Creatinine (mg/dL)-Day 168 | 1 mg/dL |
| T2: PGDM1400 + VRC07-523LS mo 0 | Chemistry and Hematology Laboratory Measures - Creatinine in mg/dL | Creatinine (mg/dL)-Day 336 | 1 mg/dL |
| T2: PGDM1400 + VRC07-523LS mo 0 | Chemistry and Hematology Laboratory Measures - Creatinine in mg/dL | Creatinine (mg/dL)-Day 0 | 1 mg/dL |
| T2: PGDM1400 + VRC07-523LS mo 0 | Chemistry and Hematology Laboratory Measures - Creatinine in mg/dL | Creatinine (mg/dL)-Day 280 | 1 mg/dL |
| T2: PGDM1400 + VRC07-523LS mo 0 | Chemistry and Hematology Laboratory Measures - Creatinine in mg/dL | Creatinine (mg/dL)-Day 224 | 1 mg/dL |
| T3: 10-1074 + VRC07-523LS | Chemistry and Hematology Laboratory Measures - Creatinine in mg/dL | Creatinine (mg/dL)-Day 112 | 1 mg/dL |
| T3: 10-1074 + VRC07-523LS | Chemistry and Hematology Laboratory Measures - Creatinine in mg/dL | Creatinine (mg/dL)-Baseline | 1 mg/dL |
| T3: 10-1074 + VRC07-523LS | Chemistry and Hematology Laboratory Measures - Creatinine in mg/dL | Creatinine (mg/dL)-Day 0 | 1 mg/dL |
| T3: 10-1074 + VRC07-523LS | Chemistry and Hematology Laboratory Measures - Creatinine in mg/dL | Creatinine (mg/dL)-Day 14 | 1 mg/dL |
| T3: 10-1074 + VRC07-523LS | Chemistry and Hematology Laboratory Measures - Creatinine in mg/dL | Creatinine (mg/dL)-Day 56 | 1 mg/dL |
| T3: 10-1074 + VRC07-523LS | Chemistry and Hematology Laboratory Measures - Creatinine in mg/dL | Creatinine (mg/dL)-Day 168 | 1 mg/dL |
| T3: 10-1074 + VRC07-523LS | Chemistry and Hematology Laboratory Measures - Creatinine in mg/dL | Creatinine (mg/dL)-Day 280 | 1 mg/dL |
| T3: 10-1074 + VRC07-523LS | Chemistry and Hematology Laboratory Measures - Creatinine in mg/dL | Creatinine (mg/dL)-Day 336 | 1 mg/dL |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Chemistry and Hematology Laboratory Measures - Creatinine in mg/dL | Creatinine (mg/dL)-Day 168 | 1 mg/dL |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Chemistry and Hematology Laboratory Measures - Creatinine in mg/dL | Creatinine (mg/dL)-Day 84 | 1 mg/dL |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Chemistry and Hematology Laboratory Measures - Creatinine in mg/dL | Creatinine (mg/dL)-Day 56 | 1 mg/dL |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Chemistry and Hematology Laboratory Measures - Creatinine in mg/dL | Creatinine (mg/dL)-Day 224 | 1 mg/dL |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Chemistry and Hematology Laboratory Measures - Creatinine in mg/dL | Creatinine (mg/dL)-Day 14 | 1 mg/dL |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Chemistry and Hematology Laboratory Measures - Creatinine in mg/dL | Creatinine (mg/dL)-Day 392 | 1 mg/dL |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Chemistry and Hematology Laboratory Measures - Creatinine in mg/dL | Creatinine (mg/dL)-Day 280 | 1 mg/dL |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Chemistry and Hematology Laboratory Measures - Creatinine in mg/dL | Creatinine (mg/dL)-Day 0 | 1 mg/dL |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Chemistry and Hematology Laboratory Measures - Creatinine in mg/dL | Creatinine (mg/dL)-Baseline | 1 mg/dL |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Chemistry and Hematology Laboratory Measures - Creatinine in mg/dL | Creatinine (mg/dL)-Day 448 | 1 mg/dL |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Chemistry and Hematology Laboratory Measures - Creatinine in mg/dL | Creatinine (mg/dL)-Day 140 | 1 mg/dL |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Chemistry and Hematology Laboratory Measures - Creatinine in mg/dL | Creatinine (mg/dL)-Day 112 | 1 mg/dL |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Chemistry and Hematology Laboratory Measures - Creatinine in mg/dL | Creatinine (mg/dL)-Day 336 | 1 mg/dL |
Primary
Chemistry and Hematology Laboratory Measures - Hemoglobin in g/dL
For each local laboratory measure, summary statistics were presented by treatment group and timepoint for the overall population.
Time frame: Measured during Screening, Days 0, 14, 56, 84*, 112, 140*, 168, 224, 280, 336, 392*, and 448*. Days with * are only available for T4
Population: Overall Number of Participants Analyzed represents participants enrolled and eligible for laboratory assessment. Participants do not have laboratory assessments if they attended the visit but laboratory specimens were not collected, missed the scheduled visit, or terminated participation in the study prior to the scheduled visit.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| T1: PGT121 + VRC07-523LS mo 0 | Chemistry and Hematology Laboratory Measures - Hemoglobin in g/dL | Hemoglobin (g/dL)-Baseline | 14 g/dL |
| T1: PGT121 + VRC07-523LS mo 0 | Chemistry and Hematology Laboratory Measures - Hemoglobin in g/dL | Hemoglobin (g/dL)-Day 112 | 13 g/dL |
| T1: PGT121 + VRC07-523LS mo 0 | Chemistry and Hematology Laboratory Measures - Hemoglobin in g/dL | Hemoglobin (g/dL)-Day 168 | 13 g/dL |
| T1: PGT121 + VRC07-523LS mo 0 | Chemistry and Hematology Laboratory Measures - Hemoglobin in g/dL | Hemoglobin (g/dL)-Day 336 | 13 g/dL |
| T1: PGT121 + VRC07-523LS mo 0 | Chemistry and Hematology Laboratory Measures - Hemoglobin in g/dL | Hemoglobin (g/dL)-Day 224 | 13 g/dL |
| T1: PGT121 + VRC07-523LS mo 0 | Chemistry and Hematology Laboratory Measures - Hemoglobin in g/dL | Hemoglobin (g/dL)-Day 14 | 13 g/dL |
| T1: PGT121 + VRC07-523LS mo 0 | Chemistry and Hematology Laboratory Measures - Hemoglobin in g/dL | Hemoglobin (g/dL)-Day 56 | 13 g/dL |
| T1: PGT121 + VRC07-523LS mo 0 | Chemistry and Hematology Laboratory Measures - Hemoglobin in g/dL | Hemoglobin (g/dL)-Day 0 | 13 g/dL |
| T2: PGDM1400 + VRC07-523LS mo 0 | Chemistry and Hematology Laboratory Measures - Hemoglobin in g/dL | Hemoglobin (g/dL)-Day 56 | 14 g/dL |
| T2: PGDM1400 + VRC07-523LS mo 0 | Chemistry and Hematology Laboratory Measures - Hemoglobin in g/dL | Hemoglobin (g/dL)-Day 336 | 13 g/dL |
| T2: PGDM1400 + VRC07-523LS mo 0 | Chemistry and Hematology Laboratory Measures - Hemoglobin in g/dL | Hemoglobin (g/dL)-Day 280 | 13 g/dL |
| T2: PGDM1400 + VRC07-523LS mo 0 | Chemistry and Hematology Laboratory Measures - Hemoglobin in g/dL | Hemoglobin (g/dL)-Day 112 | 13 g/dL |
| T2: PGDM1400 + VRC07-523LS mo 0 | Chemistry and Hematology Laboratory Measures - Hemoglobin in g/dL | Hemoglobin (g/dL)-Baseline | 14 g/dL |
| T2: PGDM1400 + VRC07-523LS mo 0 | Chemistry and Hematology Laboratory Measures - Hemoglobin in g/dL | Hemoglobin (g/dL)-Day 0 | 13 g/dL |
| T2: PGDM1400 + VRC07-523LS mo 0 | Chemistry and Hematology Laboratory Measures - Hemoglobin in g/dL | Hemoglobin (g/dL)-Day 14 | 14 g/dL |
| T2: PGDM1400 + VRC07-523LS mo 0 | Chemistry and Hematology Laboratory Measures - Hemoglobin in g/dL | Hemoglobin (g/dL)-Day 224 | 13 g/dL |
| T2: PGDM1400 + VRC07-523LS mo 0 | Chemistry and Hematology Laboratory Measures - Hemoglobin in g/dL | Hemoglobin (g/dL)-Day 168 | 13 g/dL |
| T3: 10-1074 + VRC07-523LS | Chemistry and Hematology Laboratory Measures - Hemoglobin in g/dL | Hemoglobin (g/dL)-Baseline | 15 g/dL |
| T3: 10-1074 + VRC07-523LS | Chemistry and Hematology Laboratory Measures - Hemoglobin in g/dL | Hemoglobin (g/dL)-Day 280 | 12 g/dL |
| T3: 10-1074 + VRC07-523LS | Chemistry and Hematology Laboratory Measures - Hemoglobin in g/dL | Hemoglobin (g/dL)-Day 336 | 13 g/dL |
| T3: 10-1074 + VRC07-523LS | Chemistry and Hematology Laboratory Measures - Hemoglobin in g/dL | Hemoglobin (g/dL)-Day 14 | 13 g/dL |
| T3: 10-1074 + VRC07-523LS | Chemistry and Hematology Laboratory Measures - Hemoglobin in g/dL | Hemoglobin (g/dL)-Day 168 | 14 g/dL |
| T3: 10-1074 + VRC07-523LS | Chemistry and Hematology Laboratory Measures - Hemoglobin in g/dL | Hemoglobin (g/dL)-Day 56 | 14 g/dL |
| T3: 10-1074 + VRC07-523LS | Chemistry and Hematology Laboratory Measures - Hemoglobin in g/dL | Hemoglobin (g/dL)-Day 112 | 14 g/dL |
| T3: 10-1074 + VRC07-523LS | Chemistry and Hematology Laboratory Measures - Hemoglobin in g/dL | Hemoglobin (g/dL)-Day 0 | 13 g/dL |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Chemistry and Hematology Laboratory Measures - Hemoglobin in g/dL | Hemoglobin (g/dL)-Day 392 | 14 g/dL |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Chemistry and Hematology Laboratory Measures - Hemoglobin in g/dL | Hemoglobin (g/dL)-Baseline | 14 g/dL |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Chemistry and Hematology Laboratory Measures - Hemoglobin in g/dL | Hemoglobin (g/dL)-Day 0 | 14 g/dL |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Chemistry and Hematology Laboratory Measures - Hemoglobin in g/dL | Hemoglobin (g/dL)-Day 14 | 14 g/dL |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Chemistry and Hematology Laboratory Measures - Hemoglobin in g/dL | Hemoglobin (g/dL)-Day 56 | 14 g/dL |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Chemistry and Hematology Laboratory Measures - Hemoglobin in g/dL | Hemoglobin (g/dL)-Day 84 | 15 g/dL |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Chemistry and Hematology Laboratory Measures - Hemoglobin in g/dL | Hemoglobin (g/dL)-Day 112 | 13 g/dL |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Chemistry and Hematology Laboratory Measures - Hemoglobin in g/dL | Hemoglobin (g/dL)-Day 140 | 14 g/dL |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Chemistry and Hematology Laboratory Measures - Hemoglobin in g/dL | Hemoglobin (g/dL)-Day 168 | 14 g/dL |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Chemistry and Hematology Laboratory Measures - Hemoglobin in g/dL | Hemoglobin (g/dL)-Day 224 | 14 g/dL |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Chemistry and Hematology Laboratory Measures - Hemoglobin in g/dL | Hemoglobin (g/dL)-Day 280 | 14 g/dL |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Chemistry and Hematology Laboratory Measures - Hemoglobin in g/dL | Hemoglobin (g/dL)-Day 336 | 14 g/dL |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Chemistry and Hematology Laboratory Measures - Hemoglobin in g/dL | Hemoglobin (g/dL)-Day 448 | 14 g/dL |
Primary
Chemistry and Hematology Laboratory Measures - Lymphocyte Count, Neutrophil Count in 1000 Cells/Cubic mm
For each local laboratory measure, summary statistics were presented by treatment group and timepoint for the overall population.
Time frame: Measured during Screening, Days 0, 14, 56, 84*, 112, 140*, 168, 224, 280, 336, 392*, and 448*. Days with * are only available for T4
Population: Overall Number of Participants Analyzed represents participants enrolled and eligible for laboratory assessment. Participants do not have laboratory assessments if they attended the visit but laboratory specimens were not collected, missed the scheduled visit, or terminated participation in the study prior to the scheduled visit.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| T1: PGT121 + VRC07-523LS mo 0 | Chemistry and Hematology Laboratory Measures - Lymphocyte Count, Neutrophil Count in 1000 Cells/Cubic mm | Lymphocytes (1000 cells/cubic mm)-Day 0 | 1.778 1000 cells/cubic mm |
| T1: PGT121 + VRC07-523LS mo 0 | Chemistry and Hematology Laboratory Measures - Lymphocyte Count, Neutrophil Count in 1000 Cells/Cubic mm | Neutrophils (1000 cells/cubic mm)-Day 224 | 5.24 1000 cells/cubic mm |
| T1: PGT121 + VRC07-523LS mo 0 | Chemistry and Hematology Laboratory Measures - Lymphocyte Count, Neutrophil Count in 1000 Cells/Cubic mm | Lymphocytes (1000 cells/cubic mm)-Day 336 | 1.651 1000 cells/cubic mm |
| T1: PGT121 + VRC07-523LS mo 0 | Chemistry and Hematology Laboratory Measures - Lymphocyte Count, Neutrophil Count in 1000 Cells/Cubic mm | Lymphocytes (1000 cells/cubic mm)-Day 168 | 1.688 1000 cells/cubic mm |
| T1: PGT121 + VRC07-523LS mo 0 | Chemistry and Hematology Laboratory Measures - Lymphocyte Count, Neutrophil Count in 1000 Cells/Cubic mm | Lymphocytes (1000 cells/cubic mm)-Day 112 | 1.693 1000 cells/cubic mm |
| T1: PGT121 + VRC07-523LS mo 0 | Chemistry and Hematology Laboratory Measures - Lymphocyte Count, Neutrophil Count in 1000 Cells/Cubic mm | Lymphocytes (1000 cells/cubic mm)-Day 56 | 1.824 1000 cells/cubic mm |
| T1: PGT121 + VRC07-523LS mo 0 | Chemistry and Hematology Laboratory Measures - Lymphocyte Count, Neutrophil Count in 1000 Cells/Cubic mm | Lymphocytes (1000 cells/cubic mm)-Day 14 | 1.63 1000 cells/cubic mm |
| T1: PGT121 + VRC07-523LS mo 0 | Chemistry and Hematology Laboratory Measures - Lymphocyte Count, Neutrophil Count in 1000 Cells/Cubic mm | Neutrophils (1000 cells/cubic mm)-Day 168 | 3.882 1000 cells/cubic mm |
| T1: PGT121 + VRC07-523LS mo 0 | Chemistry and Hematology Laboratory Measures - Lymphocyte Count, Neutrophil Count in 1000 Cells/Cubic mm | Neutrophils (1000 cells/cubic mm)-Day 112 | 3.377 1000 cells/cubic mm |
| T1: PGT121 + VRC07-523LS mo 0 | Chemistry and Hematology Laboratory Measures - Lymphocyte Count, Neutrophil Count in 1000 Cells/Cubic mm | Lymphocytes (1000 cells/cubic mm)-Baseline | 1.65 1000 cells/cubic mm |
| T1: PGT121 + VRC07-523LS mo 0 | Chemistry and Hematology Laboratory Measures - Lymphocyte Count, Neutrophil Count in 1000 Cells/Cubic mm | Neutrophils (1000 cells/cubic mm)-Day 56 | 2.762 1000 cells/cubic mm |
| T1: PGT121 + VRC07-523LS mo 0 | Chemistry and Hematology Laboratory Measures - Lymphocyte Count, Neutrophil Count in 1000 Cells/Cubic mm | Neutrophils (1000 cells/cubic mm)-Day 14 | 3.181 1000 cells/cubic mm |
| T1: PGT121 + VRC07-523LS mo 0 | Chemistry and Hematology Laboratory Measures - Lymphocyte Count, Neutrophil Count in 1000 Cells/Cubic mm | Lymphocytes (1000 cells/cubic mm)-Day 224 | 1.02 1000 cells/cubic mm |
| T1: PGT121 + VRC07-523LS mo 0 | Chemistry and Hematology Laboratory Measures - Lymphocyte Count, Neutrophil Count in 1000 Cells/Cubic mm | Neutrophils (1000 cells/cubic mm)-Day 336 | 3.93 1000 cells/cubic mm |
| T1: PGT121 + VRC07-523LS mo 0 | Chemistry and Hematology Laboratory Measures - Lymphocyte Count, Neutrophil Count in 1000 Cells/Cubic mm | Neutrophils (1000 cells/cubic mm)-Day 0 | 3.307 1000 cells/cubic mm |
| T1: PGT121 + VRC07-523LS mo 0 | Chemistry and Hematology Laboratory Measures - Lymphocyte Count, Neutrophil Count in 1000 Cells/Cubic mm | Neutrophils (1000 cells/cubic mm)-Baseline | 3.338 1000 cells/cubic mm |
| T2: PGDM1400 + VRC07-523LS mo 0 | Chemistry and Hematology Laboratory Measures - Lymphocyte Count, Neutrophil Count in 1000 Cells/Cubic mm | Lymphocytes (1000 cells/cubic mm)-Day 112 | 1.768 1000 cells/cubic mm |
| T2: PGDM1400 + VRC07-523LS mo 0 | Chemistry and Hematology Laboratory Measures - Lymphocyte Count, Neutrophil Count in 1000 Cells/Cubic mm | Lymphocytes (1000 cells/cubic mm)-Day 14 | 1.781 1000 cells/cubic mm |
| T2: PGDM1400 + VRC07-523LS mo 0 | Chemistry and Hematology Laboratory Measures - Lymphocyte Count, Neutrophil Count in 1000 Cells/Cubic mm | Lymphocytes (1000 cells/cubic mm)-Day 56 | 1.667 1000 cells/cubic mm |
| T2: PGDM1400 + VRC07-523LS mo 0 | Chemistry and Hematology Laboratory Measures - Lymphocyte Count, Neutrophil Count in 1000 Cells/Cubic mm | Lymphocytes (1000 cells/cubic mm)-Baseline | 2.191 1000 cells/cubic mm |
| T2: PGDM1400 + VRC07-523LS mo 0 | Chemistry and Hematology Laboratory Measures - Lymphocyte Count, Neutrophil Count in 1000 Cells/Cubic mm | Lymphocytes (1000 cells/cubic mm)-Day 0 | 1.785 1000 cells/cubic mm |
| T2: PGDM1400 + VRC07-523LS mo 0 | Chemistry and Hematology Laboratory Measures - Lymphocyte Count, Neutrophil Count in 1000 Cells/Cubic mm | Lymphocytes (1000 cells/cubic mm)-Day 168 | 2.015 1000 cells/cubic mm |
| T2: PGDM1400 + VRC07-523LS mo 0 | Chemistry and Hematology Laboratory Measures - Lymphocyte Count, Neutrophil Count in 1000 Cells/Cubic mm | Lymphocytes (1000 cells/cubic mm)-Day 224 | 2.9 1000 cells/cubic mm |
| T2: PGDM1400 + VRC07-523LS mo 0 | Chemistry and Hematology Laboratory Measures - Lymphocyte Count, Neutrophil Count in 1000 Cells/Cubic mm | Lymphocytes (1000 cells/cubic mm)-Day 280 | 2.14 1000 cells/cubic mm |
| T2: PGDM1400 + VRC07-523LS mo 0 | Chemistry and Hematology Laboratory Measures - Lymphocyte Count, Neutrophil Count in 1000 Cells/Cubic mm | Lymphocytes (1000 cells/cubic mm)-Day 336 | 1.764 1000 cells/cubic mm |
| T2: PGDM1400 + VRC07-523LS mo 0 | Chemistry and Hematology Laboratory Measures - Lymphocyte Count, Neutrophil Count in 1000 Cells/Cubic mm | Neutrophils (1000 cells/cubic mm)-Baseline | 3.56 1000 cells/cubic mm |
| T2: PGDM1400 + VRC07-523LS mo 0 | Chemistry and Hematology Laboratory Measures - Lymphocyte Count, Neutrophil Count in 1000 Cells/Cubic mm | Neutrophils (1000 cells/cubic mm)-Day 0 | 3.032 1000 cells/cubic mm |
| T2: PGDM1400 + VRC07-523LS mo 0 | Chemistry and Hematology Laboratory Measures - Lymphocyte Count, Neutrophil Count in 1000 Cells/Cubic mm | Neutrophils (1000 cells/cubic mm)-Day 14 | 4.037 1000 cells/cubic mm |
| T2: PGDM1400 + VRC07-523LS mo 0 | Chemistry and Hematology Laboratory Measures - Lymphocyte Count, Neutrophil Count in 1000 Cells/Cubic mm | Neutrophils (1000 cells/cubic mm)-Day 56 | 3.581 1000 cells/cubic mm |
| T2: PGDM1400 + VRC07-523LS mo 0 | Chemistry and Hematology Laboratory Measures - Lymphocyte Count, Neutrophil Count in 1000 Cells/Cubic mm | Neutrophils (1000 cells/cubic mm)-Day 112 | 3.22 1000 cells/cubic mm |
| T2: PGDM1400 + VRC07-523LS mo 0 | Chemistry and Hematology Laboratory Measures - Lymphocyte Count, Neutrophil Count in 1000 Cells/Cubic mm | Neutrophils (1000 cells/cubic mm)-Day 168 | 4.285 1000 cells/cubic mm |
| T2: PGDM1400 + VRC07-523LS mo 0 | Chemistry and Hematology Laboratory Measures - Lymphocyte Count, Neutrophil Count in 1000 Cells/Cubic mm | Neutrophils (1000 cells/cubic mm)-Day 224 | 3.38 1000 cells/cubic mm |
| T2: PGDM1400 + VRC07-523LS mo 0 | Chemistry and Hematology Laboratory Measures - Lymphocyte Count, Neutrophil Count in 1000 Cells/Cubic mm | Neutrophils (1000 cells/cubic mm)-Day 280 | 3.35 1000 cells/cubic mm |
| T2: PGDM1400 + VRC07-523LS mo 0 | Chemistry and Hematology Laboratory Measures - Lymphocyte Count, Neutrophil Count in 1000 Cells/Cubic mm | Neutrophils (1000 cells/cubic mm)-Day 336 | 2.858 1000 cells/cubic mm |
| T3: 10-1074 + VRC07-523LS | Chemistry and Hematology Laboratory Measures - Lymphocyte Count, Neutrophil Count in 1000 Cells/Cubic mm | Lymphocytes (1000 cells/cubic mm)-Day 14 | 1.54 1000 cells/cubic mm |
| T3: 10-1074 + VRC07-523LS | Chemistry and Hematology Laboratory Measures - Lymphocyte Count, Neutrophil Count in 1000 Cells/Cubic mm | Neutrophils (1000 cells/cubic mm)-Day 336 | 2.315 1000 cells/cubic mm |
| T3: 10-1074 + VRC07-523LS | Chemistry and Hematology Laboratory Measures - Lymphocyte Count, Neutrophil Count in 1000 Cells/Cubic mm | Neutrophils (1000 cells/cubic mm)-Day 168 | 3.272 1000 cells/cubic mm |
| T3: 10-1074 + VRC07-523LS | Chemistry and Hematology Laboratory Measures - Lymphocyte Count, Neutrophil Count in 1000 Cells/Cubic mm | Lymphocytes (1000 cells/cubic mm)-Day 56 | 1.723 1000 cells/cubic mm |
| T3: 10-1074 + VRC07-523LS | Chemistry and Hematology Laboratory Measures - Lymphocyte Count, Neutrophil Count in 1000 Cells/Cubic mm | Neutrophils (1000 cells/cubic mm)-Day 56 | 3.55 1000 cells/cubic mm |
| T3: 10-1074 + VRC07-523LS | Chemistry and Hematology Laboratory Measures - Lymphocyte Count, Neutrophil Count in 1000 Cells/Cubic mm | Neutrophils (1000 cells/cubic mm)-Baseline | 3.39 1000 cells/cubic mm |
| T3: 10-1074 + VRC07-523LS | Chemistry and Hematology Laboratory Measures - Lymphocyte Count, Neutrophil Count in 1000 Cells/Cubic mm | Lymphocytes (1000 cells/cubic mm)-Baseline | 1.551 1000 cells/cubic mm |
| T3: 10-1074 + VRC07-523LS | Chemistry and Hematology Laboratory Measures - Lymphocyte Count, Neutrophil Count in 1000 Cells/Cubic mm | Neutrophils (1000 cells/cubic mm)-Day 280 | 3.922 1000 cells/cubic mm |
| T3: 10-1074 + VRC07-523LS | Chemistry and Hematology Laboratory Measures - Lymphocyte Count, Neutrophil Count in 1000 Cells/Cubic mm | Lymphocytes (1000 cells/cubic mm)-Day 168 | 1.918 1000 cells/cubic mm |
| T3: 10-1074 + VRC07-523LS | Chemistry and Hematology Laboratory Measures - Lymphocyte Count, Neutrophil Count in 1000 Cells/Cubic mm | Neutrophils (1000 cells/cubic mm)-Day 14 | 4.024 1000 cells/cubic mm |
| T3: 10-1074 + VRC07-523LS | Chemistry and Hematology Laboratory Measures - Lymphocyte Count, Neutrophil Count in 1000 Cells/Cubic mm | Neutrophils (1000 cells/cubic mm)-Day 112 | 2.944 1000 cells/cubic mm |
| T3: 10-1074 + VRC07-523LS | Chemistry and Hematology Laboratory Measures - Lymphocyte Count, Neutrophil Count in 1000 Cells/Cubic mm | Neutrophils (1000 cells/cubic mm)-Day 0 | 2.962 1000 cells/cubic mm |
| T3: 10-1074 + VRC07-523LS | Chemistry and Hematology Laboratory Measures - Lymphocyte Count, Neutrophil Count in 1000 Cells/Cubic mm | Lymphocytes (1000 cells/cubic mm)-Day 280 | 1.563 1000 cells/cubic mm |
| T3: 10-1074 + VRC07-523LS | Chemistry and Hematology Laboratory Measures - Lymphocyte Count, Neutrophil Count in 1000 Cells/Cubic mm | Lymphocytes (1000 cells/cubic mm)-Day 112 | 1.22 1000 cells/cubic mm |
| T3: 10-1074 + VRC07-523LS | Chemistry and Hematology Laboratory Measures - Lymphocyte Count, Neutrophil Count in 1000 Cells/Cubic mm | Lymphocytes (1000 cells/cubic mm)-Day 0 | 1.445 1000 cells/cubic mm |
| T3: 10-1074 + VRC07-523LS | Chemistry and Hematology Laboratory Measures - Lymphocyte Count, Neutrophil Count in 1000 Cells/Cubic mm | Lymphocytes (1000 cells/cubic mm)-Day 336 | 1.927 1000 cells/cubic mm |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Chemistry and Hematology Laboratory Measures - Lymphocyte Count, Neutrophil Count in 1000 Cells/Cubic mm | Neutrophils (1000 cells/cubic mm)-Day 140 | 4.108 1000 cells/cubic mm |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Chemistry and Hematology Laboratory Measures - Lymphocyte Count, Neutrophil Count in 1000 Cells/Cubic mm | Lymphocytes (1000 cells/cubic mm)-Day 56 | 2.176 1000 cells/cubic mm |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Chemistry and Hematology Laboratory Measures - Lymphocyte Count, Neutrophil Count in 1000 Cells/Cubic mm | Lymphocytes (1000 cells/cubic mm)-Day 112 | 2.002 1000 cells/cubic mm |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Chemistry and Hematology Laboratory Measures - Lymphocyte Count, Neutrophil Count in 1000 Cells/Cubic mm | Lymphocytes (1000 cells/cubic mm)-Day 140 | 1.487 1000 cells/cubic mm |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Chemistry and Hematology Laboratory Measures - Lymphocyte Count, Neutrophil Count in 1000 Cells/Cubic mm | Lymphocytes (1000 cells/cubic mm)-Day 0 | 1.802 1000 cells/cubic mm |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Chemistry and Hematology Laboratory Measures - Lymphocyte Count, Neutrophil Count in 1000 Cells/Cubic mm | Neutrophils (1000 cells/cubic mm)-Day 168 | 3.155 1000 cells/cubic mm |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Chemistry and Hematology Laboratory Measures - Lymphocyte Count, Neutrophil Count in 1000 Cells/Cubic mm | Lymphocytes (1000 cells/cubic mm)-Day 14 | 1.99 1000 cells/cubic mm |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Chemistry and Hematology Laboratory Measures - Lymphocyte Count, Neutrophil Count in 1000 Cells/Cubic mm | Lymphocytes (1000 cells/cubic mm)-Day 224 | 2.015 1000 cells/cubic mm |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Chemistry and Hematology Laboratory Measures - Lymphocyte Count, Neutrophil Count in 1000 Cells/Cubic mm | Neutrophils (1000 cells/cubic mm)-Day 336 | 3 1000 cells/cubic mm |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Chemistry and Hematology Laboratory Measures - Lymphocyte Count, Neutrophil Count in 1000 Cells/Cubic mm | Lymphocytes (1000 cells/cubic mm)-Day 280 | 1.74 1000 cells/cubic mm |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Chemistry and Hematology Laboratory Measures - Lymphocyte Count, Neutrophil Count in 1000 Cells/Cubic mm | Neutrophils (1000 cells/cubic mm)-Day 224 | 2.855 1000 cells/cubic mm |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Chemistry and Hematology Laboratory Measures - Lymphocyte Count, Neutrophil Count in 1000 Cells/Cubic mm | Lymphocytes (1000 cells/cubic mm)-Day 336 | 1.898 1000 cells/cubic mm |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Chemistry and Hematology Laboratory Measures - Lymphocyte Count, Neutrophil Count in 1000 Cells/Cubic mm | Lymphocytes (1000 cells/cubic mm)-Day 392 | 1.849 1000 cells/cubic mm |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Chemistry and Hematology Laboratory Measures - Lymphocyte Count, Neutrophil Count in 1000 Cells/Cubic mm | Lymphocytes (1000 cells/cubic mm)-Day 448 | 1.76 1000 cells/cubic mm |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Chemistry and Hematology Laboratory Measures - Lymphocyte Count, Neutrophil Count in 1000 Cells/Cubic mm | Lymphocytes (1000 cells/cubic mm)-Baseline | 2.31 1000 cells/cubic mm |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Chemistry and Hematology Laboratory Measures - Lymphocyte Count, Neutrophil Count in 1000 Cells/Cubic mm | Neutrophils (1000 cells/cubic mm)-Day 392 | 3.565 1000 cells/cubic mm |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Chemistry and Hematology Laboratory Measures - Lymphocyte Count, Neutrophil Count in 1000 Cells/Cubic mm | Neutrophils (1000 cells/cubic mm)-Baseline | 4.194 1000 cells/cubic mm |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Chemistry and Hematology Laboratory Measures - Lymphocyte Count, Neutrophil Count in 1000 Cells/Cubic mm | Neutrophils (1000 cells/cubic mm)-Day 0 | 4.3 1000 cells/cubic mm |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Chemistry and Hematology Laboratory Measures - Lymphocyte Count, Neutrophil Count in 1000 Cells/Cubic mm | Lymphocytes (1000 cells/cubic mm)-Day 168 | 1.65 1000 cells/cubic mm |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Chemistry and Hematology Laboratory Measures - Lymphocyte Count, Neutrophil Count in 1000 Cells/Cubic mm | Neutrophils (1000 cells/cubic mm)-Day 280 | 4.14 1000 cells/cubic mm |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Chemistry and Hematology Laboratory Measures - Lymphocyte Count, Neutrophil Count in 1000 Cells/Cubic mm | Neutrophils (1000 cells/cubic mm)-Day 14 | 4.831 1000 cells/cubic mm |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Chemistry and Hematology Laboratory Measures - Lymphocyte Count, Neutrophil Count in 1000 Cells/Cubic mm | Neutrophils (1000 cells/cubic mm)-Day 56 | 4.98 1000 cells/cubic mm |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Chemistry and Hematology Laboratory Measures - Lymphocyte Count, Neutrophil Count in 1000 Cells/Cubic mm | Neutrophils (1000 cells/cubic mm)-Day 84 | 4.12 1000 cells/cubic mm |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Chemistry and Hematology Laboratory Measures - Lymphocyte Count, Neutrophil Count in 1000 Cells/Cubic mm | Lymphocytes (1000 cells/cubic mm)-Day 84 | 1.83 1000 cells/cubic mm |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Chemistry and Hematology Laboratory Measures - Lymphocyte Count, Neutrophil Count in 1000 Cells/Cubic mm | Neutrophils (1000 cells/cubic mm)-Day 448 | 3.81 1000 cells/cubic mm |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Chemistry and Hematology Laboratory Measures - Lymphocyte Count, Neutrophil Count in 1000 Cells/Cubic mm | Neutrophils (1000 cells/cubic mm)-Day 112 | 3.735 1000 cells/cubic mm |
Primary
Chemistry and Hematology Laboratory Measures - Platelets, WBC in 1000 Cells/Cubic mm
For each local laboratory measure, summary statistics were presented by treatment group and timepoint for the overall population.
Time frame: Measured during Screening, Days 0, 14, 56, 84*, 112, 140*, 168, 224, 280, 336, 392*, and 448*. Days with * are only available for T4
Population: Overall Number of Participants Analyzed represents participants enrolled and eligible for laboratory assessment. Participants do not have laboratory assessments if they attended the visit but laboratory specimens were not collected, missed the scheduled visit, or terminated participation in the study prior to the scheduled visit.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| T1: PGT121 + VRC07-523LS mo 0 | Chemistry and Hematology Laboratory Measures - Platelets, WBC in 1000 Cells/Cubic mm | WBC (1000 cells/cubic mm)-Day 14 | 5.55 1000 cells/cubic mm |
| T1: PGT121 + VRC07-523LS mo 0 | Chemistry and Hematology Laboratory Measures - Platelets, WBC in 1000 Cells/Cubic mm | Platelets (1000 cells/cubic mm)-Day 168 | 208 1000 cells/cubic mm |
| T1: PGT121 + VRC07-523LS mo 0 | Chemistry and Hematology Laboratory Measures - Platelets, WBC in 1000 Cells/Cubic mm | WBC (1000 cells/cubic mm)-Day 112 | 5.85 1000 cells/cubic mm |
| T1: PGT121 + VRC07-523LS mo 0 | Chemistry and Hematology Laboratory Measures - Platelets, WBC in 1000 Cells/Cubic mm | WBC (1000 cells/cubic mm)-Baseline | 6.25 1000 cells/cubic mm |
| T1: PGT121 + VRC07-523LS mo 0 | Chemistry and Hematology Laboratory Measures - Platelets, WBC in 1000 Cells/Cubic mm | WBC (1000 cells/cubic mm)-Day 56 | 5.25 1000 cells/cubic mm |
| T1: PGT121 + VRC07-523LS mo 0 | Chemistry and Hematology Laboratory Measures - Platelets, WBC in 1000 Cells/Cubic mm | Platelets (1000 cells/cubic mm)-Day 0 | 217 1000 cells/cubic mm |
| T1: PGT121 + VRC07-523LS mo 0 | Chemistry and Hematology Laboratory Measures - Platelets, WBC in 1000 Cells/Cubic mm | WBC (1000 cells/cubic mm)-Day 336 | 5.9 1000 cells/cubic mm |
| T1: PGT121 + VRC07-523LS mo 0 | Chemistry and Hematology Laboratory Measures - Platelets, WBC in 1000 Cells/Cubic mm | Platelets (1000 cells/cubic mm)-Day 56 | 228.5 1000 cells/cubic mm |
| T1: PGT121 + VRC07-523LS mo 0 | Chemistry and Hematology Laboratory Measures - Platelets, WBC in 1000 Cells/Cubic mm | Platelets (1000 cells/cubic mm)-Baseline | 219.5 1000 cells/cubic mm |
| T1: PGT121 + VRC07-523LS mo 0 | Chemistry and Hematology Laboratory Measures - Platelets, WBC in 1000 Cells/Cubic mm | WBC (1000 cells/cubic mm)-Day 168 | 6.29 1000 cells/cubic mm |
| T1: PGT121 + VRC07-523LS mo 0 | Chemistry and Hematology Laboratory Measures - Platelets, WBC in 1000 Cells/Cubic mm | WBC (1000 cells/cubic mm)-Day 0 | 6.145 1000 cells/cubic mm |
| T1: PGT121 + VRC07-523LS mo 0 | Chemistry and Hematology Laboratory Measures - Platelets, WBC in 1000 Cells/Cubic mm | Platelets (1000 cells/cubic mm)-Day 224 | 158 1000 cells/cubic mm |
| T1: PGT121 + VRC07-523LS mo 0 | Chemistry and Hematology Laboratory Measures - Platelets, WBC in 1000 Cells/Cubic mm | Platelets (1000 cells/cubic mm)-Day 14 | 218.5 1000 cells/cubic mm |
| T1: PGT121 + VRC07-523LS mo 0 | Chemistry and Hematology Laboratory Measures - Platelets, WBC in 1000 Cells/Cubic mm | WBC (1000 cells/cubic mm)-Day 224 | 6.93 1000 cells/cubic mm |
| T1: PGT121 + VRC07-523LS mo 0 | Chemistry and Hematology Laboratory Measures - Platelets, WBC in 1000 Cells/Cubic mm | Platelets (1000 cells/cubic mm)-Day 336 | 233 1000 cells/cubic mm |
| T1: PGT121 + VRC07-523LS mo 0 | Chemistry and Hematology Laboratory Measures - Platelets, WBC in 1000 Cells/Cubic mm | Platelets (1000 cells/cubic mm)-Day 112 | 221.5 1000 cells/cubic mm |
| T2: PGDM1400 + VRC07-523LS mo 0 | Chemistry and Hematology Laboratory Measures - Platelets, WBC in 1000 Cells/Cubic mm | WBC (1000 cells/cubic mm)-Day 224 | 7.07 1000 cells/cubic mm |
| T2: PGDM1400 + VRC07-523LS mo 0 | Chemistry and Hematology Laboratory Measures - Platelets, WBC in 1000 Cells/Cubic mm | WBC (1000 cells/cubic mm)-Day 280 | 6.24 1000 cells/cubic mm |
| T2: PGDM1400 + VRC07-523LS mo 0 | Chemistry and Hematology Laboratory Measures - Platelets, WBC in 1000 Cells/Cubic mm | Platelets (1000 cells/cubic mm)-Day 0 | 317 1000 cells/cubic mm |
| T2: PGDM1400 + VRC07-523LS mo 0 | Chemistry and Hematology Laboratory Measures - Platelets, WBC in 1000 Cells/Cubic mm | WBC (1000 cells/cubic mm)-Day 336 | 5.18 1000 cells/cubic mm |
| T2: PGDM1400 + VRC07-523LS mo 0 | Chemistry and Hematology Laboratory Measures - Platelets, WBC in 1000 Cells/Cubic mm | Platelets (1000 cells/cubic mm)-Day 168 | 380 1000 cells/cubic mm |
| T2: PGDM1400 + VRC07-523LS mo 0 | Chemistry and Hematology Laboratory Measures - Platelets, WBC in 1000 Cells/Cubic mm | Platelets (1000 cells/cubic mm)-Baseline | 303 1000 cells/cubic mm |
| T2: PGDM1400 + VRC07-523LS mo 0 | Chemistry and Hematology Laboratory Measures - Platelets, WBC in 1000 Cells/Cubic mm | Platelets (1000 cells/cubic mm)-Day 280 | 361 1000 cells/cubic mm |
| T2: PGDM1400 + VRC07-523LS mo 0 | Chemistry and Hematology Laboratory Measures - Platelets, WBC in 1000 Cells/Cubic mm | WBC (1000 cells/cubic mm)-Baseline | 6.615 1000 cells/cubic mm |
| T2: PGDM1400 + VRC07-523LS mo 0 | Chemistry and Hematology Laboratory Measures - Platelets, WBC in 1000 Cells/Cubic mm | Platelets (1000 cells/cubic mm)-Day 336 | 373.5 1000 cells/cubic mm |
| T2: PGDM1400 + VRC07-523LS mo 0 | Chemistry and Hematology Laboratory Measures - Platelets, WBC in 1000 Cells/Cubic mm | Platelets (1000 cells/cubic mm)-Day 112 | 349 1000 cells/cubic mm |
| T2: PGDM1400 + VRC07-523LS mo 0 | Chemistry and Hematology Laboratory Measures - Platelets, WBC in 1000 Cells/Cubic mm | WBC (1000 cells/cubic mm)-Day 0 | 5.665 1000 cells/cubic mm |
| T2: PGDM1400 + VRC07-523LS mo 0 | Chemistry and Hematology Laboratory Measures - Platelets, WBC in 1000 Cells/Cubic mm | WBC (1000 cells/cubic mm)-Day 14 | 6.645 1000 cells/cubic mm |
| T2: PGDM1400 + VRC07-523LS mo 0 | Chemistry and Hematology Laboratory Measures - Platelets, WBC in 1000 Cells/Cubic mm | Platelets (1000 cells/cubic mm)-Day 56 | 327.5 1000 cells/cubic mm |
| T2: PGDM1400 + VRC07-523LS mo 0 | Chemistry and Hematology Laboratory Measures - Platelets, WBC in 1000 Cells/Cubic mm | WBC (1000 cells/cubic mm)-Day 56 | 5.985 1000 cells/cubic mm |
| T2: PGDM1400 + VRC07-523LS mo 0 | Chemistry and Hematology Laboratory Measures - Platelets, WBC in 1000 Cells/Cubic mm | WBC (1000 cells/cubic mm)-Day 112 | 6.4 1000 cells/cubic mm |
| T2: PGDM1400 + VRC07-523LS mo 0 | Chemistry and Hematology Laboratory Measures - Platelets, WBC in 1000 Cells/Cubic mm | Platelets (1000 cells/cubic mm)-Day 14 | 291 1000 cells/cubic mm |
| T2: PGDM1400 + VRC07-523LS mo 0 | Chemistry and Hematology Laboratory Measures - Platelets, WBC in 1000 Cells/Cubic mm | WBC (1000 cells/cubic mm)-Day 168 | 6.9 1000 cells/cubic mm |
| T2: PGDM1400 + VRC07-523LS mo 0 | Chemistry and Hematology Laboratory Measures - Platelets, WBC in 1000 Cells/Cubic mm | Platelets (1000 cells/cubic mm)-Day 224 | 336 1000 cells/cubic mm |
| T3: 10-1074 + VRC07-523LS | Chemistry and Hematology Laboratory Measures - Platelets, WBC in 1000 Cells/Cubic mm | WBC (1000 cells/cubic mm)-Day 56 | 5.6 1000 cells/cubic mm |
| T3: 10-1074 + VRC07-523LS | Chemistry and Hematology Laboratory Measures - Platelets, WBC in 1000 Cells/Cubic mm | WBC (1000 cells/cubic mm)-Baseline | 5.6 1000 cells/cubic mm |
| T3: 10-1074 + VRC07-523LS | Chemistry and Hematology Laboratory Measures - Platelets, WBC in 1000 Cells/Cubic mm | WBC (1000 cells/cubic mm)-Day 0 | 5.4 1000 cells/cubic mm |
| T3: 10-1074 + VRC07-523LS | Chemistry and Hematology Laboratory Measures - Platelets, WBC in 1000 Cells/Cubic mm | WBC (1000 cells/cubic mm)-Day 14 | 6.27 1000 cells/cubic mm |
| T3: 10-1074 + VRC07-523LS | Chemistry and Hematology Laboratory Measures - Platelets, WBC in 1000 Cells/Cubic mm | WBC (1000 cells/cubic mm)-Day 112 | 4.9 1000 cells/cubic mm |
| T3: 10-1074 + VRC07-523LS | Chemistry and Hematology Laboratory Measures - Platelets, WBC in 1000 Cells/Cubic mm | WBC (1000 cells/cubic mm)-Day 168 | 5.35 1000 cells/cubic mm |
| T3: 10-1074 + VRC07-523LS | Chemistry and Hematology Laboratory Measures - Platelets, WBC in 1000 Cells/Cubic mm | WBC (1000 cells/cubic mm)-Day 280 | 5.9 1000 cells/cubic mm |
| T3: 10-1074 + VRC07-523LS | Chemistry and Hematology Laboratory Measures - Platelets, WBC in 1000 Cells/Cubic mm | WBC (1000 cells/cubic mm)-Day 336 | 5.1 1000 cells/cubic mm |
| T3: 10-1074 + VRC07-523LS | Chemistry and Hematology Laboratory Measures - Platelets, WBC in 1000 Cells/Cubic mm | Platelets (1000 cells/cubic mm)-Baseline | 245.5 1000 cells/cubic mm |
| T3: 10-1074 + VRC07-523LS | Chemistry and Hematology Laboratory Measures - Platelets, WBC in 1000 Cells/Cubic mm | Platelets (1000 cells/cubic mm)-Day 0 | 241.5 1000 cells/cubic mm |
| T3: 10-1074 + VRC07-523LS | Chemistry and Hematology Laboratory Measures - Platelets, WBC in 1000 Cells/Cubic mm | Platelets (1000 cells/cubic mm)-Day 14 | 244.5 1000 cells/cubic mm |
| T3: 10-1074 + VRC07-523LS | Chemistry and Hematology Laboratory Measures - Platelets, WBC in 1000 Cells/Cubic mm | Platelets (1000 cells/cubic mm)-Day 56 | 278 1000 cells/cubic mm |
| T3: 10-1074 + VRC07-523LS | Chemistry and Hematology Laboratory Measures - Platelets, WBC in 1000 Cells/Cubic mm | Platelets (1000 cells/cubic mm)-Day 112 | 259 1000 cells/cubic mm |
| T3: 10-1074 + VRC07-523LS | Chemistry and Hematology Laboratory Measures - Platelets, WBC in 1000 Cells/Cubic mm | Platelets (1000 cells/cubic mm)-Day 168 | 239 1000 cells/cubic mm |
| T3: 10-1074 + VRC07-523LS | Chemistry and Hematology Laboratory Measures - Platelets, WBC in 1000 Cells/Cubic mm | Platelets (1000 cells/cubic mm)-Day 280 | 218 1000 cells/cubic mm |
| T3: 10-1074 + VRC07-523LS | Chemistry and Hematology Laboratory Measures - Platelets, WBC in 1000 Cells/Cubic mm | Platelets (1000 cells/cubic mm)-Day 336 | 249 1000 cells/cubic mm |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Chemistry and Hematology Laboratory Measures - Platelets, WBC in 1000 Cells/Cubic mm | WBC (1000 cells/cubic mm)-Day 140 | 6.3 1000 cells/cubic mm |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Chemistry and Hematology Laboratory Measures - Platelets, WBC in 1000 Cells/Cubic mm | Platelets (1000 cells/cubic mm)-Day 280 | 254 1000 cells/cubic mm |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Chemistry and Hematology Laboratory Measures - Platelets, WBC in 1000 Cells/Cubic mm | Platelets (1000 cells/cubic mm)-Day 14 | 250 1000 cells/cubic mm |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Chemistry and Hematology Laboratory Measures - Platelets, WBC in 1000 Cells/Cubic mm | WBC (1000 cells/cubic mm)-Day 112 | 6.15 1000 cells/cubic mm |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Chemistry and Hematology Laboratory Measures - Platelets, WBC in 1000 Cells/Cubic mm | WBC (1000 cells/cubic mm)-Day 14 | 7.49 1000 cells/cubic mm |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Chemistry and Hematology Laboratory Measures - Platelets, WBC in 1000 Cells/Cubic mm | WBC (1000 cells/cubic mm)-Day 84 | 6.5 1000 cells/cubic mm |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Chemistry and Hematology Laboratory Measures - Platelets, WBC in 1000 Cells/Cubic mm | Platelets (1000 cells/cubic mm)-Day 56 | 288 1000 cells/cubic mm |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Chemistry and Hematology Laboratory Measures - Platelets, WBC in 1000 Cells/Cubic mm | Platelets (1000 cells/cubic mm)-Day 84 | 259 1000 cells/cubic mm |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Chemistry and Hematology Laboratory Measures - Platelets, WBC in 1000 Cells/Cubic mm | WBC (1000 cells/cubic mm)-Day 0 | 6.53 1000 cells/cubic mm |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Chemistry and Hematology Laboratory Measures - Platelets, WBC in 1000 Cells/Cubic mm | WBC (1000 cells/cubic mm)-Baseline | 6.1 1000 cells/cubic mm |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Chemistry and Hematology Laboratory Measures - Platelets, WBC in 1000 Cells/Cubic mm | WBC (1000 cells/cubic mm)-Day 56 | 7.8 1000 cells/cubic mm |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Chemistry and Hematology Laboratory Measures - Platelets, WBC in 1000 Cells/Cubic mm | Platelets (1000 cells/cubic mm)-Day 112 | 243 1000 cells/cubic mm |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Chemistry and Hematology Laboratory Measures - Platelets, WBC in 1000 Cells/Cubic mm | Platelets (1000 cells/cubic mm)-Day 140 | 195 1000 cells/cubic mm |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Chemistry and Hematology Laboratory Measures - Platelets, WBC in 1000 Cells/Cubic mm | Platelets (1000 cells/cubic mm)-Day 392 | 264.5 1000 cells/cubic mm |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Chemistry and Hematology Laboratory Measures - Platelets, WBC in 1000 Cells/Cubic mm | Platelets (1000 cells/cubic mm)-Day 224 | 250.5 1000 cells/cubic mm |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Chemistry and Hematology Laboratory Measures - Platelets, WBC in 1000 Cells/Cubic mm | Platelets (1000 cells/cubic mm)-Day 448 | 246 1000 cells/cubic mm |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Chemistry and Hematology Laboratory Measures - Platelets, WBC in 1000 Cells/Cubic mm | Platelets (1000 cells/cubic mm)-Day 168 | 159 1000 cells/cubic mm |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Chemistry and Hematology Laboratory Measures - Platelets, WBC in 1000 Cells/Cubic mm | WBC (1000 cells/cubic mm)-Day 448 | 6.2 1000 cells/cubic mm |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Chemistry and Hematology Laboratory Measures - Platelets, WBC in 1000 Cells/Cubic mm | WBC (1000 cells/cubic mm)-Day 336 | 5.76 1000 cells/cubic mm |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Chemistry and Hematology Laboratory Measures - Platelets, WBC in 1000 Cells/Cubic mm | WBC (1000 cells/cubic mm)-Day 392 | 6.25 1000 cells/cubic mm |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Chemistry and Hematology Laboratory Measures - Platelets, WBC in 1000 Cells/Cubic mm | Platelets (1000 cells/cubic mm)-Baseline | 248 1000 cells/cubic mm |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Chemistry and Hematology Laboratory Measures - Platelets, WBC in 1000 Cells/Cubic mm | WBC (1000 cells/cubic mm)-Day 280 | 6.2 1000 cells/cubic mm |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Chemistry and Hematology Laboratory Measures - Platelets, WBC in 1000 Cells/Cubic mm | WBC (1000 cells/cubic mm)-Day 224 | 5.6 1000 cells/cubic mm |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Chemistry and Hematology Laboratory Measures - Platelets, WBC in 1000 Cells/Cubic mm | Platelets (1000 cells/cubic mm)-Day 336 | 242 1000 cells/cubic mm |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Chemistry and Hematology Laboratory Measures - Platelets, WBC in 1000 Cells/Cubic mm | Platelets (1000 cells/cubic mm)-Day 0 | 267 1000 cells/cubic mm |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Chemistry and Hematology Laboratory Measures - Platelets, WBC in 1000 Cells/Cubic mm | WBC (1000 cells/cubic mm)-Day 168 | 5.35 1000 cells/cubic mm |
Primary
Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration
Graded according to the Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events, Version 2.1 \[July 2017\]. The maximum grade observed for each symptom over the time frame is presented.
Time frame: Measured through 3 days after each vaccine dose at T1-T3: Day 0 and T4: Days 0, 112
| Arm | Measure | Group | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|---|
| T1: PGT121 + VRC07-523LS mo 0 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Erythema/redness | None | 6 Participants |
| T1: PGT121 + VRC07-523LS mo 0 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Erythema/redness | Not Gradable | 0 Participants |
| T1: PGT121 + VRC07-523LS mo 0 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Erythema/redness | Gr 1: 2.5 to less than 5 cm dim. | 0 Participants |
| T1: PGT121 + VRC07-523LS mo 0 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Erythema/redness | Gr 2: 5 to less than 10 cm dim. | 0 Participants |
| T1: PGT121 + VRC07-523LS mo 0 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Erythema/redness | Gr 3: >=10 cm dim. | 0 Participants |
| T1: PGT121 + VRC07-523LS mo 0 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Erythema/redness | Gr 3: Complications AE | 0 Participants |
| T1: PGT121 + VRC07-523LS mo 0 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Erythema/redness | Gr 4: Complications AE | 0 Participants |
| T1: PGT121 + VRC07-523LS mo 0 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Induration/swelling | None | 5 Participants |
| T1: PGT121 + VRC07-523LS mo 0 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Induration/swelling | Not Gradable | 1 Participants |
| T1: PGT121 + VRC07-523LS mo 0 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Induration/swelling | Gr 1: 2.5 to less than 5 cm dim. | 0 Participants |
| T1: PGT121 + VRC07-523LS mo 0 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Induration/swelling | Gr 2: 5 to less than 10 cm dim. | 0 Participants |
| T1: PGT121 + VRC07-523LS mo 0 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Induration/swelling | Gr 3: >=10 cm dim. | 0 Participants |
| T1: PGT121 + VRC07-523LS mo 0 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Induration/swelling | Gr 3: Complications AE | 0 Participants |
| T1: PGT121 + VRC07-523LS mo 0 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Induration/swelling | Gr 4: Complications AE | 0 Participants |
| T1: PGT121 + VRC07-523LS mo 0 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Erythema and/or Induration | None | 5 Participants |
| T1: PGT121 + VRC07-523LS mo 0 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Erythema and/or Induration | Not Gradable | 1 Participants |
| T1: PGT121 + VRC07-523LS mo 0 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Erythema and/or Induration | Gr 1: 2.5 to less than 5 cm dim. | 0 Participants |
| T1: PGT121 + VRC07-523LS mo 0 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Erythema and/or Induration | Gr 2: 5 to less than 10 cm dim. | 0 Participants |
| T1: PGT121 + VRC07-523LS mo 0 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Erythema and/or Induration | Gr 3: >=10 cm dim. | 0 Participants |
| T1: PGT121 + VRC07-523LS mo 0 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Erythema and/or Induration | Gr 3: Complications AE | 0 Participants |
| T1: PGT121 + VRC07-523LS mo 0 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Erythema and/or Induration | Gr 4: Complications AE | 0 Participants |
| T2: PGDM1400 + VRC07-523LS mo 0 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Erythema and/or Induration | Gr 2: 5 to less than 10 cm dim. | 0 Participants |
| T2: PGDM1400 + VRC07-523LS mo 0 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Erythema/redness | None | 6 Participants |
| T2: PGDM1400 + VRC07-523LS mo 0 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Induration/swelling | None | 6 Participants |
| T2: PGDM1400 + VRC07-523LS mo 0 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Induration/swelling | Gr 3: >=10 cm dim. | 0 Participants |
| T2: PGDM1400 + VRC07-523LS mo 0 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Erythema/redness | Gr 4: Complications AE | 0 Participants |
| T2: PGDM1400 + VRC07-523LS mo 0 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Erythema and/or Induration | Not Gradable | 0 Participants |
| T2: PGDM1400 + VRC07-523LS mo 0 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Erythema and/or Induration | None | 6 Participants |
| T2: PGDM1400 + VRC07-523LS mo 0 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Induration/swelling | Gr 3: Complications AE | 0 Participants |
| T2: PGDM1400 + VRC07-523LS mo 0 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Erythema/redness | Gr 1: 2.5 to less than 5 cm dim. | 0 Participants |
| T2: PGDM1400 + VRC07-523LS mo 0 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Erythema and/or Induration | Gr 3: Complications AE | 0 Participants |
| T2: PGDM1400 + VRC07-523LS mo 0 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Erythema and/or Induration | Gr 1: 2.5 to less than 5 cm dim. | 0 Participants |
| T2: PGDM1400 + VRC07-523LS mo 0 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Induration/swelling | Gr 4: Complications AE | 0 Participants |
| T2: PGDM1400 + VRC07-523LS mo 0 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Induration/swelling | Not Gradable | 0 Participants |
| T2: PGDM1400 + VRC07-523LS mo 0 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Erythema/redness | Gr 3: >=10 cm dim. | 0 Participants |
| T2: PGDM1400 + VRC07-523LS mo 0 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Erythema/redness | Gr 3: Complications AE | 0 Participants |
| T2: PGDM1400 + VRC07-523LS mo 0 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Erythema and/or Induration | Gr 4: Complications AE | 0 Participants |
| T2: PGDM1400 + VRC07-523LS mo 0 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Induration/swelling | Gr 1: 2.5 to less than 5 cm dim. | 0 Participants |
| T2: PGDM1400 + VRC07-523LS mo 0 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Erythema/redness | Gr 2: 5 to less than 10 cm dim. | 0 Participants |
| T2: PGDM1400 + VRC07-523LS mo 0 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Erythema/redness | Not Gradable | 0 Participants |
| T2: PGDM1400 + VRC07-523LS mo 0 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Erythema and/or Induration | Gr 3: >=10 cm dim. | 0 Participants |
| T2: PGDM1400 + VRC07-523LS mo 0 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Induration/swelling | Gr 2: 5 to less than 10 cm dim. | 0 Participants |
| T3: 10-1074 + VRC07-523LS | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Erythema/redness | Not Gradable | 0 Participants |
| T3: 10-1074 + VRC07-523LS | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Erythema/redness | Gr 3: Complications AE | 0 Participants |
| T3: 10-1074 + VRC07-523LS | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Erythema/redness | Gr 4: Complications AE | 0 Participants |
| T3: 10-1074 + VRC07-523LS | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Erythema and/or Induration | Gr 2: 5 to less than 10 cm dim. | 0 Participants |
| T3: 10-1074 + VRC07-523LS | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Induration/swelling | None | 6 Participants |
| T3: 10-1074 + VRC07-523LS | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Induration/swelling | Not Gradable | 0 Participants |
| T3: 10-1074 + VRC07-523LS | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Induration/swelling | Gr 1: 2.5 to less than 5 cm dim. | 0 Participants |
| T3: 10-1074 + VRC07-523LS | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Induration/swelling | Gr 2: 5 to less than 10 cm dim. | 0 Participants |
| T3: 10-1074 + VRC07-523LS | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Erythema and/or Induration | Gr 3: >=10 cm dim. | 0 Participants |
| T3: 10-1074 + VRC07-523LS | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Induration/swelling | Gr 3: >=10 cm dim. | 0 Participants |
| T3: 10-1074 + VRC07-523LS | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Induration/swelling | Gr 3: Complications AE | 0 Participants |
| T3: 10-1074 + VRC07-523LS | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Erythema and/or Induration | Gr 4: Complications AE | 0 Participants |
| T3: 10-1074 + VRC07-523LS | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Induration/swelling | Gr 4: Complications AE | 0 Participants |
| T3: 10-1074 + VRC07-523LS | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Erythema and/or Induration | None | 6 Participants |
| T3: 10-1074 + VRC07-523LS | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Erythema and/or Induration | Gr 3: Complications AE | 0 Participants |
| T3: 10-1074 + VRC07-523LS | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Erythema and/or Induration | Not Gradable | 0 Participants |
| T3: 10-1074 + VRC07-523LS | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Erythema/redness | None | 6 Participants |
| T3: 10-1074 + VRC07-523LS | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Erythema/redness | Gr 1: 2.5 to less than 5 cm dim. | 0 Participants |
| T3: 10-1074 + VRC07-523LS | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Erythema and/or Induration | Gr 1: 2.5 to less than 5 cm dim. | 0 Participants |
| T3: 10-1074 + VRC07-523LS | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Erythema/redness | Gr 2: 5 to less than 10 cm dim. | 0 Participants |
| T3: 10-1074 + VRC07-523LS | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Erythema/redness | Gr 3: >=10 cm dim. | 0 Participants |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Erythema and/or Induration | Not Gradable | 0 Participants |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Induration/swelling | Gr 2: 5 to less than 10 cm dim. | 0 Participants |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Erythema and/or Induration | Gr 1: 2.5 to less than 5 cm dim. | 0 Participants |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Erythema/redness | None | 9 Participants |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Erythema and/or Induration | Gr 3: Complications AE | 0 Participants |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Induration/swelling | Gr 1: 2.5 to less than 5 cm dim. | 0 Participants |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Induration/swelling | Not Gradable | 0 Participants |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Erythema/redness | Not Gradable | 0 Participants |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Erythema and/or Induration | Gr 2: 5 to less than 10 cm dim. | 0 Participants |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Induration/swelling | None | 9 Participants |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Erythema/redness | Gr 3: Complications AE | 0 Participants |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Erythema/redness | Gr 1: 2.5 to less than 5 cm dim. | 0 Participants |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Erythema and/or Induration | Gr 4: Complications AE | 0 Participants |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Induration/swelling | Gr 4: Complications AE | 0 Participants |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Induration/swelling | Gr 3: Complications AE | 0 Participants |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Erythema and/or Induration | Gr 3: >=10 cm dim. | 0 Participants |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Erythema/redness | Gr 4: Complications AE | 0 Participants |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Erythema and/or Induration | None | 9 Participants |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Erythema/redness | Gr 3: >=10 cm dim. | 0 Participants |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Induration/swelling | Gr 3: >=10 cm dim. | 0 Participants |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration | Erythema/redness | Gr 2: 5 to less than 10 cm dim. | 0 Participants |
Primary
Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Pain and/or Tenderness
Graded according to the Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events, Version 2.1 \[July 2017\]. The maximum grade observed for each symptom over the time frame is presented.
Time frame: Measured through 3 days after each vaccine dose at T1-T3: Day 0 and T4: Days 0, 112
| Arm | Measure | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| T1: PGT121 + VRC07-523LS mo 0 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Pain and/or Tenderness | Severe | 0 Participants |
| T1: PGT121 + VRC07-523LS mo 0 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Pain and/or Tenderness | Mild | 1 Participants |
| T1: PGT121 + VRC07-523LS mo 0 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Pain and/or Tenderness | Potentially life-threatening | 0 Participants |
| T1: PGT121 + VRC07-523LS mo 0 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Pain and/or Tenderness | Moderate | 0 Participants |
| T1: PGT121 + VRC07-523LS mo 0 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Pain and/or Tenderness | None | 5 Participants |
| T2: PGDM1400 + VRC07-523LS mo 0 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Pain and/or Tenderness | Moderate | 0 Participants |
| T2: PGDM1400 + VRC07-523LS mo 0 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Pain and/or Tenderness | Severe | 0 Participants |
| T2: PGDM1400 + VRC07-523LS mo 0 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Pain and/or Tenderness | Potentially life-threatening | 0 Participants |
| T2: PGDM1400 + VRC07-523LS mo 0 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Pain and/or Tenderness | Mild | 0 Participants |
| T2: PGDM1400 + VRC07-523LS mo 0 | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Pain and/or Tenderness | None | 6 Participants |
| T3: 10-1074 + VRC07-523LS | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Pain and/or Tenderness | Moderate | 0 Participants |
| T3: 10-1074 + VRC07-523LS | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Pain and/or Tenderness | None | 6 Participants |
| T3: 10-1074 + VRC07-523LS | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Pain and/or Tenderness | Mild | 0 Participants |
| T3: 10-1074 + VRC07-523LS | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Pain and/or Tenderness | Severe | 0 Participants |
| T3: 10-1074 + VRC07-523LS | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Pain and/or Tenderness | Potentially life-threatening | 0 Participants |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Pain and/or Tenderness | Severe | 0 Participants |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Pain and/or Tenderness | Mild | 2 Participants |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Pain and/or Tenderness | None | 7 Participants |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Pain and/or Tenderness | Moderate | 0 Participants |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Pain and/or Tenderness | Potentially life-threatening | 0 Participants |
Primary
Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms
Graded according to the Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events, Version 2.1 \[July 2017\]. The following symptoms are considered as systemic reactogenicity if the onset date was within the periods of assessment specified in the protocol: malaise and/or fatigue, myalgia, headache, nausea, vomiting, chills, arthralgia, and body temperature. The item Max. Systemic Symptoms is the maximum of the individual systemic reactogenicities excluding body temperature for a participant.
Time frame: Measured through 3 days after each vaccine dose at T1-T3: Day 0 and T4: Days 0, 112
| Arm | Measure | Group | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|---|
| T1: PGT121 + VRC07-523LS mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Temperature (C) | None | 6 Participants |
| T1: PGT121 + VRC07-523LS mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Max. Systemic Symptoms | Moderate | 1 Participants |
| T1: PGT121 + VRC07-523LS mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Unexplained diaphoresis | Moderate | 0 Participants |
| T1: PGT121 + VRC07-523LS mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Generalized pruritus | None | 6 Participants |
| T1: PGT121 + VRC07-523LS mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Facial flushing | Potentially life-threatening | 0 Participants |
| T1: PGT121 + VRC07-523LS mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Max. Systemic Symptoms | Severe | 0 Participants |
| T1: PGT121 + VRC07-523LS mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Facial flushing | Severe | 0 Participants |
| T1: PGT121 + VRC07-523LS mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Facial flushing | Moderate | 0 Participants |
| T1: PGT121 + VRC07-523LS mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Temperature (C) | Moderate | 0 Participants |
| T1: PGT121 + VRC07-523LS mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Max. Systemic Symptoms | Potentially life-threatening | 0 Participants |
| T1: PGT121 + VRC07-523LS mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Nausea | None | 6 Participants |
| T1: PGT121 + VRC07-523LS mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Facial flushing | Mild | 0 Participants |
| T1: PGT121 + VRC07-523LS mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Increased body temperature | Potentially life-threatening | 0 Participants |
| T1: PGT121 + VRC07-523LS mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Increased body temperature | Mild | 0 Participants |
| T1: PGT121 + VRC07-523LS mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Temperature (C) | Mild | 0 Participants |
| T1: PGT121 + VRC07-523LS mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Urticaria | Potentially life-threatening | 0 Participants |
| T1: PGT121 + VRC07-523LS mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Facial flushing | None | 6 Participants |
| T1: PGT121 + VRC07-523LS mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Chills | Potentially life-threatening | 0 Participants |
| T1: PGT121 + VRC07-523LS mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Temperature (C) | Severe | 0 Participants |
| T1: PGT121 + VRC07-523LS mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Nausea | Mild | 0 Participants |
| T1: PGT121 + VRC07-523LS mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Chills | Severe | 0 Participants |
| T1: PGT121 + VRC07-523LS mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Unexplained diaphoresis | None | 6 Participants |
| T1: PGT121 + VRC07-523LS mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Unexplained diaphoresis | Mild | 0 Participants |
| T1: PGT121 + VRC07-523LS mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Chills | Moderate | 0 Participants |
| T1: PGT121 + VRC07-523LS mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Arthralgia | None | 5 Participants |
| T1: PGT121 + VRC07-523LS mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Nausea | Moderate | 0 Participants |
| T1: PGT121 + VRC07-523LS mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Headache | None | 3 Participants |
| T1: PGT121 + VRC07-523LS mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Non-exertional dyspnea | Moderate | 0 Participants |
| T1: PGT121 + VRC07-523LS mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Arthralgia | Mild | 1 Participants |
| T1: PGT121 + VRC07-523LS mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Myalgia | Mild | 0 Participants |
| T1: PGT121 + VRC07-523LS mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Chills | Mild | 0 Participants |
| T1: PGT121 + VRC07-523LS mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Temperature (C) | Potentially life-threatening | 0 Participants |
| T1: PGT121 + VRC07-523LS mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Arthralgia | Moderate | 0 Participants |
| T1: PGT121 + VRC07-523LS mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Increased body temperature | None | 6 Participants |
| T1: PGT121 + VRC07-523LS mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Chills | None | 6 Participants |
| T1: PGT121 + VRC07-523LS mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Arthralgia | Potentially life-threatening | 0 Participants |
| T1: PGT121 + VRC07-523LS mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Arthralgia | Severe | 0 Participants |
| T1: PGT121 + VRC07-523LS mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Malaise and/or fatigue | Mild | 1 Participants |
| T1: PGT121 + VRC07-523LS mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Nausea | Severe | 0 Participants |
| T1: PGT121 + VRC07-523LS mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Increased body temperature | Severe | 0 Participants |
| T1: PGT121 + VRC07-523LS mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Malaise and/or fatigue | Moderate | 0 Participants |
| T1: PGT121 + VRC07-523LS mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Headache | Potentially life-threatening | 0 Participants |
| T1: PGT121 + VRC07-523LS mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Nausea | Potentially life-threatening | 0 Participants |
| T1: PGT121 + VRC07-523LS mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Urticaria | Severe | 0 Participants |
| T1: PGT121 + VRC07-523LS mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Urticaria | None | 6 Participants |
| T1: PGT121 + VRC07-523LS mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Myalgia | Moderate | 1 Participants |
| T1: PGT121 + VRC07-523LS mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Non-exertional dyspnea | None | 6 Participants |
| T1: PGT121 + VRC07-523LS mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Malaise and/or fatigue | Potentially life-threatening | 0 Participants |
| T1: PGT121 + VRC07-523LS mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Headache | Severe | 0 Participants |
| T1: PGT121 + VRC07-523LS mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Urticaria | Mild | 0 Participants |
| T1: PGT121 + VRC07-523LS mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Non-exertional dyspnea | Mild | 0 Participants |
| T1: PGT121 + VRC07-523LS mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Malaise and/or fatigue | Severe | 0 Participants |
| T1: PGT121 + VRC07-523LS mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Headache | Moderate | 0 Participants |
| T1: PGT121 + VRC07-523LS mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Headache | Mild | 3 Participants |
| T1: PGT121 + VRC07-523LS mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Non-exertional dyspnea | Severe | 0 Participants |
| T1: PGT121 + VRC07-523LS mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Myalgia | Severe | 0 Participants |
| T1: PGT121 + VRC07-523LS mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Unexplained diaphoresis | Potentially life-threatening | 0 Participants |
| T1: PGT121 + VRC07-523LS mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Max. Systemic Symptoms | None | 3 Participants |
| T1: PGT121 + VRC07-523LS mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Generalized pruritus | Potentially life-threatening | 0 Participants |
| T1: PGT121 + VRC07-523LS mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Non-exertional dyspnea | Potentially life-threatening | 0 Participants |
| T1: PGT121 + VRC07-523LS mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Malaise and/or fatigue | None | 5 Participants |
| T1: PGT121 + VRC07-523LS mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Myalgia | None | 5 Participants |
| T1: PGT121 + VRC07-523LS mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Max. Systemic Symptoms | Mild | 2 Participants |
| T1: PGT121 + VRC07-523LS mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Non-exertional tachycardia | None | 6 Participants |
| T1: PGT121 + VRC07-523LS mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Non-exertional tachycardia | Mild | 0 Participants |
| T1: PGT121 + VRC07-523LS mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Increased body temperature | Moderate | 0 Participants |
| T1: PGT121 + VRC07-523LS mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Generalized pruritus | Severe | 0 Participants |
| T1: PGT121 + VRC07-523LS mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Non-exertional tachycardia | Moderate | 0 Participants |
| T1: PGT121 + VRC07-523LS mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Myalgia | Potentially life-threatening | 0 Participants |
| T1: PGT121 + VRC07-523LS mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Generalized pruritus | Moderate | 0 Participants |
| T1: PGT121 + VRC07-523LS mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Urticaria | Moderate | 0 Participants |
| T1: PGT121 + VRC07-523LS mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Non-exertional tachycardia | Severe | 0 Participants |
| T1: PGT121 + VRC07-523LS mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Non-exertional tachycardia | Potentially life-threatening | 0 Participants |
| T1: PGT121 + VRC07-523LS mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Generalized pruritus | Mild | 0 Participants |
| T1: PGT121 + VRC07-523LS mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Unexplained diaphoresis | Severe | 0 Participants |
| T2: PGDM1400 + VRC07-523LS mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Urticaria | None | 6 Participants |
| T2: PGDM1400 + VRC07-523LS mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Malaise and/or fatigue | Moderate | 1 Participants |
| T2: PGDM1400 + VRC07-523LS mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Urticaria | Moderate | 0 Participants |
| T2: PGDM1400 + VRC07-523LS mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Malaise and/or fatigue | Severe | 0 Participants |
| T2: PGDM1400 + VRC07-523LS mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Malaise and/or fatigue | Potentially life-threatening | 0 Participants |
| T2: PGDM1400 + VRC07-523LS mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Myalgia | None | 5 Participants |
| T2: PGDM1400 + VRC07-523LS mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Myalgia | Mild | 1 Participants |
| T2: PGDM1400 + VRC07-523LS mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Myalgia | Moderate | 0 Participants |
| T2: PGDM1400 + VRC07-523LS mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Urticaria | Severe | 0 Participants |
| T2: PGDM1400 + VRC07-523LS mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Myalgia | Severe | 0 Participants |
| T2: PGDM1400 + VRC07-523LS mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Myalgia | Potentially life-threatening | 0 Participants |
| T2: PGDM1400 + VRC07-523LS mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Nausea | None | 5 Participants |
| T2: PGDM1400 + VRC07-523LS mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Nausea | Mild | 1 Participants |
| T2: PGDM1400 + VRC07-523LS mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Nausea | Moderate | 0 Participants |
| T2: PGDM1400 + VRC07-523LS mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Urticaria | Potentially life-threatening | 0 Participants |
| T2: PGDM1400 + VRC07-523LS mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Nausea | Severe | 0 Participants |
| T2: PGDM1400 + VRC07-523LS mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Nausea | Potentially life-threatening | 0 Participants |
| T2: PGDM1400 + VRC07-523LS mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Max. Systemic Symptoms | Severe | 0 Participants |
| T2: PGDM1400 + VRC07-523LS mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Non-exertional dyspnea | None | 6 Participants |
| T2: PGDM1400 + VRC07-523LS mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Max. Systemic Symptoms | None | 1 Participants |
| T2: PGDM1400 + VRC07-523LS mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Non-exertional dyspnea | Mild | 0 Participants |
| T2: PGDM1400 + VRC07-523LS mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Non-exertional dyspnea | Moderate | 0 Participants |
| T2: PGDM1400 + VRC07-523LS mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Non-exertional dyspnea | Potentially life-threatening | 0 Participants |
| T2: PGDM1400 + VRC07-523LS mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Non-exertional tachycardia | Mild | 0 Participants |
| T2: PGDM1400 + VRC07-523LS mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Non-exertional tachycardia | Moderate | 0 Participants |
| T2: PGDM1400 + VRC07-523LS mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Max. Systemic Symptoms | Mild | 3 Participants |
| T2: PGDM1400 + VRC07-523LS mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Non-exertional tachycardia | Severe | 0 Participants |
| T2: PGDM1400 + VRC07-523LS mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Max. Systemic Symptoms | Moderate | 2 Participants |
| T2: PGDM1400 + VRC07-523LS mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Max. Systemic Symptoms | Potentially life-threatening | 0 Participants |
| T2: PGDM1400 + VRC07-523LS mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Temperature (C) | Moderate | 0 Participants |
| T2: PGDM1400 + VRC07-523LS mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Temperature (C) | None | 6 Participants |
| T2: PGDM1400 + VRC07-523LS mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Temperature (C) | Mild | 0 Participants |
| T2: PGDM1400 + VRC07-523LS mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Temperature (C) | Severe | 0 Participants |
| T2: PGDM1400 + VRC07-523LS mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Temperature (C) | Potentially life-threatening | 0 Participants |
| T2: PGDM1400 + VRC07-523LS mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Arthralgia | None | 5 Participants |
| T2: PGDM1400 + VRC07-523LS mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Arthralgia | Mild | 1 Participants |
| T2: PGDM1400 + VRC07-523LS mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Arthralgia | Moderate | 0 Participants |
| T2: PGDM1400 + VRC07-523LS mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Arthralgia | Severe | 0 Participants |
| T2: PGDM1400 + VRC07-523LS mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Non-exertional dyspnea | Severe | 0 Participants |
| T2: PGDM1400 + VRC07-523LS mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Arthralgia | Potentially life-threatening | 0 Participants |
| T2: PGDM1400 + VRC07-523LS mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Unexplained diaphoresis | None | 6 Participants |
| T2: PGDM1400 + VRC07-523LS mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Chills | None | 4 Participants |
| T2: PGDM1400 + VRC07-523LS mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Chills | Mild | 1 Participants |
| T2: PGDM1400 + VRC07-523LS mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Chills | Moderate | 1 Participants |
| T2: PGDM1400 + VRC07-523LS mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Chills | Severe | 0 Participants |
| T2: PGDM1400 + VRC07-523LS mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Unexplained diaphoresis | Mild | 0 Participants |
| T2: PGDM1400 + VRC07-523LS mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Chills | Potentially life-threatening | 0 Participants |
| T2: PGDM1400 + VRC07-523LS mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Facial flushing | None | 5 Participants |
| T2: PGDM1400 + VRC07-523LS mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Non-exertional tachycardia | None | 6 Participants |
| T2: PGDM1400 + VRC07-523LS mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Facial flushing | Mild | 1 Participants |
| T2: PGDM1400 + VRC07-523LS mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Facial flushing | Moderate | 0 Participants |
| T2: PGDM1400 + VRC07-523LS mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Unexplained diaphoresis | Moderate | 0 Participants |
| T2: PGDM1400 + VRC07-523LS mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Facial flushing | Severe | 0 Participants |
| T2: PGDM1400 + VRC07-523LS mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Facial flushing | Potentially life-threatening | 0 Participants |
| T2: PGDM1400 + VRC07-523LS mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Generalized pruritus | None | 6 Participants |
| T2: PGDM1400 + VRC07-523LS mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Generalized pruritus | Mild | 0 Participants |
| T2: PGDM1400 + VRC07-523LS mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Unexplained diaphoresis | Severe | 0 Participants |
| T2: PGDM1400 + VRC07-523LS mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Generalized pruritus | Moderate | 0 Participants |
| T2: PGDM1400 + VRC07-523LS mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Generalized pruritus | Severe | 0 Participants |
| T2: PGDM1400 + VRC07-523LS mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Generalized pruritus | Potentially life-threatening | 0 Participants |
| T2: PGDM1400 + VRC07-523LS mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Headache | None | 4 Participants |
| T2: PGDM1400 + VRC07-523LS mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Unexplained diaphoresis | Potentially life-threatening | 0 Participants |
| T2: PGDM1400 + VRC07-523LS mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Headache | Mild | 2 Participants |
| T2: PGDM1400 + VRC07-523LS mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Headache | Moderate | 0 Participants |
| T2: PGDM1400 + VRC07-523LS mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Headache | Severe | 0 Participants |
| T2: PGDM1400 + VRC07-523LS mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Headache | Potentially life-threatening | 0 Participants |
| T2: PGDM1400 + VRC07-523LS mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Increased body temperature | None | 6 Participants |
| T2: PGDM1400 + VRC07-523LS mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Increased body temperature | Mild | 0 Participants |
| T2: PGDM1400 + VRC07-523LS mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Increased body temperature | Moderate | 0 Participants |
| T2: PGDM1400 + VRC07-523LS mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Increased body temperature | Severe | 0 Participants |
| T2: PGDM1400 + VRC07-523LS mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Urticaria | Mild | 0 Participants |
| T2: PGDM1400 + VRC07-523LS mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Increased body temperature | Potentially life-threatening | 0 Participants |
| T2: PGDM1400 + VRC07-523LS mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Malaise and/or fatigue | None | 2 Participants |
| T2: PGDM1400 + VRC07-523LS mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Non-exertional tachycardia | Potentially life-threatening | 0 Participants |
| T2: PGDM1400 + VRC07-523LS mo 0 | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Malaise and/or fatigue | Mild | 3 Participants |
| T3: 10-1074 + VRC07-523LS | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Max. Systemic Symptoms | Severe | 0 Participants |
| T3: 10-1074 + VRC07-523LS | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Malaise and/or fatigue | Potentially life-threatening | 0 Participants |
| T3: 10-1074 + VRC07-523LS | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Facial flushing | Severe | 0 Participants |
| T3: 10-1074 + VRC07-523LS | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Unexplained diaphoresis | Moderate | 0 Participants |
| T3: 10-1074 + VRC07-523LS | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Nausea | Mild | 2 Participants |
| T3: 10-1074 + VRC07-523LS | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Increased body temperature | Mild | 0 Participants |
| T3: 10-1074 + VRC07-523LS | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Facial flushing | Potentially life-threatening | 0 Participants |
| T3: 10-1074 + VRC07-523LS | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Non-exertional tachycardia | None | 6 Participants |
| T3: 10-1074 + VRC07-523LS | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Max. Systemic Symptoms | Moderate | 1 Participants |
| T3: 10-1074 + VRC07-523LS | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Myalgia | Potentially life-threatening | 0 Participants |
| T3: 10-1074 + VRC07-523LS | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Generalized pruritus | None | 5 Participants |
| T3: 10-1074 + VRC07-523LS | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Max. Systemic Symptoms | Mild | 3 Participants |
| T3: 10-1074 + VRC07-523LS | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Non-exertional tachycardia | Severe | 0 Participants |
| T3: 10-1074 + VRC07-523LS | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Urticaria | Severe | 0 Participants |
| T3: 10-1074 + VRC07-523LS | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Generalized pruritus | Mild | 1 Participants |
| T3: 10-1074 + VRC07-523LS | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Malaise and/or fatigue | Moderate | 1 Participants |
| T3: 10-1074 + VRC07-523LS | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Non-exertional tachycardia | Moderate | 0 Participants |
| T3: 10-1074 + VRC07-523LS | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Increased body temperature | Moderate | 0 Participants |
| T3: 10-1074 + VRC07-523LS | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Generalized pruritus | Moderate | 0 Participants |
| T3: 10-1074 + VRC07-523LS | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Unexplained diaphoresis | Severe | 0 Participants |
| T3: 10-1074 + VRC07-523LS | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Non-exertional tachycardia | Mild | 0 Participants |
| T3: 10-1074 + VRC07-523LS | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Myalgia | Moderate | 0 Participants |
| T3: 10-1074 + VRC07-523LS | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Generalized pruritus | Severe | 0 Participants |
| T3: 10-1074 + VRC07-523LS | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Non-exertional dyspnea | Potentially life-threatening | 0 Participants |
| T3: 10-1074 + VRC07-523LS | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Non-exertional dyspnea | Severe | 0 Participants |
| T3: 10-1074 + VRC07-523LS | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Myalgia | Mild | 0 Participants |
| T3: 10-1074 + VRC07-523LS | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Generalized pruritus | Potentially life-threatening | 0 Participants |
| T3: 10-1074 + VRC07-523LS | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Non-exertional dyspnea | Moderate | 0 Participants |
| T3: 10-1074 + VRC07-523LS | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Malaise and/or fatigue | None | 4 Participants |
| T3: 10-1074 + VRC07-523LS | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Headache | None | 5 Participants |
| T3: 10-1074 + VRC07-523LS | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Increased body temperature | Severe | 0 Participants |
| T3: 10-1074 + VRC07-523LS | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Max. Systemic Symptoms | None | 2 Participants |
| T3: 10-1074 + VRC07-523LS | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Malaise and/or fatigue | Mild | 1 Participants |
| T3: 10-1074 + VRC07-523LS | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Headache | Mild | 1 Participants |
| T3: 10-1074 + VRC07-523LS | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Unexplained diaphoresis | Potentially life-threatening | 0 Participants |
| T3: 10-1074 + VRC07-523LS | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Non-exertional dyspnea | Mild | 0 Participants |
| T3: 10-1074 + VRC07-523LS | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Myalgia | None | 6 Participants |
| T3: 10-1074 + VRC07-523LS | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Headache | Moderate | 0 Participants |
| T3: 10-1074 + VRC07-523LS | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Arthralgia | Severe | 0 Participants |
| T3: 10-1074 + VRC07-523LS | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Myalgia | Severe | 0 Participants |
| T3: 10-1074 + VRC07-523LS | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Non-exertional tachycardia | Potentially life-threatening | 0 Participants |
| T3: 10-1074 + VRC07-523LS | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Non-exertional dyspnea | None | 6 Participants |
| T3: 10-1074 + VRC07-523LS | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Arthralgia | Potentially life-threatening | 0 Participants |
| T3: 10-1074 + VRC07-523LS | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Urticaria | Moderate | 0 Participants |
| T3: 10-1074 + VRC07-523LS | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Arthralgia | Moderate | 0 Participants |
| T3: 10-1074 + VRC07-523LS | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Headache | Severe | 0 Participants |
| T3: 10-1074 + VRC07-523LS | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Chills | None | 6 Participants |
| T3: 10-1074 + VRC07-523LS | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Unexplained diaphoresis | None | 6 Participants |
| T3: 10-1074 + VRC07-523LS | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Arthralgia | Mild | 1 Participants |
| T3: 10-1074 + VRC07-523LS | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Nausea | Potentially life-threatening | 0 Participants |
| T3: 10-1074 + VRC07-523LS | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Chills | Mild | 0 Participants |
| T3: 10-1074 + VRC07-523LS | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Arthralgia | None | 5 Participants |
| T3: 10-1074 + VRC07-523LS | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Malaise and/or fatigue | Severe | 0 Participants |
| T3: 10-1074 + VRC07-523LS | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Urticaria | Potentially life-threatening | 0 Participants |
| T3: 10-1074 + VRC07-523LS | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Chills | Moderate | 0 Participants |
| T3: 10-1074 + VRC07-523LS | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Temperature (C) | Potentially life-threatening | 0 Participants |
| T3: 10-1074 + VRC07-523LS | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Temperature (C) | Severe | 0 Participants |
| T3: 10-1074 + VRC07-523LS | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Increased body temperature | Potentially life-threatening | 0 Participants |
| T3: 10-1074 + VRC07-523LS | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Chills | Severe | 0 Participants |
| T3: 10-1074 + VRC07-523LS | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Headache | Potentially life-threatening | 0 Participants |
| T3: 10-1074 + VRC07-523LS | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Temperature (C) | Moderate | 0 Participants |
| T3: 10-1074 + VRC07-523LS | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Nausea | Severe | 0 Participants |
| T3: 10-1074 + VRC07-523LS | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Chills | Potentially life-threatening | 0 Participants |
| T3: 10-1074 + VRC07-523LS | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Unexplained diaphoresis | Mild | 0 Participants |
| T3: 10-1074 + VRC07-523LS | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Temperature (C) | Mild | 0 Participants |
| T3: 10-1074 + VRC07-523LS | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Nausea | Moderate | 0 Participants |
| T3: 10-1074 + VRC07-523LS | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Facial flushing | None | 6 Participants |
| T3: 10-1074 + VRC07-523LS | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Urticaria | Mild | 0 Participants |
| T3: 10-1074 + VRC07-523LS | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Max. Systemic Symptoms | Potentially life-threatening | 0 Participants |
| T3: 10-1074 + VRC07-523LS | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Increased body temperature | None | 6 Participants |
| T3: 10-1074 + VRC07-523LS | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Facial flushing | Mild | 0 Participants |
| T3: 10-1074 + VRC07-523LS | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Temperature (C) | None | 6 Participants |
| T3: 10-1074 + VRC07-523LS | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Urticaria | None | 6 Participants |
| T3: 10-1074 + VRC07-523LS | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Facial flushing | Moderate | 0 Participants |
| T3: 10-1074 + VRC07-523LS | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Nausea | None | 4 Participants |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Non-exertional tachycardia | Severe | 0 Participants |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Malaise and/or fatigue | Potentially life-threatening | 0 Participants |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Nausea | Mild | 0 Participants |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Non-exertional dyspnea | Severe | 0 Participants |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Non-exertional tachycardia | None | 9 Participants |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Non-exertional tachycardia | Mild | 0 Participants |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Temperature (C) | None | 9 Participants |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Temperature (C) | Moderate | 0 Participants |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Temperature (C) | Severe | 0 Participants |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Non-exertional tachycardia | Potentially life-threatening | 0 Participants |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Unexplained diaphoresis | None | 9 Participants |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Unexplained diaphoresis | Mild | 0 Participants |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Unexplained diaphoresis | Moderate | 0 Participants |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Unexplained diaphoresis | Severe | 0 Participants |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Unexplained diaphoresis | Potentially life-threatening | 0 Participants |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Urticaria | None | 9 Participants |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Urticaria | Mild | 0 Participants |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Urticaria | Moderate | 0 Participants |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Urticaria | Severe | 0 Participants |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Urticaria | Potentially life-threatening | 0 Participants |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Max. Systemic Symptoms | None | 3 Participants |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Max. Systemic Symptoms | Mild | 5 Participants |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Max. Systemic Symptoms | Moderate | 1 Participants |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Max. Systemic Symptoms | Severe | 0 Participants |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Max. Systemic Symptoms | Potentially life-threatening | 0 Participants |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Temperature (C) | Mild | 0 Participants |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Temperature (C) | Potentially life-threatening | 0 Participants |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Arthralgia | None | 9 Participants |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Arthralgia | Mild | 0 Participants |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Arthralgia | Moderate | 0 Participants |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Arthralgia | Severe | 0 Participants |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Arthralgia | Potentially life-threatening | 0 Participants |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Chills | None | 7 Participants |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Chills | Mild | 2 Participants |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Chills | Moderate | 0 Participants |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Chills | Severe | 0 Participants |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Chills | Potentially life-threatening | 0 Participants |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Facial flushing | None | 9 Participants |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Facial flushing | Moderate | 0 Participants |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Facial flushing | Severe | 0 Participants |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Facial flushing | Potentially life-threatening | 0 Participants |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Generalized pruritus | None | 9 Participants |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Generalized pruritus | Mild | 0 Participants |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Generalized pruritus | Moderate | 0 Participants |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Generalized pruritus | Severe | 0 Participants |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Generalized pruritus | Potentially life-threatening | 0 Participants |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Headache | None | 9 Participants |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Headache | Mild | 0 Participants |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Headache | Moderate | 0 Participants |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Headache | Severe | 0 Participants |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Headache | Potentially life-threatening | 0 Participants |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Increased body temperature | None | 9 Participants |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Increased body temperature | Mild | 0 Participants |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Increased body temperature | Moderate | 0 Participants |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Increased body temperature | Severe | 0 Participants |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Increased body temperature | Potentially life-threatening | 0 Participants |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Malaise and/or fatigue | None | 3 Participants |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Malaise and/or fatigue | Mild | 5 Participants |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Malaise and/or fatigue | Moderate | 1 Participants |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Malaise and/or fatigue | Severe | 0 Participants |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Myalgia | None | 7 Participants |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Myalgia | Mild | 2 Participants |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Myalgia | Moderate | 0 Participants |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Myalgia | Severe | 0 Participants |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Myalgia | Potentially life-threatening | 0 Participants |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Nausea | None | 9 Participants |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Nausea | Moderate | 0 Participants |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Nausea | Severe | 0 Participants |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Nausea | Potentially life-threatening | 0 Participants |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Non-exertional dyspnea | None | 9 Participants |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Non-exertional dyspnea | Mild | 0 Participants |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Non-exertional dyspnea | Moderate | 0 Participants |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Non-exertional dyspnea | Potentially life-threatening | 0 Participants |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Non-exertional tachycardia | Moderate | 0 Participants |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms | Facial flushing | Mild | 0 Participants |
Primary
Number of Participants With Early Discontinuation of Vaccinations and Reason for Discontinuation
The number (percentage) of participants with early discontinuation of vaccinations and reason for discontinuation was summarized by arm. The three participants discontinued treatment in T4 were due to the COVID-19 pandemic lockdown.
Time frame: Measured through Month 4
Population: Safety population
| Arm | Measure | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| T1: PGT121 + VRC07-523LS mo 0 | Number of Participants With Early Discontinuation of Vaccinations and Reason for Discontinuation | Co-Enrollment in a study with an investigational research agent | 0 Participants |
| T1: PGT121 + VRC07-523LS mo 0 | Number of Participants With Early Discontinuation of Vaccinations and Reason for Discontinuation | Investigator Reason | 0 Participants |
| T1: PGT121 + VRC07-523LS mo 0 | Number of Participants With Early Discontinuation of Vaccinations and Reason for Discontinuation | Death | 0 Participants |
| T1: PGT121 + VRC07-523LS mo 0 | Number of Participants With Early Discontinuation of Vaccinations and Reason for Discontinuation | Incarceration | 0 Participants |
| T1: PGT121 + VRC07-523LS mo 0 | Number of Participants With Early Discontinuation of Vaccinations and Reason for Discontinuation | Clinical event other than reactogenicity, HIV infection, or death | 0 Participants |
| T1: PGT121 + VRC07-523LS mo 0 | Number of Participants With Early Discontinuation of Vaccinations and Reason for Discontinuation | Participant refused SPA | 0 Participants |
| T1: PGT121 + VRC07-523LS mo 0 | Number of Participants With Early Discontinuation of Vaccinations and Reason for Discontinuation | Participant unable to schedule visit within window | 0 Participants |
| T1: PGT121 + VRC07-523LS mo 0 | Number of Participants With Early Discontinuation of Vaccinations and Reason for Discontinuation | Did not Discontinue SPA | 6 Participants |
| T1: PGT121 + VRC07-523LS mo 0 | Number of Participants With Early Discontinuation of Vaccinations and Reason for Discontinuation | Pregnancy | 0 Participants |
| T1: PGT121 + VRC07-523LS mo 0 | Number of Participants With Early Discontinuation of Vaccinations and Reason for Discontinuation | Solicited adverse event symptom | 0 Participants |
| T1: PGT121 + VRC07-523LS mo 0 | Number of Participants With Early Discontinuation of Vaccinations and Reason for Discontinuation | Unable to contact participant | 0 Participants |
| T1: PGT121 + VRC07-523LS mo 0 | Number of Participants With Early Discontinuation of Vaccinations and Reason for Discontinuation | Psychiatric reason | 0 Participants |
| T1: PGT121 + VRC07-523LS mo 0 | Number of Participants With Early Discontinuation of Vaccinations and Reason for Discontinuation | HIV infection | 0 Participants |
| T1: PGT121 + VRC07-523LS mo 0 | Number of Participants With Early Discontinuation of Vaccinations and Reason for Discontinuation | Other | 0 Participants |
| T2: PGDM1400 + VRC07-523LS mo 0 | Number of Participants With Early Discontinuation of Vaccinations and Reason for Discontinuation | Unable to contact participant | 0 Participants |
| T2: PGDM1400 + VRC07-523LS mo 0 | Number of Participants With Early Discontinuation of Vaccinations and Reason for Discontinuation | Participant unable to schedule visit within window | 0 Participants |
| T2: PGDM1400 + VRC07-523LS mo 0 | Number of Participants With Early Discontinuation of Vaccinations and Reason for Discontinuation | Pregnancy | 0 Participants |
| T2: PGDM1400 + VRC07-523LS mo 0 | Number of Participants With Early Discontinuation of Vaccinations and Reason for Discontinuation | HIV infection | 0 Participants |
| T2: PGDM1400 + VRC07-523LS mo 0 | Number of Participants With Early Discontinuation of Vaccinations and Reason for Discontinuation | Death | 0 Participants |
| T2: PGDM1400 + VRC07-523LS mo 0 | Number of Participants With Early Discontinuation of Vaccinations and Reason for Discontinuation | Clinical event other than reactogenicity, HIV infection, or death | 0 Participants |
| T2: PGDM1400 + VRC07-523LS mo 0 | Number of Participants With Early Discontinuation of Vaccinations and Reason for Discontinuation | Solicited adverse event symptom | 0 Participants |
| T2: PGDM1400 + VRC07-523LS mo 0 | Number of Participants With Early Discontinuation of Vaccinations and Reason for Discontinuation | Investigator Reason | 0 Participants |
| T2: PGDM1400 + VRC07-523LS mo 0 | Number of Participants With Early Discontinuation of Vaccinations and Reason for Discontinuation | Participant refused SPA | 0 Participants |
| T2: PGDM1400 + VRC07-523LS mo 0 | Number of Participants With Early Discontinuation of Vaccinations and Reason for Discontinuation | Co-Enrollment in a study with an investigational research agent | 0 Participants |
| T2: PGDM1400 + VRC07-523LS mo 0 | Number of Participants With Early Discontinuation of Vaccinations and Reason for Discontinuation | Psychiatric reason | 0 Participants |
| T2: PGDM1400 + VRC07-523LS mo 0 | Number of Participants With Early Discontinuation of Vaccinations and Reason for Discontinuation | Incarceration | 0 Participants |
| T2: PGDM1400 + VRC07-523LS mo 0 | Number of Participants With Early Discontinuation of Vaccinations and Reason for Discontinuation | Other | 0 Participants |
| T2: PGDM1400 + VRC07-523LS mo 0 | Number of Participants With Early Discontinuation of Vaccinations and Reason for Discontinuation | Did not Discontinue SPA | 6 Participants |
| T3: 10-1074 + VRC07-523LS | Number of Participants With Early Discontinuation of Vaccinations and Reason for Discontinuation | Other | 0 Participants |
| T3: 10-1074 + VRC07-523LS | Number of Participants With Early Discontinuation of Vaccinations and Reason for Discontinuation | HIV infection | 0 Participants |
| T3: 10-1074 + VRC07-523LS | Number of Participants With Early Discontinuation of Vaccinations and Reason for Discontinuation | Co-Enrollment in a study with an investigational research agent | 0 Participants |
| T3: 10-1074 + VRC07-523LS | Number of Participants With Early Discontinuation of Vaccinations and Reason for Discontinuation | Psychiatric reason | 0 Participants |
| T3: 10-1074 + VRC07-523LS | Number of Participants With Early Discontinuation of Vaccinations and Reason for Discontinuation | Participant unable to schedule visit within window | 0 Participants |
| T3: 10-1074 + VRC07-523LS | Number of Participants With Early Discontinuation of Vaccinations and Reason for Discontinuation | Pregnancy | 0 Participants |
| T3: 10-1074 + VRC07-523LS | Number of Participants With Early Discontinuation of Vaccinations and Reason for Discontinuation | Clinical event other than reactogenicity, HIV infection, or death | 0 Participants |
| T3: 10-1074 + VRC07-523LS | Number of Participants With Early Discontinuation of Vaccinations and Reason for Discontinuation | Unable to contact participant | 0 Participants |
| T3: 10-1074 + VRC07-523LS | Number of Participants With Early Discontinuation of Vaccinations and Reason for Discontinuation | Incarceration | 0 Participants |
| T3: 10-1074 + VRC07-523LS | Number of Participants With Early Discontinuation of Vaccinations and Reason for Discontinuation | Death | 0 Participants |
| T3: 10-1074 + VRC07-523LS | Number of Participants With Early Discontinuation of Vaccinations and Reason for Discontinuation | Investigator Reason | 0 Participants |
| T3: 10-1074 + VRC07-523LS | Number of Participants With Early Discontinuation of Vaccinations and Reason for Discontinuation | Solicited adverse event symptom | 0 Participants |
| T3: 10-1074 + VRC07-523LS | Number of Participants With Early Discontinuation of Vaccinations and Reason for Discontinuation | Did not Discontinue SPA | 6 Participants |
| T3: 10-1074 + VRC07-523LS | Number of Participants With Early Discontinuation of Vaccinations and Reason for Discontinuation | Participant refused SPA | 0 Participants |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Number of Participants With Early Discontinuation of Vaccinations and Reason for Discontinuation | Incarceration | 0 Participants |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Number of Participants With Early Discontinuation of Vaccinations and Reason for Discontinuation | Participant refused SPA | 0 Participants |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Number of Participants With Early Discontinuation of Vaccinations and Reason for Discontinuation | Unable to contact participant | 0 Participants |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Number of Participants With Early Discontinuation of Vaccinations and Reason for Discontinuation | Other | 3 Participants |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Number of Participants With Early Discontinuation of Vaccinations and Reason for Discontinuation | Investigator Reason | 0 Participants |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Number of Participants With Early Discontinuation of Vaccinations and Reason for Discontinuation | Co-Enrollment in a study with an investigational research agent | 0 Participants |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Number of Participants With Early Discontinuation of Vaccinations and Reason for Discontinuation | Pregnancy | 0 Participants |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Number of Participants With Early Discontinuation of Vaccinations and Reason for Discontinuation | Clinical event other than reactogenicity, HIV infection, or death | 0 Participants |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Number of Participants With Early Discontinuation of Vaccinations and Reason for Discontinuation | Did not Discontinue SPA | 6 Participants |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Number of Participants With Early Discontinuation of Vaccinations and Reason for Discontinuation | Psychiatric reason | 0 Participants |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Number of Participants With Early Discontinuation of Vaccinations and Reason for Discontinuation | Solicited adverse event symptom | 0 Participants |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Number of Participants With Early Discontinuation of Vaccinations and Reason for Discontinuation | Participant unable to schedule visit within window | 0 Participants |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Number of Participants With Early Discontinuation of Vaccinations and Reason for Discontinuation | Death | 0 Participants |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Number of Participants With Early Discontinuation of Vaccinations and Reason for Discontinuation | HIV infection | 0 Participants |
Primary
The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm
The number (percentage) of participants with lab grade \> 1 for alanine aminotransferase (ALT), creatinine, hemoglobin, lymphocyte count, neutrophil count, platelets, white blood cells (WBC) was summarized by arm
Time frame: Measured during Screening, Days 0, 14, 56, 84*, 112, 140*, 168, 224, 280, 336, 392*, 448*, and 504* Days with * are only available for T4
Population: Overall Number of Participants Analyzed represents participants enrolled and eligible for laboratory assessment. Participants do not have laboratory assessments if they attended the visit but laboratory specimens were not collected, missed the scheduled visit, or terminated participation in the study prior to the scheduled visit.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| T1: PGT121 + VRC07-523LS mo 0 | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Alanine Aminotransferase (U/L)-Day 336 | 0 Participants |
| T1: PGT121 + VRC07-523LS mo 0 | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Hemoglobin (g/dL)-Day 336 | 0 Participants |
| T1: PGT121 + VRC07-523LS mo 0 | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | WBC (1000 cells/cubic mm)-Day 14 | 0 Participants |
| T1: PGT121 + VRC07-523LS mo 0 | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Hemoglobin (g/dL)-Day 84 | 0 Participants |
| T1: PGT121 + VRC07-523LS mo 0 | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Hemoglobin (g/dL)-Day 448 | 0 Participants |
| T1: PGT121 + VRC07-523LS mo 0 | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Alanine Aminotransferase (U/L)-Day 392 | 0 Participants |
| T1: PGT121 + VRC07-523LS mo 0 | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Platelets (1000 cells/cubic mm)-Day 140 | 0 Participants |
| T1: PGT121 + VRC07-523LS mo 0 | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Alanine Aminotransferase (U/L)-Baseline | 0 Participants |
| T1: PGT121 + VRC07-523LS mo 0 | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Creatinine (mg/dL)-Baseline | 0 Participants |
| T1: PGT121 + VRC07-523LS mo 0 | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | WBC (1000 cells/cubic mm)-Day 0 | 0 Participants |
| T1: PGT121 + VRC07-523LS mo 0 | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Platelets (1000 cells/cubic mm)-Day 168 | 1 Participants |
| T1: PGT121 + VRC07-523LS mo 0 | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Platelets (1000 cells/cubic mm)-Day 280 | 0 Participants |
| T1: PGT121 + VRC07-523LS mo 0 | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Creatinine (mg/dL)-Day 0 | 0 Participants |
| T1: PGT121 + VRC07-523LS mo 0 | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | WBC (1000 cells/cubic mm)-Day 336 | 0 Participants |
| T1: PGT121 + VRC07-523LS mo 0 | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Platelets (1000 cells/cubic mm)-Day 224 | 0 Participants |
| T1: PGT121 + VRC07-523LS mo 0 | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | WBC (1000 cells/cubic mm)-Day 168 | 0 Participants |
| T1: PGT121 + VRC07-523LS mo 0 | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Alanine Aminotransferase (U/L)-Day 56 | 0 Participants |
| T1: PGT121 + VRC07-523LS mo 0 | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Hemoglobin (g/dL)-Baseline | 0 Participants |
| T1: PGT121 + VRC07-523LS mo 0 | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Platelets (1000 cells/cubic mm)-Day 84 | 0 Participants |
| T1: PGT121 + VRC07-523LS mo 0 | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | WBC (1000 cells/cubic mm)-Baseline | 0 Participants |
| T1: PGT121 + VRC07-523LS mo 0 | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Platelets (1000 cells/cubic mm)-Day 336 | 0 Participants |
| T1: PGT121 + VRC07-523LS mo 0 | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Hemoglobin (g/dL)-Day 112 | 0 Participants |
| T1: PGT121 + VRC07-523LS mo 0 | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Platelets (1000 cells/cubic mm)-Baseline | 0 Participants |
| T1: PGT121 + VRC07-523LS mo 0 | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Platelets (1000 cells/cubic mm)-Day 0 | 0 Participants |
| T1: PGT121 + VRC07-523LS mo 0 | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Platelets (1000 cells/cubic mm)-Day 392 | 0 Participants |
| T1: PGT121 + VRC07-523LS mo 0 | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Hemoglobin (g/dL)-Day 224 | 0 Participants |
| T1: PGT121 + VRC07-523LS mo 0 | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Creatinine (mg/dL)-Day 84 | 0 Participants |
| T1: PGT121 + VRC07-523LS mo 0 | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Platelets (1000 cells/cubic mm)-Day 448 | 0 Participants |
| T1: PGT121 + VRC07-523LS mo 0 | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Hemoglobin (g/dL)-Day 14 | 0 Participants |
| T1: PGT121 + VRC07-523LS mo 0 | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Alanine Aminotransferase (U/L)-Day 112 | 0 Participants |
| T1: PGT121 + VRC07-523LS mo 0 | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Creatinine (mg/dL)-Day 448 | 0 Participants |
| T1: PGT121 + VRC07-523LS mo 0 | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Lymphocytes (1000 cells/cubic mm)-Day 0 | 0 Participants |
| T1: PGT121 + VRC07-523LS mo 0 | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Lymphocytes (1000 cells/cubic mm)-Baseline | 0 Participants |
| T1: PGT121 + VRC07-523LS mo 0 | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Alanine Aminotransferase (U/L)-Day 84 | 0 Participants |
| T1: PGT121 + VRC07-523LS mo 0 | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Hemoglobin (g/dL)-Day 56 | 0 Participants |
| T1: PGT121 + VRC07-523LS mo 0 | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Creatinine (mg/dL)-Day 392 | 0 Participants |
| T1: PGT121 + VRC07-523LS mo 0 | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Creatinine (mg/dL)-Day 140 | 0 Participants |
| T1: PGT121 + VRC07-523LS mo 0 | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Hemoglobin (g/dL)-Day 392 | 0 Participants |
| T1: PGT121 + VRC07-523LS mo 0 | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Lymphocytes (1000 cells/cubic mm)-Day 140 | 0 Participants |
| T1: PGT121 + VRC07-523LS mo 0 | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | WBC (1000 cells/cubic mm)-Day 280 | 0 Participants |
| T1: PGT121 + VRC07-523LS mo 0 | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Lymphocytes (1000 cells/cubic mm)-Day 14 | 0 Participants |
| T1: PGT121 + VRC07-523LS mo 0 | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Neutrophils (1000 cells/cubic mm)-Day 448 | 0 Participants |
| T1: PGT121 + VRC07-523LS mo 0 | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Alanine Aminotransferase (U/L)-Day 140 | 0 Participants |
| T1: PGT121 + VRC07-523LS mo 0 | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Creatinine (mg/dL)-Day 168 | 0 Participants |
| T1: PGT121 + VRC07-523LS mo 0 | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Creatinine (mg/dL)-Day 280 | 0 Participants |
| T1: PGT121 + VRC07-523LS mo 0 | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Lymphocytes (1000 cells/cubic mm)-Day 336 | 0 Participants |
| T1: PGT121 + VRC07-523LS mo 0 | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Lymphocytes (1000 cells/cubic mm)-Day 56 | 0 Participants |
| T1: PGT121 + VRC07-523LS mo 0 | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Creatinine (mg/dL)-Day 224 | 0 Participants |
| T1: PGT121 + VRC07-523LS mo 0 | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | WBC (1000 cells/cubic mm)-Day 224 | 0 Participants |
| T1: PGT121 + VRC07-523LS mo 0 | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Lymphocytes (1000 cells/cubic mm)-Day 392 | 0 Participants |
| T1: PGT121 + VRC07-523LS mo 0 | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Hemoglobin (g/dL)-Day 168 | 0 Participants |
| T1: PGT121 + VRC07-523LS mo 0 | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | WBC (1000 cells/cubic mm)-Day 140 | 0 Participants |
| T1: PGT121 + VRC07-523LS mo 0 | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Lymphocytes (1000 cells/cubic mm)-Day 84 | 0 Participants |
| T1: PGT121 + VRC07-523LS mo 0 | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Lymphocytes (1000 cells/cubic mm)-Day 448 | 0 Participants |
| T1: PGT121 + VRC07-523LS mo 0 | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Neutrophils (1000 cells/cubic mm)-Baseline | 0 Participants |
| T1: PGT121 + VRC07-523LS mo 0 | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Alanine Aminotransferase (U/L)-Day 168 | 0 Participants |
| T1: PGT121 + VRC07-523LS mo 0 | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Alanine Aminotransferase (U/L)-Day 448 | 0 Participants |
| T1: PGT121 + VRC07-523LS mo 0 | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Platelets (1000 cells/cubic mm)-Day 14 | 0 Participants |
| T1: PGT121 + VRC07-523LS mo 0 | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Neutrophils (1000 cells/cubic mm)-Day 0 | 0 Participants |
| T1: PGT121 + VRC07-523LS mo 0 | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Platelets (1000 cells/cubic mm)-Day 112 | 2 Participants |
| T1: PGT121 + VRC07-523LS mo 0 | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | WBC (1000 cells/cubic mm)-Day 448 | 0 Participants |
| T1: PGT121 + VRC07-523LS mo 0 | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Creatinine (mg/dL)-Day 112 | 0 Participants |
| T1: PGT121 + VRC07-523LS mo 0 | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Neutrophils (1000 cells/cubic mm)-Day 14 | 0 Participants |
| T1: PGT121 + VRC07-523LS mo 0 | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Lymphocytes (1000 cells/cubic mm)-Day 112 | 0 Participants |
| T1: PGT121 + VRC07-523LS mo 0 | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Platelets (1000 cells/cubic mm)-Day 56 | 1 Participants |
| T1: PGT121 + VRC07-523LS mo 0 | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Alanine Aminotransferase (U/L)-Day 0 | 0 Participants |
| T1: PGT121 + VRC07-523LS mo 0 | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Neutrophils (1000 cells/cubic mm)-Day 56 | 0 Participants |
| T1: PGT121 + VRC07-523LS mo 0 | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | WBC (1000 cells/cubic mm)-Day 112 | 0 Participants |
| T1: PGT121 + VRC07-523LS mo 0 | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Lymphocytes (1000 cells/cubic mm)-Day 168 | 0 Participants |
| T1: PGT121 + VRC07-523LS mo 0 | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Creatinine (mg/dL)-Day 56 | 0 Participants |
| T1: PGT121 + VRC07-523LS mo 0 | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Neutrophils (1000 cells/cubic mm)-Day 84 | 0 Participants |
| T1: PGT121 + VRC07-523LS mo 0 | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Alanine Aminotransferase (U/L)-Day 224 | 0 Participants |
| T1: PGT121 + VRC07-523LS mo 0 | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Creatinine (mg/dL)-Day 336 | 0 Participants |
| T1: PGT121 + VRC07-523LS mo 0 | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Neutrophils (1000 cells/cubic mm)-Day 392 | 0 Participants |
| T1: PGT121 + VRC07-523LS mo 0 | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Neutrophils (1000 cells/cubic mm)-Day 112 | 0 Participants |
| T1: PGT121 + VRC07-523LS mo 0 | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Neutrophils (1000 cells/cubic mm)-Day 336 | 0 Participants |
| T1: PGT121 + VRC07-523LS mo 0 | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Lymphocytes (1000 cells/cubic mm)-Day 224 | 0 Participants |
| T1: PGT121 + VRC07-523LS mo 0 | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Creatinine (mg/dL)-Day 14 | 0 Participants |
| T1: PGT121 + VRC07-523LS mo 0 | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Neutrophils (1000 cells/cubic mm)-Day 140 | 0 Participants |
| T1: PGT121 + VRC07-523LS mo 0 | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Hemoglobin (g/dL)-Day 140 | 0 Participants |
| T1: PGT121 + VRC07-523LS mo 0 | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Hemoglobin (g/dL)-Day 0 | 0 Participants |
| T1: PGT121 + VRC07-523LS mo 0 | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | WBC (1000 cells/cubic mm)-Day 84 | 0 Participants |
| T1: PGT121 + VRC07-523LS mo 0 | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Neutrophils (1000 cells/cubic mm)-Day 168 | 0 Participants |
| T1: PGT121 + VRC07-523LS mo 0 | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Lymphocytes (1000 cells/cubic mm)-Day 280 | 0 Participants |
| T1: PGT121 + VRC07-523LS mo 0 | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | WBC (1000 cells/cubic mm)-Day 392 | 0 Participants |
| T1: PGT121 + VRC07-523LS mo 0 | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Neutrophils (1000 cells/cubic mm)-Day 224 | 0 Participants |
| T1: PGT121 + VRC07-523LS mo 0 | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Alanine Aminotransferase (U/L)-Day 280 | 0 Participants |
| T1: PGT121 + VRC07-523LS mo 0 | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Hemoglobin (g/dL)-Day 280 | 0 Participants |
| T1: PGT121 + VRC07-523LS mo 0 | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Alanine Aminotransferase (U/L)-Day 14 | 0 Participants |
| T1: PGT121 + VRC07-523LS mo 0 | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Neutrophils (1000 cells/cubic mm)-Day 280 | 0 Participants |
| T1: PGT121 + VRC07-523LS mo 0 | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | WBC (1000 cells/cubic mm)-Day 56 | 0 Participants |
| T2: PGDM1400 + VRC07-523LS mo 0 | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Neutrophils (1000 cells/cubic mm)-Day 280 | 0 Participants |
| T2: PGDM1400 + VRC07-523LS mo 0 | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Hemoglobin (g/dL)-Day 392 | 0 Participants |
| T2: PGDM1400 + VRC07-523LS mo 0 | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Neutrophils (1000 cells/cubic mm)-Day 336 | 0 Participants |
| T2: PGDM1400 + VRC07-523LS mo 0 | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | WBC (1000 cells/cubic mm)-Day 336 | 0 Participants |
| T2: PGDM1400 + VRC07-523LS mo 0 | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Neutrophils (1000 cells/cubic mm)-Day 392 | 0 Participants |
| T2: PGDM1400 + VRC07-523LS mo 0 | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Hemoglobin (g/dL)-Day 336 | 0 Participants |
| T2: PGDM1400 + VRC07-523LS mo 0 | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Neutrophils (1000 cells/cubic mm)-Day 448 | 0 Participants |
| T2: PGDM1400 + VRC07-523LS mo 0 | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | WBC (1000 cells/cubic mm)-Day 14 | 0 Participants |
| T2: PGDM1400 + VRC07-523LS mo 0 | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Alanine Aminotransferase (U/L)-Baseline | 0 Participants |
| T2: PGDM1400 + VRC07-523LS mo 0 | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Platelets (1000 cells/cubic mm)-Day 14 | 0 Participants |
| T2: PGDM1400 + VRC07-523LS mo 0 | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Hemoglobin (g/dL)-Day 280 | 0 Participants |
| T2: PGDM1400 + VRC07-523LS mo 0 | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Alanine Aminotransferase (U/L)-Day 0 | 0 Participants |
| T2: PGDM1400 + VRC07-523LS mo 0 | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | WBC (1000 cells/cubic mm)-Day 224 | 0 Participants |
| T2: PGDM1400 + VRC07-523LS mo 0 | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Alanine Aminotransferase (U/L)-Day 14 | 0 Participants |
| T2: PGDM1400 + VRC07-523LS mo 0 | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | WBC (1000 cells/cubic mm)-Day 280 | 0 Participants |
| T2: PGDM1400 + VRC07-523LS mo 0 | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Hemoglobin (g/dL)-Day 224 | 0 Participants |
| T2: PGDM1400 + VRC07-523LS mo 0 | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Alanine Aminotransferase (U/L)-Day 112 | 0 Participants |
| T2: PGDM1400 + VRC07-523LS mo 0 | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Hemoglobin (g/dL)-Day 168 | 0 Participants |
| T2: PGDM1400 + VRC07-523LS mo 0 | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Hemoglobin (g/dL)-Day 140 | 0 Participants |
| T2: PGDM1400 + VRC07-523LS mo 0 | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Alanine Aminotransferase (U/L)-Day 224 | 0 Participants |
| T2: PGDM1400 + VRC07-523LS mo 0 | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | WBC (1000 cells/cubic mm)-Day 168 | 0 Participants |
| T2: PGDM1400 + VRC07-523LS mo 0 | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Alanine Aminotransferase (U/L)-Day 280 | 0 Participants |
| T2: PGDM1400 + VRC07-523LS mo 0 | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Hemoglobin (g/dL)-Day 84 | 0 Participants |
| T2: PGDM1400 + VRC07-523LS mo 0 | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Alanine Aminotransferase (U/L)-Day 336 | 0 Participants |
| T2: PGDM1400 + VRC07-523LS mo 0 | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Alanine Aminotransferase (U/L)-Day 392 | 0 Participants |
| T2: PGDM1400 + VRC07-523LS mo 0 | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Alanine Aminotransferase (U/L)-Day 448 | 0 Participants |
| T2: PGDM1400 + VRC07-523LS mo 0 | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Hemoglobin (g/dL)-Day 56 | 0 Participants |
| T2: PGDM1400 + VRC07-523LS mo 0 | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Hemoglobin (g/dL)-Baseline | 0 Participants |
| T2: PGDM1400 + VRC07-523LS mo 0 | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | WBC (1000 cells/cubic mm)-Day 140 | 0 Participants |
| T2: PGDM1400 + VRC07-523LS mo 0 | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Hemoglobin (g/dL)-Day 0 | 0 Participants |
| T2: PGDM1400 + VRC07-523LS mo 0 | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Hemoglobin (g/dL)-Day 14 | 0 Participants |
| T2: PGDM1400 + VRC07-523LS mo 0 | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Lymphocytes (1000 cells/cubic mm)-Baseline | 0 Participants |
| T2: PGDM1400 + VRC07-523LS mo 0 | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Hemoglobin (g/dL)-Day 112 | 0 Participants |
| T2: PGDM1400 + VRC07-523LS mo 0 | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Lymphocytes (1000 cells/cubic mm)-Day 14 | 0 Participants |
| T2: PGDM1400 + VRC07-523LS mo 0 | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Lymphocytes (1000 cells/cubic mm)-Day 56 | 0 Participants |
| T2: PGDM1400 + VRC07-523LS mo 0 | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Alanine Aminotransferase (U/L)-Day 140 | 0 Participants |
| T2: PGDM1400 + VRC07-523LS mo 0 | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Lymphocytes (1000 cells/cubic mm)-Day 84 | 0 Participants |
| T2: PGDM1400 + VRC07-523LS mo 0 | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | WBC (1000 cells/cubic mm)-Day 112 | 0 Participants |
| T2: PGDM1400 + VRC07-523LS mo 0 | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Lymphocytes (1000 cells/cubic mm)-Day 112 | 0 Participants |
| T2: PGDM1400 + VRC07-523LS mo 0 | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Lymphocytes (1000 cells/cubic mm)-Day 168 | 0 Participants |
| T2: PGDM1400 + VRC07-523LS mo 0 | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Alanine Aminotransferase (U/L)-Day 168 | 0 Participants |
| T2: PGDM1400 + VRC07-523LS mo 0 | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | WBC (1000 cells/cubic mm)-Day 84 | 0 Participants |
| T2: PGDM1400 + VRC07-523LS mo 0 | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Lymphocytes (1000 cells/cubic mm)-Day 224 | 0 Participants |
| T2: PGDM1400 + VRC07-523LS mo 0 | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Lymphocytes (1000 cells/cubic mm)-Day 448 | 0 Participants |
| T2: PGDM1400 + VRC07-523LS mo 0 | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Platelets (1000 cells/cubic mm)-Day 0 | 0 Participants |
| T2: PGDM1400 + VRC07-523LS mo 0 | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | WBC (1000 cells/cubic mm)-Day 56 | 0 Participants |
| T2: PGDM1400 + VRC07-523LS mo 0 | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Platelets (1000 cells/cubic mm)-Day 84 | 0 Participants |
| T2: PGDM1400 + VRC07-523LS mo 0 | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Platelets (1000 cells/cubic mm)-Baseline | 0 Participants |
| T2: PGDM1400 + VRC07-523LS mo 0 | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Platelets (1000 cells/cubic mm)-Day 112 | 0 Participants |
| T2: PGDM1400 + VRC07-523LS mo 0 | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | WBC (1000 cells/cubic mm)-Day 0 | 0 Participants |
| T2: PGDM1400 + VRC07-523LS mo 0 | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Platelets (1000 cells/cubic mm)-Day 140 | 0 Participants |
| T2: PGDM1400 + VRC07-523LS mo 0 | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Platelets (1000 cells/cubic mm)-Day 168 | 0 Participants |
| T2: PGDM1400 + VRC07-523LS mo 0 | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | WBC (1000 cells/cubic mm)-Baseline | 0 Participants |
| T2: PGDM1400 + VRC07-523LS mo 0 | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Platelets (1000 cells/cubic mm)-Day 224 | 0 Participants |
| T2: PGDM1400 + VRC07-523LS mo 0 | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Creatinine (mg/dL)-Day 0 | 0 Participants |
| T2: PGDM1400 + VRC07-523LS mo 0 | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Platelets (1000 cells/cubic mm)-Day 280 | 0 Participants |
| T2: PGDM1400 + VRC07-523LS mo 0 | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Platelets (1000 cells/cubic mm)-Day 336 | 0 Participants |
| T2: PGDM1400 + VRC07-523LS mo 0 | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Creatinine (mg/dL)-Day 448 | 0 Participants |
| T2: PGDM1400 + VRC07-523LS mo 0 | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Platelets (1000 cells/cubic mm)-Day 392 | 0 Participants |
| T2: PGDM1400 + VRC07-523LS mo 0 | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Platelets (1000 cells/cubic mm)-Day 448 | 0 Participants |
| T2: PGDM1400 + VRC07-523LS mo 0 | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Creatinine (mg/dL)-Day 84 | 0 Participants |
| T2: PGDM1400 + VRC07-523LS mo 0 | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Lymphocytes (1000 cells/cubic mm)-Day 0 | 0 Participants |
| T2: PGDM1400 + VRC07-523LS mo 0 | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Creatinine (mg/dL)-Day 392 | 0 Participants |
| T2: PGDM1400 + VRC07-523LS mo 0 | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Creatinine (mg/dL)-Day 280 | 0 Participants |
| T2: PGDM1400 + VRC07-523LS mo 0 | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Lymphocytes (1000 cells/cubic mm)-Day 140 | 0 Participants |
| T2: PGDM1400 + VRC07-523LS mo 0 | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Platelets (1000 cells/cubic mm)-Day 56 | 0 Participants |
| T2: PGDM1400 + VRC07-523LS mo 0 | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | WBC (1000 cells/cubic mm)-Day 448 | 0 Participants |
| T2: PGDM1400 + VRC07-523LS mo 0 | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Lymphocytes (1000 cells/cubic mm)-Day 280 | 0 Participants |
| T2: PGDM1400 + VRC07-523LS mo 0 | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Lymphocytes (1000 cells/cubic mm)-Day 336 | 0 Participants |
| T2: PGDM1400 + VRC07-523LS mo 0 | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Creatinine (mg/dL)-Day 168 | 0 Participants |
| T2: PGDM1400 + VRC07-523LS mo 0 | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Lymphocytes (1000 cells/cubic mm)-Day 392 | 0 Participants |
| T2: PGDM1400 + VRC07-523LS mo 0 | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Creatinine (mg/dL)-Day 224 | 0 Participants |
| T2: PGDM1400 + VRC07-523LS mo 0 | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Creatinine (mg/dL)-Day 140 | 0 Participants |
| T2: PGDM1400 + VRC07-523LS mo 0 | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Neutrophils (1000 cells/cubic mm)-Baseline | 0 Participants |
| T2: PGDM1400 + VRC07-523LS mo 0 | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Creatinine (mg/dL)-Day 112 | 0 Participants |
| T2: PGDM1400 + VRC07-523LS mo 0 | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Neutrophils (1000 cells/cubic mm)-Day 0 | 0 Participants |
| T2: PGDM1400 + VRC07-523LS mo 0 | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Neutrophils (1000 cells/cubic mm)-Day 14 | 0 Participants |
| T2: PGDM1400 + VRC07-523LS mo 0 | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Creatinine (mg/dL)-Day 56 | 0 Participants |
| T2: PGDM1400 + VRC07-523LS mo 0 | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Neutrophils (1000 cells/cubic mm)-Day 56 | 0 Participants |
| T2: PGDM1400 + VRC07-523LS mo 0 | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | WBC (1000 cells/cubic mm)-Day 392 | 0 Participants |
| T2: PGDM1400 + VRC07-523LS mo 0 | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Neutrophils (1000 cells/cubic mm)-Day 84 | 0 Participants |
| T2: PGDM1400 + VRC07-523LS mo 0 | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Creatinine (mg/dL)-Day 14 | 0 Participants |
| T2: PGDM1400 + VRC07-523LS mo 0 | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Neutrophils (1000 cells/cubic mm)-Day 112 | 0 Participants |
| T2: PGDM1400 + VRC07-523LS mo 0 | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Creatinine (mg/dL)-Day 336 | 0 Participants |
| T2: PGDM1400 + VRC07-523LS mo 0 | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Neutrophils (1000 cells/cubic mm)-Day 140 | 0 Participants |
| T2: PGDM1400 + VRC07-523LS mo 0 | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Creatinine (mg/dL)-Baseline | 0 Participants |
| T2: PGDM1400 + VRC07-523LS mo 0 | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Neutrophils (1000 cells/cubic mm)-Day 168 | 0 Participants |
| T2: PGDM1400 + VRC07-523LS mo 0 | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Neutrophils (1000 cells/cubic mm)-Day 224 | 0 Participants |
| T2: PGDM1400 + VRC07-523LS mo 0 | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Alanine Aminotransferase (U/L)-Day 84 | 0 Participants |
| T2: PGDM1400 + VRC07-523LS mo 0 | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Hemoglobin (g/dL)-Day 448 | 0 Participants |
| T2: PGDM1400 + VRC07-523LS mo 0 | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Alanine Aminotransferase (U/L)-Day 56 | 0 Participants |
| T3: 10-1074 + VRC07-523LS | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Neutrophils (1000 cells/cubic mm)-Day 280 | 0 Participants |
| T3: 10-1074 + VRC07-523LS | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Alanine Aminotransferase (U/L)-Day 280 | 0 Participants |
| T3: 10-1074 + VRC07-523LS | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Alanine Aminotransferase (U/L)-Day 336 | 0 Participants |
| T3: 10-1074 + VRC07-523LS | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Hemoglobin (g/dL)-Day 0 | 0 Participants |
| T3: 10-1074 + VRC07-523LS | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Hemoglobin (g/dL)-Day 112 | 0 Participants |
| T3: 10-1074 + VRC07-523LS | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Hemoglobin (g/dL)-Day 168 | 0 Participants |
| T3: 10-1074 + VRC07-523LS | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Hemoglobin (g/dL)-Day 336 | 0 Participants |
| T3: 10-1074 + VRC07-523LS | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Creatinine (mg/dL)-Day 56 | 0 Participants |
| T3: 10-1074 + VRC07-523LS | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Creatinine (mg/dL)-Day 112 | 0 Participants |
| T3: 10-1074 + VRC07-523LS | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Creatinine (mg/dL)-Day 140 | 0 Participants |
| T3: 10-1074 + VRC07-523LS | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Creatinine (mg/dL)-Day 224 | 0 Participants |
| T3: 10-1074 + VRC07-523LS | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Creatinine (mg/dL)-Day 280 | 0 Participants |
| T3: 10-1074 + VRC07-523LS | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Creatinine (mg/dL)-Day 336 | 0 Participants |
| T3: 10-1074 + VRC07-523LS | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Creatinine (mg/dL)-Day 448 | 0 Participants |
| T3: 10-1074 + VRC07-523LS | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | WBC (1000 cells/cubic mm)-Day 14 | 0 Participants |
| T3: 10-1074 + VRC07-523LS | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Platelets (1000 cells/cubic mm)-Baseline | 0 Participants |
| T3: 10-1074 + VRC07-523LS | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Lymphocytes (1000 cells/cubic mm)-Baseline | 0 Participants |
| T3: 10-1074 + VRC07-523LS | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Lymphocytes (1000 cells/cubic mm)-Day 14 | 0 Participants |
| T3: 10-1074 + VRC07-523LS | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Lymphocytes (1000 cells/cubic mm)-Day 56 | 0 Participants |
| T3: 10-1074 + VRC07-523LS | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Lymphocytes (1000 cells/cubic mm)-Day 84 | 0 Participants |
| T3: 10-1074 + VRC07-523LS | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Lymphocytes (1000 cells/cubic mm)-Day 168 | 0 Participants |
| T3: 10-1074 + VRC07-523LS | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Lymphocytes (1000 cells/cubic mm)-Day 448 | 0 Participants |
| T3: 10-1074 + VRC07-523LS | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Platelets (1000 cells/cubic mm)-Day 84 | 0 Participants |
| T3: 10-1074 + VRC07-523LS | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Platelets (1000 cells/cubic mm)-Day 112 | 0 Participants |
| T3: 10-1074 + VRC07-523LS | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Platelets (1000 cells/cubic mm)-Day 140 | 0 Participants |
| T3: 10-1074 + VRC07-523LS | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Platelets (1000 cells/cubic mm)-Day 168 | 0 Participants |
| T3: 10-1074 + VRC07-523LS | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Platelets (1000 cells/cubic mm)-Day 224 | 0 Participants |
| T3: 10-1074 + VRC07-523LS | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Platelets (1000 cells/cubic mm)-Day 280 | 1 Participants |
| T3: 10-1074 + VRC07-523LS | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Platelets (1000 cells/cubic mm)-Day 336 | 0 Participants |
| T3: 10-1074 + VRC07-523LS | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Platelets (1000 cells/cubic mm)-Day 392 | 0 Participants |
| T3: 10-1074 + VRC07-523LS | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Platelets (1000 cells/cubic mm)-Day 448 | 0 Participants |
| T3: 10-1074 + VRC07-523LS | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Lymphocytes (1000 cells/cubic mm)-Day 0 | 0 Participants |
| T3: 10-1074 + VRC07-523LS | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Lymphocytes (1000 cells/cubic mm)-Day 112 | 0 Participants |
| T3: 10-1074 + VRC07-523LS | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Lymphocytes (1000 cells/cubic mm)-Day 140 | 0 Participants |
| T3: 10-1074 + VRC07-523LS | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Lymphocytes (1000 cells/cubic mm)-Day 224 | 0 Participants |
| T3: 10-1074 + VRC07-523LS | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Lymphocytes (1000 cells/cubic mm)-Day 280 | 0 Participants |
| T3: 10-1074 + VRC07-523LS | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Lymphocytes (1000 cells/cubic mm)-Day 336 | 0 Participants |
| T3: 10-1074 + VRC07-523LS | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Lymphocytes (1000 cells/cubic mm)-Day 392 | 0 Participants |
| T3: 10-1074 + VRC07-523LS | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Neutrophils (1000 cells/cubic mm)-Baseline | 0 Participants |
| T3: 10-1074 + VRC07-523LS | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Neutrophils (1000 cells/cubic mm)-Day 0 | 0 Participants |
| T3: 10-1074 + VRC07-523LS | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Neutrophils (1000 cells/cubic mm)-Day 14 | 0 Participants |
| T3: 10-1074 + VRC07-523LS | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Neutrophils (1000 cells/cubic mm)-Day 56 | 0 Participants |
| T3: 10-1074 + VRC07-523LS | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Neutrophils (1000 cells/cubic mm)-Day 84 | 0 Participants |
| T3: 10-1074 + VRC07-523LS | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Neutrophils (1000 cells/cubic mm)-Day 112 | 0 Participants |
| T3: 10-1074 + VRC07-523LS | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Neutrophils (1000 cells/cubic mm)-Day 140 | 0 Participants |
| T3: 10-1074 + VRC07-523LS | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Neutrophils (1000 cells/cubic mm)-Day 168 | 0 Participants |
| T3: 10-1074 + VRC07-523LS | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Neutrophils (1000 cells/cubic mm)-Day 224 | 0 Participants |
| T3: 10-1074 + VRC07-523LS | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Neutrophils (1000 cells/cubic mm)-Day 336 | 0 Participants |
| T3: 10-1074 + VRC07-523LS | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Neutrophils (1000 cells/cubic mm)-Day 392 | 0 Participants |
| T3: 10-1074 + VRC07-523LS | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Neutrophils (1000 cells/cubic mm)-Day 448 | 0 Participants |
| T3: 10-1074 + VRC07-523LS | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Alanine Aminotransferase (U/L)-Baseline | 0 Participants |
| T3: 10-1074 + VRC07-523LS | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Alanine Aminotransferase (U/L)-Day 0 | 0 Participants |
| T3: 10-1074 + VRC07-523LS | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Alanine Aminotransferase (U/L)-Day 14 | 0 Participants |
| T3: 10-1074 + VRC07-523LS | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Alanine Aminotransferase (U/L)-Day 56 | 0 Participants |
| T3: 10-1074 + VRC07-523LS | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Alanine Aminotransferase (U/L)-Day 84 | 0 Participants |
| T3: 10-1074 + VRC07-523LS | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Alanine Aminotransferase (U/L)-Day 112 | 0 Participants |
| T3: 10-1074 + VRC07-523LS | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Alanine Aminotransferase (U/L)-Day 140 | 0 Participants |
| T3: 10-1074 + VRC07-523LS | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Alanine Aminotransferase (U/L)-Day 168 | 0 Participants |
| T3: 10-1074 + VRC07-523LS | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Alanine Aminotransferase (U/L)-Day 224 | 0 Participants |
| T3: 10-1074 + VRC07-523LS | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Alanine Aminotransferase (U/L)-Day 392 | 0 Participants |
| T3: 10-1074 + VRC07-523LS | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Alanine Aminotransferase (U/L)-Day 448 | 0 Participants |
| T3: 10-1074 + VRC07-523LS | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Hemoglobin (g/dL)-Baseline | 0 Participants |
| T3: 10-1074 + VRC07-523LS | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Hemoglobin (g/dL)-Day 14 | 1 Participants |
| T3: 10-1074 + VRC07-523LS | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Hemoglobin (g/dL)-Day 56 | 1 Participants |
| T3: 10-1074 + VRC07-523LS | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Hemoglobin (g/dL)-Day 84 | 0 Participants |
| T3: 10-1074 + VRC07-523LS | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Hemoglobin (g/dL)-Day 140 | 0 Participants |
| T3: 10-1074 + VRC07-523LS | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Hemoglobin (g/dL)-Day 224 | 0 Participants |
| T3: 10-1074 + VRC07-523LS | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Hemoglobin (g/dL)-Day 280 | 0 Participants |
| T3: 10-1074 + VRC07-523LS | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Hemoglobin (g/dL)-Day 392 | 0 Participants |
| T3: 10-1074 + VRC07-523LS | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Hemoglobin (g/dL)-Day 448 | 0 Participants |
| T3: 10-1074 + VRC07-523LS | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Creatinine (mg/dL)-Baseline | 0 Participants |
| T3: 10-1074 + VRC07-523LS | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Creatinine (mg/dL)-Day 0 | 0 Participants |
| T3: 10-1074 + VRC07-523LS | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Creatinine (mg/dL)-Day 14 | 0 Participants |
| T3: 10-1074 + VRC07-523LS | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Creatinine (mg/dL)-Day 84 | 0 Participants |
| T3: 10-1074 + VRC07-523LS | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Creatinine (mg/dL)-Day 168 | 0 Participants |
| T3: 10-1074 + VRC07-523LS | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Creatinine (mg/dL)-Day 392 | 0 Participants |
| T3: 10-1074 + VRC07-523LS | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | WBC (1000 cells/cubic mm)-Baseline | 0 Participants |
| T3: 10-1074 + VRC07-523LS | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | WBC (1000 cells/cubic mm)-Day 0 | 0 Participants |
| T3: 10-1074 + VRC07-523LS | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | WBC (1000 cells/cubic mm)-Day 56 | 0 Participants |
| T3: 10-1074 + VRC07-523LS | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | WBC (1000 cells/cubic mm)-Day 84 | 0 Participants |
| T3: 10-1074 + VRC07-523LS | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | WBC (1000 cells/cubic mm)-Day 112 | 0 Participants |
| T3: 10-1074 + VRC07-523LS | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | WBC (1000 cells/cubic mm)-Day 140 | 0 Participants |
| T3: 10-1074 + VRC07-523LS | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | WBC (1000 cells/cubic mm)-Day 168 | 0 Participants |
| T3: 10-1074 + VRC07-523LS | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | WBC (1000 cells/cubic mm)-Day 224 | 0 Participants |
| T3: 10-1074 + VRC07-523LS | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | WBC (1000 cells/cubic mm)-Day 280 | 0 Participants |
| T3: 10-1074 + VRC07-523LS | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | WBC (1000 cells/cubic mm)-Day 336 | 0 Participants |
| T3: 10-1074 + VRC07-523LS | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | WBC (1000 cells/cubic mm)-Day 392 | 0 Participants |
| T3: 10-1074 + VRC07-523LS | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | WBC (1000 cells/cubic mm)-Day 448 | 0 Participants |
| T3: 10-1074 + VRC07-523LS | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Platelets (1000 cells/cubic mm)-Day 0 | 0 Participants |
| T3: 10-1074 + VRC07-523LS | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Platelets (1000 cells/cubic mm)-Day 14 | 1 Participants |
| T3: 10-1074 + VRC07-523LS | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Platelets (1000 cells/cubic mm)-Day 56 | 0 Participants |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Neutrophils (1000 cells/cubic mm)-Day 224 | 0 Participants |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Alanine Aminotransferase (U/L)-Day 56 | 0 Participants |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Hemoglobin (g/dL)-Day 448 | 0 Participants |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Neutrophils (1000 cells/cubic mm)-Day 140 | 0 Participants |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | WBC (1000 cells/cubic mm)-Day 336 | 0 Participants |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Creatinine (mg/dL)-Baseline | 0 Participants |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Creatinine (mg/dL)-Day 336 | 0 Participants |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Creatinine (mg/dL)-Day 0 | 0 Participants |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Neutrophils (1000 cells/cubic mm)-Day 112 | 0 Participants |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Neutrophils (1000 cells/cubic mm)-Day 84 | 0 Participants |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Creatinine (mg/dL)-Day 280 | 0 Participants |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Creatinine (mg/dL)-Day 14 | 0 Participants |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Neutrophils (1000 cells/cubic mm)-Day 56 | 0 Participants |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Neutrophils (1000 cells/cubic mm)-Day 14 | 0 Participants |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Platelets (1000 cells/cubic mm)-Day 14 | 0 Participants |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Creatinine (mg/dL)-Day 84 | 0 Participants |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Neutrophils (1000 cells/cubic mm)-Day 0 | 0 Participants |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Neutrophils (1000 cells/cubic mm)-Baseline | 0 Participants |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Creatinine (mg/dL)-Day 112 | 0 Participants |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Lymphocytes (1000 cells/cubic mm)-Day 392 | 0 Participants |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Lymphocytes (1000 cells/cubic mm)-Day 336 | 0 Participants |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Creatinine (mg/dL)-Day 224 | 0 Participants |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Creatinine (mg/dL)-Day 168 | 0 Participants |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Lymphocytes (1000 cells/cubic mm)-Day 280 | 0 Participants |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Lymphocytes (1000 cells/cubic mm)-Day 112 | 0 Participants |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Lymphocytes (1000 cells/cubic mm)-Day 14 | 2 Participants |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Lymphocytes (1000 cells/cubic mm)-Day 0 | 0 Participants |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Creatinine (mg/dL)-Day 140 | 0 Participants |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Creatinine (mg/dL)-Day 392 | 0 Participants |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Lymphocytes (1000 cells/cubic mm)-Baseline | 0 Participants |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Platelets (1000 cells/cubic mm)-Day 336 | 1 Participants |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Platelets (1000 cells/cubic mm)-Day 280 | 0 Participants |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Platelets (1000 cells/cubic mm)-Day 168 | 0 Participants |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Hemoglobin (g/dL)-Baseline | 0 Participants |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | WBC (1000 cells/cubic mm)-Baseline | 0 Participants |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Platelets (1000 cells/cubic mm)-Day 140 | 0 Participants |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Platelets (1000 cells/cubic mm)-Day 112 | 0 Participants |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | WBC (1000 cells/cubic mm)-Day 448 | 0 Participants |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Platelets (1000 cells/cubic mm)-Day 84 | 0 Participants |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | WBC (1000 cells/cubic mm)-Day 14 | 0 Participants |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Neutrophils (1000 cells/cubic mm)-Day 168 | 0 Participants |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Lymphocytes (1000 cells/cubic mm)-Day 448 | 0 Participants |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Creatinine (mg/dL)-Day 56 | 0 Participants |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | WBC (1000 cells/cubic mm)-Day 56 | 0 Participants |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Lymphocytes (1000 cells/cubic mm)-Day 224 | 0 Participants |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Lymphocytes (1000 cells/cubic mm)-Day 168 | 0 Participants |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Hemoglobin (g/dL)-Day 392 | 0 Participants |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | WBC (1000 cells/cubic mm)-Day 84 | 0 Participants |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Lymphocytes (1000 cells/cubic mm)-Day 140 | 0 Participants |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Lymphocytes (1000 cells/cubic mm)-Day 84 | 0 Participants |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Platelets (1000 cells/cubic mm)-Baseline | 0 Participants |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | WBC (1000 cells/cubic mm)-Day 112 | 0 Participants |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Lymphocytes (1000 cells/cubic mm)-Day 56 | 0 Participants |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Platelets (1000 cells/cubic mm)-Day 448 | 0 Participants |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Hemoglobin (g/dL)-Day 336 | 0 Participants |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | WBC (1000 cells/cubic mm)-Day 140 | 0 Participants |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Platelets (1000 cells/cubic mm)-Day 392 | 0 Participants |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Platelets (1000 cells/cubic mm)-Day 224 | 0 Participants |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Alanine Aminotransferase (U/L)-Day 392 | 0 Participants |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | WBC (1000 cells/cubic mm)-Day 168 | 0 Participants |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Platelets (1000 cells/cubic mm)-Day 56 | 1 Participants |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Hemoglobin (g/dL)-Day 168 | 0 Participants |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | WBC (1000 cells/cubic mm)-Day 224 | 0 Participants |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Hemoglobin (g/dL)-Day 14 | 0 Participants |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Alanine Aminotransferase (U/L)-Day 448 | 0 Participants |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Platelets (1000 cells/cubic mm)-Day 0 | 0 Participants |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Hemoglobin (g/dL)-Day 56 | 0 Participants |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Alanine Aminotransferase (U/L)-Day 336 | 0 Participants |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Alanine Aminotransferase (U/L)-Day 280 | 0 Participants |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | WBC (1000 cells/cubic mm)-Day 392 | 0 Participants |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Hemoglobin (g/dL)-Day 84 | 0 Participants |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Hemoglobin (g/dL)-Day 112 | 0 Participants |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Alanine Aminotransferase (U/L)-Day 224 | 0 Participants |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Alanine Aminotransferase (U/L)-Day 168 | 0 Participants |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Hemoglobin (g/dL)-Day 0 | 0 Participants |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Hemoglobin (g/dL)-Day 140 | 0 Participants |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Alanine Aminotransferase (U/L)-Day 140 | 0 Participants |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Alanine Aminotransferase (U/L)-Day 112 | 0 Participants |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Alanine Aminotransferase (U/L)-Day 84 | 0 Participants |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Alanine Aminotransferase (U/L)-Day 14 | 0 Participants |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | WBC (1000 cells/cubic mm)-Day 280 | 0 Participants |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Hemoglobin (g/dL)-Day 224 | 0 Participants |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Alanine Aminotransferase (U/L)-Day 0 | 0 Participants |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Alanine Aminotransferase (U/L)-Baseline | 0 Participants |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | WBC (1000 cells/cubic mm)-Day 0 | 0 Participants |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Hemoglobin (g/dL)-Day 280 | 0 Participants |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Neutrophils (1000 cells/cubic mm)-Day 448 | 0 Participants |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Neutrophils (1000 cells/cubic mm)-Day 392 | 0 Participants |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Neutrophils (1000 cells/cubic mm)-Day 336 | 0 Participants |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Neutrophils (1000 cells/cubic mm)-Day 280 | 0 Participants |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | The Number (Percentage) of Participants With Lab Grade > 1 for Alanine Aminotransferase (ALT), Creatinine, Hemoglobin, Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) Was Summarized by Arm | Creatinine (mg/dL)-Day 448 | 0 Participants |
Secondary
Magnitude of Neutralizing Activity Against a Panel of Env Pseudotyped Reference Viruses in TZM-bl Cells for All Participants
Neutralizing antibodies against HIV-1 were measured as a function of reductions in Tat-regulated luciferase (Luc) reporter gene expression in TZM-bl cells. The assay performed in TZM-bl cells measured neutralization titers against the Env-pseudotyped viruses sensitive to the bnAbs (i.e., bnAb-specific viruses) in each infusion group.
Time frame: Measured during Screening, Days 0*, 3, 28, 56*, 112, 140*, 224* Days with * are only available for T4
Population: All participants enrolled with available neutralizing antibody data. Visits with 0 participants are due to: Treatment group T4 had more scheduled sample collection visits than treatment groups T1-T3.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| T1: PGT121 + VRC07-523LS mo 0 | Magnitude of Neutralizing Activity Against a Panel of Env Pseudotyped Reference Viruses in TZM-bl Cells for All Participants | DU156.12 (Day- 3) | 18539.26 Relative luminescence units (RLU) |
| T1: PGT121 + VRC07-523LS mo 0 | Magnitude of Neutralizing Activity Against a Panel of Env Pseudotyped Reference Viruses in TZM-bl Cells for All Participants | 377.v4.c09 (Day- 28) | 108.14 Relative luminescence units (RLU) |
| T1: PGT121 + VRC07-523LS mo 0 | Magnitude of Neutralizing Activity Against a Panel of Env Pseudotyped Reference Viruses in TZM-bl Cells for All Participants | TRO.11 (Day- 3) | 7813.45 Relative luminescence units (RLU) |
| T1: PGT121 + VRC07-523LS mo 0 | Magnitude of Neutralizing Activity Against a Panel of Env Pseudotyped Reference Viruses in TZM-bl Cells for All Participants | 0330.v4.c3 (Day-112) | 242.94 Relative luminescence units (RLU) |
| T1: PGT121 + VRC07-523LS mo 0 | Magnitude of Neutralizing Activity Against a Panel of Env Pseudotyped Reference Viruses in TZM-bl Cells for All Participants | DU156.12 (Day- 28) | 4812.81 Relative luminescence units (RLU) |
| T1: PGT121 + VRC07-523LS mo 0 | Magnitude of Neutralizing Activity Against a Panel of Env Pseudotyped Reference Viruses in TZM-bl Cells for All Participants | SC422661.8 (Day- 3) | 3925.17 Relative luminescence units (RLU) |
| T1: PGT121 + VRC07-523LS mo 0 | Magnitude of Neutralizing Activity Against a Panel of Env Pseudotyped Reference Viruses in TZM-bl Cells for All Participants | PVO.4 (Day- 28) | 523.42 Relative luminescence units (RLU) |
| T1: PGT121 + VRC07-523LS mo 0 | Magnitude of Neutralizing Activity Against a Panel of Env Pseudotyped Reference Viruses in TZM-bl Cells for All Participants | T263-8 (Day-112) | 168.55 Relative luminescence units (RLU) |
| T1: PGT121 + VRC07-523LS mo 0 | Magnitude of Neutralizing Activity Against a Panel of Env Pseudotyped Reference Viruses in TZM-bl Cells for All Participants | RHPA4259.7 (Day- 3) | 15786.94 Relative luminescence units (RLU) |
| T1: PGT121 + VRC07-523LS mo 0 | Magnitude of Neutralizing Activity Against a Panel of Env Pseudotyped Reference Viruses in TZM-bl Cells for All Participants | DU156.12 (Day-112) | 632.13 Relative luminescence units (RLU) |
| T1: PGT121 + VRC07-523LS mo 0 | Magnitude of Neutralizing Activity Against a Panel of Env Pseudotyped Reference Viruses in TZM-bl Cells for All Participants | RHPA4259.7 (Day-112) | 663.30 Relative luminescence units (RLU) |
| T1: PGT121 + VRC07-523LS mo 0 | Magnitude of Neutralizing Activity Against a Panel of Env Pseudotyped Reference Viruses in TZM-bl Cells for All Participants | T263-8 (Day- 28) | 652.72 Relative luminescence units (RLU) |
| T1: PGT121 + VRC07-523LS mo 0 | Magnitude of Neutralizing Activity Against a Panel of Env Pseudotyped Reference Viruses in TZM-bl Cells for All Participants | 0330.v4.c3 (Day- 3) | 6396.28 Relative luminescence units (RLU) |
| T1: PGT121 + VRC07-523LS mo 0 | Magnitude of Neutralizing Activity Against a Panel of Env Pseudotyped Reference Viruses in TZM-bl Cells for All Participants | PVO.4 (Day-112) | 80.37 Relative luminescence units (RLU) |
| T1: PGT121 + VRC07-523LS mo 0 | Magnitude of Neutralizing Activity Against a Panel of Env Pseudotyped Reference Viruses in TZM-bl Cells for All Participants | DU172.17 (Day- 28) | 434.85 Relative luminescence units (RLU) |
| T1: PGT121 + VRC07-523LS mo 0 | Magnitude of Neutralizing Activity Against a Panel of Env Pseudotyped Reference Viruses in TZM-bl Cells for All Participants | 377.v4.c09 (Day- 3) | 441.18 Relative luminescence units (RLU) |
| T1: PGT121 + VRC07-523LS mo 0 | Magnitude of Neutralizing Activity Against a Panel of Env Pseudotyped Reference Viruses in TZM-bl Cells for All Participants | DU172.17 (Day- 3) | 1518.88 Relative luminescence units (RLU) |
| T1: PGT121 + VRC07-523LS mo 0 | Magnitude of Neutralizing Activity Against a Panel of Env Pseudotyped Reference Viruses in TZM-bl Cells for All Participants | SC422661.8 (Day-112) | 213.39 Relative luminescence units (RLU) |
| T1: PGT121 + VRC07-523LS mo 0 | Magnitude of Neutralizing Activity Against a Panel of Env Pseudotyped Reference Viruses in TZM-bl Cells for All Participants | 0330.v4.c3 (Day- 28) | 1714.47 Relative luminescence units (RLU) |
| T1: PGT121 + VRC07-523LS mo 0 | Magnitude of Neutralizing Activity Against a Panel of Env Pseudotyped Reference Viruses in TZM-bl Cells for All Participants | SC422661.8 (Day- 28) | 1389.90 Relative luminescence units (RLU) |
| T1: PGT121 + VRC07-523LS mo 0 | Magnitude of Neutralizing Activity Against a Panel of Env Pseudotyped Reference Viruses in TZM-bl Cells for All Participants | Ce1176_A3 (Day- 3) | 11645.78 Relative luminescence units (RLU) |
| T1: PGT121 + VRC07-523LS mo 0 | Magnitude of Neutralizing Activity Against a Panel of Env Pseudotyped Reference Viruses in TZM-bl Cells for All Participants | AC10.0.29 (Day- 28) | 730.53 Relative luminescence units (RLU) |
| T1: PGT121 + VRC07-523LS mo 0 | Magnitude of Neutralizing Activity Against a Panel of Env Pseudotyped Reference Viruses in TZM-bl Cells for All Participants | 3426.v5.c17 (Day- 28) | 3041.45 Relative luminescence units (RLU) |
| T1: PGT121 + VRC07-523LS mo 0 | Magnitude of Neutralizing Activity Against a Panel of Env Pseudotyped Reference Viruses in TZM-bl Cells for All Participants | 3426.v5.c17 (Day- 3) | 16924.30 Relative luminescence units (RLU) |
| T1: PGT121 + VRC07-523LS mo 0 | Magnitude of Neutralizing Activity Against a Panel of Env Pseudotyped Reference Viruses in TZM-bl Cells for All Participants | Ce1176_A3 (Day- 28) | 1869.57 Relative luminescence units (RLU) |
| T1: PGT121 + VRC07-523LS mo 0 | Magnitude of Neutralizing Activity Against a Panel of Env Pseudotyped Reference Viruses in TZM-bl Cells for All Participants | DU172.17 (Day-112) | 45.10 Relative luminescence units (RLU) |
| T1: PGT121 + VRC07-523LS mo 0 | Magnitude of Neutralizing Activity Against a Panel of Env Pseudotyped Reference Viruses in TZM-bl Cells for All Participants | PVO.4 (Day- 3) | 1834.12 Relative luminescence units (RLU) |
| T1: PGT121 + VRC07-523LS mo 0 | Magnitude of Neutralizing Activity Against a Panel of Env Pseudotyped Reference Viruses in TZM-bl Cells for All Participants | TRO.11 (Day-112) | 116.90 Relative luminescence units (RLU) |
| T1: PGT121 + VRC07-523LS mo 0 | Magnitude of Neutralizing Activity Against a Panel of Env Pseudotyped Reference Viruses in TZM-bl Cells for All Participants | 377.v4.c09 (Day-112) | 16.27 Relative luminescence units (RLU) |
| T1: PGT121 + VRC07-523LS mo 0 | Magnitude of Neutralizing Activity Against a Panel of Env Pseudotyped Reference Viruses in TZM-bl Cells for All Participants | Ce1176_A3 (Day-112) | 139.63 Relative luminescence units (RLU) |
| T1: PGT121 + VRC07-523LS mo 0 | Magnitude of Neutralizing Activity Against a Panel of Env Pseudotyped Reference Viruses in TZM-bl Cells for All Participants | AC10.0.29 (Day- 3) | 3307.09 Relative luminescence units (RLU) |
| T1: PGT121 + VRC07-523LS mo 0 | Magnitude of Neutralizing Activity Against a Panel of Env Pseudotyped Reference Viruses in TZM-bl Cells for All Participants | RHPA4259.7 (Day- 28) | 3718.80 Relative luminescence units (RLU) |
| T1: PGT121 + VRC07-523LS mo 0 | Magnitude of Neutralizing Activity Against a Panel of Env Pseudotyped Reference Viruses in TZM-bl Cells for All Participants | TRO.11 (Day- 28) | 1503.04 Relative luminescence units (RLU) |
| T1: PGT121 + VRC07-523LS mo 0 | Magnitude of Neutralizing Activity Against a Panel of Env Pseudotyped Reference Viruses in TZM-bl Cells for All Participants | 3426.v5.c17 (Day-112) | 362.56 Relative luminescence units (RLU) |
| T1: PGT121 + VRC07-523LS mo 0 | Magnitude of Neutralizing Activity Against a Panel of Env Pseudotyped Reference Viruses in TZM-bl Cells for All Participants | T263-8 (Day- 3) | 2776.59 Relative luminescence units (RLU) |
| T1: PGT121 + VRC07-523LS mo 0 | Magnitude of Neutralizing Activity Against a Panel of Env Pseudotyped Reference Viruses in TZM-bl Cells for All Participants | AC10.0.29 (Day-112) | 58.82 Relative luminescence units (RLU) |
| T2: PGDM1400 + VRC07-523LS mo 0 | Magnitude of Neutralizing Activity Against a Panel of Env Pseudotyped Reference Viruses in TZM-bl Cells for All Participants | DU156.12 (Day- 28) | 6655.88 Relative luminescence units (RLU) |
| T2: PGDM1400 + VRC07-523LS mo 0 | Magnitude of Neutralizing Activity Against a Panel of Env Pseudotyped Reference Viruses in TZM-bl Cells for All Participants | SC422661.8 (Day- 3) | 2519.42 Relative luminescence units (RLU) |
| T2: PGDM1400 + VRC07-523LS mo 0 | Magnitude of Neutralizing Activity Against a Panel of Env Pseudotyped Reference Viruses in TZM-bl Cells for All Participants | AC10.0.29 (Day- 3) | 1198.26 Relative luminescence units (RLU) |
| T2: PGDM1400 + VRC07-523LS mo 0 | Magnitude of Neutralizing Activity Against a Panel of Env Pseudotyped Reference Viruses in TZM-bl Cells for All Participants | AC10.0.29 (Day- 28) | 285.36 Relative luminescence units (RLU) |
| T2: PGDM1400 + VRC07-523LS mo 0 | Magnitude of Neutralizing Activity Against a Panel of Env Pseudotyped Reference Viruses in TZM-bl Cells for All Participants | SC422661.8 (Day- 28) | 1035.29 Relative luminescence units (RLU) |
| T2: PGDM1400 + VRC07-523LS mo 0 | Magnitude of Neutralizing Activity Against a Panel of Env Pseudotyped Reference Viruses in TZM-bl Cells for All Participants | AC10.0.29 (Day-112) | 37.55 Relative luminescence units (RLU) |
| T2: PGDM1400 + VRC07-523LS mo 0 | Magnitude of Neutralizing Activity Against a Panel of Env Pseudotyped Reference Viruses in TZM-bl Cells for All Participants | PVO.4 (Day-112) | 50.58 Relative luminescence units (RLU) |
| T2: PGDM1400 + VRC07-523LS mo 0 | Magnitude of Neutralizing Activity Against a Panel of Env Pseudotyped Reference Viruses in TZM-bl Cells for All Participants | SC422661.8 (Day-112) | 163.39 Relative luminescence units (RLU) |
| T2: PGDM1400 + VRC07-523LS mo 0 | Magnitude of Neutralizing Activity Against a Panel of Env Pseudotyped Reference Viruses in TZM-bl Cells for All Participants | Ce1176_A3 (Day- 3) | 537.29 Relative luminescence units (RLU) |
| T2: PGDM1400 + VRC07-523LS mo 0 | Magnitude of Neutralizing Activity Against a Panel of Env Pseudotyped Reference Viruses in TZM-bl Cells for All Participants | Ce1176_A3 (Day- 28) | 137.78 Relative luminescence units (RLU) |
| T2: PGDM1400 + VRC07-523LS mo 0 | Magnitude of Neutralizing Activity Against a Panel of Env Pseudotyped Reference Viruses in TZM-bl Cells for All Participants | DU172.17 (Day-112) | 16.67 Relative luminescence units (RLU) |
| T2: PGDM1400 + VRC07-523LS mo 0 | Magnitude of Neutralizing Activity Against a Panel of Env Pseudotyped Reference Viruses in TZM-bl Cells for All Participants | Ce1176_A3 (Day-112) | 28.13 Relative luminescence units (RLU) |
| T2: PGDM1400 + VRC07-523LS mo 0 | Magnitude of Neutralizing Activity Against a Panel of Env Pseudotyped Reference Viruses in TZM-bl Cells for All Participants | DU172.17 (Day- 28) | 170.68 Relative luminescence units (RLU) |
| T2: PGDM1400 + VRC07-523LS mo 0 | Magnitude of Neutralizing Activity Against a Panel of Env Pseudotyped Reference Viruses in TZM-bl Cells for All Participants | T263-8 (Day- 3) | 8794.97 Relative luminescence units (RLU) |
| T2: PGDM1400 + VRC07-523LS mo 0 | Magnitude of Neutralizing Activity Against a Panel of Env Pseudotyped Reference Viruses in TZM-bl Cells for All Participants | DU156.12 (Day- 3) | 27452.85 Relative luminescence units (RLU) |
| T2: PGDM1400 + VRC07-523LS mo 0 | Magnitude of Neutralizing Activity Against a Panel of Env Pseudotyped Reference Viruses in TZM-bl Cells for All Participants | DU156.12 (Day-112) | 620.22 Relative luminescence units (RLU) |
| T2: PGDM1400 + VRC07-523LS mo 0 | Magnitude of Neutralizing Activity Against a Panel of Env Pseudotyped Reference Viruses in TZM-bl Cells for All Participants | 0330.v4.c3 (Day- 3) | 74297.85 Relative luminescence units (RLU) |
| T2: PGDM1400 + VRC07-523LS mo 0 | Magnitude of Neutralizing Activity Against a Panel of Env Pseudotyped Reference Viruses in TZM-bl Cells for All Participants | RHPA4259.7 (Day- 3) | 4313.94 Relative luminescence units (RLU) |
| T2: PGDM1400 + VRC07-523LS mo 0 | Magnitude of Neutralizing Activity Against a Panel of Env Pseudotyped Reference Viruses in TZM-bl Cells for All Participants | DU172.17 (Day- 3) | 448.77 Relative luminescence units (RLU) |
| T2: PGDM1400 + VRC07-523LS mo 0 | Magnitude of Neutralizing Activity Against a Panel of Env Pseudotyped Reference Viruses in TZM-bl Cells for All Participants | T263-8 (Day- 28) | 2180.36 Relative luminescence units (RLU) |
| T2: PGDM1400 + VRC07-523LS mo 0 | Magnitude of Neutralizing Activity Against a Panel of Env Pseudotyped Reference Viruses in TZM-bl Cells for All Participants | 0330.v4.c3 (Day- 28) | 12264.66 Relative luminescence units (RLU) |
| T2: PGDM1400 + VRC07-523LS mo 0 | Magnitude of Neutralizing Activity Against a Panel of Env Pseudotyped Reference Viruses in TZM-bl Cells for All Participants | T263-8 (Day-112) | 260.69 Relative luminescence units (RLU) |
| T2: PGDM1400 + VRC07-523LS mo 0 | Magnitude of Neutralizing Activity Against a Panel of Env Pseudotyped Reference Viruses in TZM-bl Cells for All Participants | 0330.v4.c3 (Day-112) | 1216.32 Relative luminescence units (RLU) |
| T2: PGDM1400 + VRC07-523LS mo 0 | Magnitude of Neutralizing Activity Against a Panel of Env Pseudotyped Reference Viruses in TZM-bl Cells for All Participants | TRO.11 (Day- 3) | 887.77 Relative luminescence units (RLU) |
| T2: PGDM1400 + VRC07-523LS mo 0 | Magnitude of Neutralizing Activity Against a Panel of Env Pseudotyped Reference Viruses in TZM-bl Cells for All Participants | TRO.11 (Day- 28) | 249.19 Relative luminescence units (RLU) |
| T2: PGDM1400 + VRC07-523LS mo 0 | Magnitude of Neutralizing Activity Against a Panel of Env Pseudotyped Reference Viruses in TZM-bl Cells for All Participants | RHPA4259.7 (Day- 28) | 1748.53 Relative luminescence units (RLU) |
| T2: PGDM1400 + VRC07-523LS mo 0 | Magnitude of Neutralizing Activity Against a Panel of Env Pseudotyped Reference Viruses in TZM-bl Cells for All Participants | TRO.11 (Day-112) | 73.93 Relative luminescence units (RLU) |
| T2: PGDM1400 + VRC07-523LS mo 0 | Magnitude of Neutralizing Activity Against a Panel of Env Pseudotyped Reference Viruses in TZM-bl Cells for All Participants | 3426.v5.c17 (Day- 3) | 144218.5 Relative luminescence units (RLU) |
| T2: PGDM1400 + VRC07-523LS mo 0 | Magnitude of Neutralizing Activity Against a Panel of Env Pseudotyped Reference Viruses in TZM-bl Cells for All Participants | PVO.4 (Day- 3) | 773.42 Relative luminescence units (RLU) |
| T2: PGDM1400 + VRC07-523LS mo 0 | Magnitude of Neutralizing Activity Against a Panel of Env Pseudotyped Reference Viruses in TZM-bl Cells for All Participants | 3426.v5.c17 (Day- 28) | 32852.84 Relative luminescence units (RLU) |
| T2: PGDM1400 + VRC07-523LS mo 0 | Magnitude of Neutralizing Activity Against a Panel of Env Pseudotyped Reference Viruses in TZM-bl Cells for All Participants | 3426.v5.c17 (Day-112) | 1488.31 Relative luminescence units (RLU) |
| T2: PGDM1400 + VRC07-523LS mo 0 | Magnitude of Neutralizing Activity Against a Panel of Env Pseudotyped Reference Viruses in TZM-bl Cells for All Participants | RHPA4259.7 (Day-112) | 506.64 Relative luminescence units (RLU) |
| T2: PGDM1400 + VRC07-523LS mo 0 | Magnitude of Neutralizing Activity Against a Panel of Env Pseudotyped Reference Viruses in TZM-bl Cells for All Participants | 377.v4.c09 (Day- 3) | 255.40 Relative luminescence units (RLU) |
| T2: PGDM1400 + VRC07-523LS mo 0 | Magnitude of Neutralizing Activity Against a Panel of Env Pseudotyped Reference Viruses in TZM-bl Cells for All Participants | PVO.4 (Day- 28) | 244.89 Relative luminescence units (RLU) |
| T2: PGDM1400 + VRC07-523LS mo 0 | Magnitude of Neutralizing Activity Against a Panel of Env Pseudotyped Reference Viruses in TZM-bl Cells for All Participants | 377.v4.c09 (Day- 28) | 63.14 Relative luminescence units (RLU) |
| T2: PGDM1400 + VRC07-523LS mo 0 | Magnitude of Neutralizing Activity Against a Panel of Env Pseudotyped Reference Viruses in TZM-bl Cells for All Participants | 377.v4.c09 (Day-112) | 5.00 Relative luminescence units (RLU) |
| T3: 10-1074 + VRC07-523LS | Magnitude of Neutralizing Activity Against a Panel of Env Pseudotyped Reference Viruses in TZM-bl Cells for All Participants | 0330.v4.c3 (Day-112) | 209.33 Relative luminescence units (RLU) |
| T3: 10-1074 + VRC07-523LS | Magnitude of Neutralizing Activity Against a Panel of Env Pseudotyped Reference Viruses in TZM-bl Cells for All Participants | DU172.17 (Day-112) | 61.30 Relative luminescence units (RLU) |
| T3: 10-1074 + VRC07-523LS | Magnitude of Neutralizing Activity Against a Panel of Env Pseudotyped Reference Viruses in TZM-bl Cells for All Participants | PVO.4 (Day- 3) | 1918.35 Relative luminescence units (RLU) |
| T3: 10-1074 + VRC07-523LS | Magnitude of Neutralizing Activity Against a Panel of Env Pseudotyped Reference Viruses in TZM-bl Cells for All Participants | TRO.11 (Day- 28) | 1085.04 Relative luminescence units (RLU) |
| T3: 10-1074 + VRC07-523LS | Magnitude of Neutralizing Activity Against a Panel of Env Pseudotyped Reference Viruses in TZM-bl Cells for All Participants | Ce1176_A3 (Day-112) | 165.45 Relative luminescence units (RLU) |
| T3: 10-1074 + VRC07-523LS | Magnitude of Neutralizing Activity Against a Panel of Env Pseudotyped Reference Viruses in TZM-bl Cells for All Participants | AC10.0.29 (Day- 28) | 842.99 Relative luminescence units (RLU) |
| T3: 10-1074 + VRC07-523LS | Magnitude of Neutralizing Activity Against a Panel of Env Pseudotyped Reference Viruses in TZM-bl Cells for All Participants | PVO.4 (Day-112) | 99.15 Relative luminescence units (RLU) |
| T3: 10-1074 + VRC07-523LS | Magnitude of Neutralizing Activity Against a Panel of Env Pseudotyped Reference Viruses in TZM-bl Cells for All Participants | AC10.0.29 (Day- 3) | 2763.45 Relative luminescence units (RLU) |
| T3: 10-1074 + VRC07-523LS | Magnitude of Neutralizing Activity Against a Panel of Env Pseudotyped Reference Viruses in TZM-bl Cells for All Participants | TRO.11 (Day-112) | 193.46 Relative luminescence units (RLU) |
| T3: 10-1074 + VRC07-523LS | Magnitude of Neutralizing Activity Against a Panel of Env Pseudotyped Reference Viruses in TZM-bl Cells for All Participants | RHPA4259.7 (Day- 28) | 2996.20 Relative luminescence units (RLU) |
| T3: 10-1074 + VRC07-523LS | Magnitude of Neutralizing Activity Against a Panel of Env Pseudotyped Reference Viruses in TZM-bl Cells for All Participants | Ce1176_A3 (Day- 28) | 1475.03 Relative luminescence units (RLU) |
| T3: 10-1074 + VRC07-523LS | Magnitude of Neutralizing Activity Against a Panel of Env Pseudotyped Reference Viruses in TZM-bl Cells for All Participants | SC422661.8 (Day-112) | 219.98 Relative luminescence units (RLU) |
| T3: 10-1074 + VRC07-523LS | Magnitude of Neutralizing Activity Against a Panel of Env Pseudotyped Reference Viruses in TZM-bl Cells for All Participants | 377.v4.c09 (Day- 28) | 116.45 Relative luminescence units (RLU) |
| T3: 10-1074 + VRC07-523LS | Magnitude of Neutralizing Activity Against a Panel of Env Pseudotyped Reference Viruses in TZM-bl Cells for All Participants | 3426.v5.c17 (Day- 3) | 9665.13 Relative luminescence units (RLU) |
| T3: 10-1074 + VRC07-523LS | Magnitude of Neutralizing Activity Against a Panel of Env Pseudotyped Reference Viruses in TZM-bl Cells for All Participants | 377.v4.c09 (Day- 3) | 380.32 Relative luminescence units (RLU) |
| T3: 10-1074 + VRC07-523LS | Magnitude of Neutralizing Activity Against a Panel of Env Pseudotyped Reference Viruses in TZM-bl Cells for All Participants | Ce1176_A3 (Day- 3) | 4781.11 Relative luminescence units (RLU) |
| T3: 10-1074 + VRC07-523LS | Magnitude of Neutralizing Activity Against a Panel of Env Pseudotyped Reference Viruses in TZM-bl Cells for All Participants | PVO.4 (Day- 28) | 548.04 Relative luminescence units (RLU) |
| T3: 10-1074 + VRC07-523LS | Magnitude of Neutralizing Activity Against a Panel of Env Pseudotyped Reference Viruses in TZM-bl Cells for All Participants | 3426.v5.c17 (Day- 28) | 2676.34 Relative luminescence units (RLU) |
| T3: 10-1074 + VRC07-523LS | Magnitude of Neutralizing Activity Against a Panel of Env Pseudotyped Reference Viruses in TZM-bl Cells for All Participants | AC10.0.29 (Day-112) | 152.58 Relative luminescence units (RLU) |
| T3: 10-1074 + VRC07-523LS | Magnitude of Neutralizing Activity Against a Panel of Env Pseudotyped Reference Viruses in TZM-bl Cells for All Participants | DU172.17 (Day- 3) | 1315.85 Relative luminescence units (RLU) |
| T3: 10-1074 + VRC07-523LS | Magnitude of Neutralizing Activity Against a Panel of Env Pseudotyped Reference Viruses in TZM-bl Cells for All Participants | 0330.v4.c3 (Day- 3) | 6121.19 Relative luminescence units (RLU) |
| T3: 10-1074 + VRC07-523LS | Magnitude of Neutralizing Activity Against a Panel of Env Pseudotyped Reference Viruses in TZM-bl Cells for All Participants | DU156.12 (Day-112) | 629.27 Relative luminescence units (RLU) |
| T3: 10-1074 + VRC07-523LS | Magnitude of Neutralizing Activity Against a Panel of Env Pseudotyped Reference Viruses in TZM-bl Cells for All Participants | SC422661.8 (Day- 28) | 1408.81 Relative luminescence units (RLU) |
| T3: 10-1074 + VRC07-523LS | Magnitude of Neutralizing Activity Against a Panel of Env Pseudotyped Reference Viruses in TZM-bl Cells for All Participants | T263-8 (Day- 28) | 709.37 Relative luminescence units (RLU) |
| T3: 10-1074 + VRC07-523LS | Magnitude of Neutralizing Activity Against a Panel of Env Pseudotyped Reference Viruses in TZM-bl Cells for All Participants | SC422661.8 (Day- 3) | 3601.22 Relative luminescence units (RLU) |
| T3: 10-1074 + VRC07-523LS | Magnitude of Neutralizing Activity Against a Panel of Env Pseudotyped Reference Viruses in TZM-bl Cells for All Participants | 0330.v4.c3 (Day- 28) | 1117.61 Relative luminescence units (RLU) |
| T3: 10-1074 + VRC07-523LS | Magnitude of Neutralizing Activity Against a Panel of Env Pseudotyped Reference Viruses in TZM-bl Cells for All Participants | DU172.17 (Day- 28) | 398.72 Relative luminescence units (RLU) |
| T3: 10-1074 + VRC07-523LS | Magnitude of Neutralizing Activity Against a Panel of Env Pseudotyped Reference Viruses in TZM-bl Cells for All Participants | 3426.v5.c17 (Day-112) | 447.09 Relative luminescence units (RLU) |
| T3: 10-1074 + VRC07-523LS | Magnitude of Neutralizing Activity Against a Panel of Env Pseudotyped Reference Viruses in TZM-bl Cells for All Participants | T263-8 (Day-112) | 156.80 Relative luminescence units (RLU) |
| T3: 10-1074 + VRC07-523LS | Magnitude of Neutralizing Activity Against a Panel of Env Pseudotyped Reference Viruses in TZM-bl Cells for All Participants | RHPA4259.7 (Day- 3) | 6847.08 Relative luminescence units (RLU) |
| T3: 10-1074 + VRC07-523LS | Magnitude of Neutralizing Activity Against a Panel of Env Pseudotyped Reference Viruses in TZM-bl Cells for All Participants | DU156.12 (Day- 28) | 2989.42 Relative luminescence units (RLU) |
| T3: 10-1074 + VRC07-523LS | Magnitude of Neutralizing Activity Against a Panel of Env Pseudotyped Reference Viruses in TZM-bl Cells for All Participants | T263-8 (Day- 3) | 1811.12 Relative luminescence units (RLU) |
| T3: 10-1074 + VRC07-523LS | Magnitude of Neutralizing Activity Against a Panel of Env Pseudotyped Reference Viruses in TZM-bl Cells for All Participants | 377.v4.c09 (Day-112) | 14.68 Relative luminescence units (RLU) |
| T3: 10-1074 + VRC07-523LS | Magnitude of Neutralizing Activity Against a Panel of Env Pseudotyped Reference Viruses in TZM-bl Cells for All Participants | DU156.12 (Day- 3) | 10841.11 Relative luminescence units (RLU) |
| T3: 10-1074 + VRC07-523LS | Magnitude of Neutralizing Activity Against a Panel of Env Pseudotyped Reference Viruses in TZM-bl Cells for All Participants | RHPA4259.7 (Day-112) | 528.88 Relative luminescence units (RLU) |
| T3: 10-1074 + VRC07-523LS | Magnitude of Neutralizing Activity Against a Panel of Env Pseudotyped Reference Viruses in TZM-bl Cells for All Participants | TRO.11 (Day- 3) | 4253.82 Relative luminescence units (RLU) |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Magnitude of Neutralizing Activity Against a Panel of Env Pseudotyped Reference Viruses in TZM-bl Cells for All Participants | TRO.11 (Day-224) | 111.00 Relative luminescence units (RLU) |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Magnitude of Neutralizing Activity Against a Panel of Env Pseudotyped Reference Viruses in TZM-bl Cells for All Participants | 377.v4.c09 (Day- 56) | 85.74 Relative luminescence units (RLU) |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Magnitude of Neutralizing Activity Against a Panel of Env Pseudotyped Reference Viruses in TZM-bl Cells for All Participants | DU172.17 (Day-140) | 43.33 Relative luminescence units (RLU) |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Magnitude of Neutralizing Activity Against a Panel of Env Pseudotyped Reference Viruses in TZM-bl Cells for All Participants | PVO.4 (Day- 28) | 611.64 Relative luminescence units (RLU) |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Magnitude of Neutralizing Activity Against a Panel of Env Pseudotyped Reference Viruses in TZM-bl Cells for All Participants | DU172.17 (Day- 28) | 413.93 Relative luminescence units (RLU) |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Magnitude of Neutralizing Activity Against a Panel of Env Pseudotyped Reference Viruses in TZM-bl Cells for All Participants | DU172.17 (Day- 56) | 187.19 Relative luminescence units (RLU) |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Magnitude of Neutralizing Activity Against a Panel of Env Pseudotyped Reference Viruses in TZM-bl Cells for All Participants | DU172.17 (Day-112) | 56.99 Relative luminescence units (RLU) |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Magnitude of Neutralizing Activity Against a Panel of Env Pseudotyped Reference Viruses in TZM-bl Cells for All Participants | DU172.17 (Day-224) | 33.71 Relative luminescence units (RLU) |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Magnitude of Neutralizing Activity Against a Panel of Env Pseudotyped Reference Viruses in TZM-bl Cells for All Participants | PVO.4 (Day- 0) | 5.00 Relative luminescence units (RLU) |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Magnitude of Neutralizing Activity Against a Panel of Env Pseudotyped Reference Viruses in TZM-bl Cells for All Participants | PVO.4 (Day- 3) | 2078.34 Relative luminescence units (RLU) |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Magnitude of Neutralizing Activity Against a Panel of Env Pseudotyped Reference Viruses in TZM-bl Cells for All Participants | PVO.4 (Day- 56) | 316.00 Relative luminescence units (RLU) |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Magnitude of Neutralizing Activity Against a Panel of Env Pseudotyped Reference Viruses in TZM-bl Cells for All Participants | PVO.4 (Day-112) | 92.98 Relative luminescence units (RLU) |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Magnitude of Neutralizing Activity Against a Panel of Env Pseudotyped Reference Viruses in TZM-bl Cells for All Participants | PVO.4 (Day-140) | 45.61 Relative luminescence units (RLU) |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Magnitude of Neutralizing Activity Against a Panel of Env Pseudotyped Reference Viruses in TZM-bl Cells for All Participants | PVO.4 (Day-224) | 58.33 Relative luminescence units (RLU) |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Magnitude of Neutralizing Activity Against a Panel of Env Pseudotyped Reference Viruses in TZM-bl Cells for All Participants | RHPA4259.7 (Day- 0) | 5.00 Relative luminescence units (RLU) |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Magnitude of Neutralizing Activity Against a Panel of Env Pseudotyped Reference Viruses in TZM-bl Cells for All Participants | RHPA4259.7 (Day- 3) | 11323.55 Relative luminescence units (RLU) |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Magnitude of Neutralizing Activity Against a Panel of Env Pseudotyped Reference Viruses in TZM-bl Cells for All Participants | RHPA4259.7 (Day- 28) | 3560.23 Relative luminescence units (RLU) |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Magnitude of Neutralizing Activity Against a Panel of Env Pseudotyped Reference Viruses in TZM-bl Cells for All Participants | RHPA4259.7 (Day- 56) | 2114.58 Relative luminescence units (RLU) |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Magnitude of Neutralizing Activity Against a Panel of Env Pseudotyped Reference Viruses in TZM-bl Cells for All Participants | RHPA4259.7 (Day-112) | 562.77 Relative luminescence units (RLU) |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Magnitude of Neutralizing Activity Against a Panel of Env Pseudotyped Reference Viruses in TZM-bl Cells for All Participants | RHPA4259.7 (Day-140) | 384.75 Relative luminescence units (RLU) |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Magnitude of Neutralizing Activity Against a Panel of Env Pseudotyped Reference Viruses in TZM-bl Cells for All Participants | RHPA4259.7 (Day-224) | 406.26 Relative luminescence units (RLU) |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Magnitude of Neutralizing Activity Against a Panel of Env Pseudotyped Reference Viruses in TZM-bl Cells for All Participants | SC422661.8 (Day- 0) | 5.00 Relative luminescence units (RLU) |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Magnitude of Neutralizing Activity Against a Panel of Env Pseudotyped Reference Viruses in TZM-bl Cells for All Participants | SC422661.8 (Day- 3) | 5345.96 Relative luminescence units (RLU) |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Magnitude of Neutralizing Activity Against a Panel of Env Pseudotyped Reference Viruses in TZM-bl Cells for All Participants | SC422661.8 (Day- 28) | 1377.52 Relative luminescence units (RLU) |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Magnitude of Neutralizing Activity Against a Panel of Env Pseudotyped Reference Viruses in TZM-bl Cells for All Participants | SC422661.8 (Day- 56) | 765.08 Relative luminescence units (RLU) |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Magnitude of Neutralizing Activity Against a Panel of Env Pseudotyped Reference Viruses in TZM-bl Cells for All Participants | SC422661.8 (Day-112) | 189.00 Relative luminescence units (RLU) |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Magnitude of Neutralizing Activity Against a Panel of Env Pseudotyped Reference Viruses in TZM-bl Cells for All Participants | SC422661.8 (Day-140) | 120.06 Relative luminescence units (RLU) |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Magnitude of Neutralizing Activity Against a Panel of Env Pseudotyped Reference Viruses in TZM-bl Cells for All Participants | SC422661.8 (Day-224) | 192.58 Relative luminescence units (RLU) |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Magnitude of Neutralizing Activity Against a Panel of Env Pseudotyped Reference Viruses in TZM-bl Cells for All Participants | T263-8 (Day- 0) | 5.00 Relative luminescence units (RLU) |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Magnitude of Neutralizing Activity Against a Panel of Env Pseudotyped Reference Viruses in TZM-bl Cells for All Participants | T263-8 (Day- 3) | 10506.56 Relative luminescence units (RLU) |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Magnitude of Neutralizing Activity Against a Panel of Env Pseudotyped Reference Viruses in TZM-bl Cells for All Participants | 0330.v4.c3 (Day- 0) | 5.00 Relative luminescence units (RLU) |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Magnitude of Neutralizing Activity Against a Panel of Env Pseudotyped Reference Viruses in TZM-bl Cells for All Participants | 0330.v4.c3 (Day- 3) | 89412.79 Relative luminescence units (RLU) |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Magnitude of Neutralizing Activity Against a Panel of Env Pseudotyped Reference Viruses in TZM-bl Cells for All Participants | 0330.v4.c3 (Day- 28) | 19794.60 Relative luminescence units (RLU) |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Magnitude of Neutralizing Activity Against a Panel of Env Pseudotyped Reference Viruses in TZM-bl Cells for All Participants | 0330.v4.c3 (Day- 56) | 5217.82 Relative luminescence units (RLU) |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Magnitude of Neutralizing Activity Against a Panel of Env Pseudotyped Reference Viruses in TZM-bl Cells for All Participants | 0330.v4.c3 (Day-112) | 611.93 Relative luminescence units (RLU) |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Magnitude of Neutralizing Activity Against a Panel of Env Pseudotyped Reference Viruses in TZM-bl Cells for All Participants | 0330.v4.c3 (Day-140) | 589.67 Relative luminescence units (RLU) |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Magnitude of Neutralizing Activity Against a Panel of Env Pseudotyped Reference Viruses in TZM-bl Cells for All Participants | 0330.v4.c3 (Day-224) | 343.14 Relative luminescence units (RLU) |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Magnitude of Neutralizing Activity Against a Panel of Env Pseudotyped Reference Viruses in TZM-bl Cells for All Participants | 3426.v5.c17 (Day- 0) | 5.00 Relative luminescence units (RLU) |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Magnitude of Neutralizing Activity Against a Panel of Env Pseudotyped Reference Viruses in TZM-bl Cells for All Participants | 3426.v5.c17 (Day- 3) | 368712.2 Relative luminescence units (RLU) |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Magnitude of Neutralizing Activity Against a Panel of Env Pseudotyped Reference Viruses in TZM-bl Cells for All Participants | 3426.v5.c17 (Day- 28) | 66390.30 Relative luminescence units (RLU) |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Magnitude of Neutralizing Activity Against a Panel of Env Pseudotyped Reference Viruses in TZM-bl Cells for All Participants | 3426.v5.c17 (Day-112) | 1288.16 Relative luminescence units (RLU) |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Magnitude of Neutralizing Activity Against a Panel of Env Pseudotyped Reference Viruses in TZM-bl Cells for All Participants | 3426.v5.c17 (Day-140) | 822.84 Relative luminescence units (RLU) |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Magnitude of Neutralizing Activity Against a Panel of Env Pseudotyped Reference Viruses in TZM-bl Cells for All Participants | 3426.v5.c17 (Day-224) | 537.48 Relative luminescence units (RLU) |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Magnitude of Neutralizing Activity Against a Panel of Env Pseudotyped Reference Viruses in TZM-bl Cells for All Participants | 377.v4.c09 (Day- 0) | 5.00 Relative luminescence units (RLU) |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Magnitude of Neutralizing Activity Against a Panel of Env Pseudotyped Reference Viruses in TZM-bl Cells for All Participants | 377.v4.c09 (Day- 3) | 591.58 Relative luminescence units (RLU) |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Magnitude of Neutralizing Activity Against a Panel of Env Pseudotyped Reference Viruses in TZM-bl Cells for All Participants | 377.v4.c09 (Day- 28) | 179.21 Relative luminescence units (RLU) |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Magnitude of Neutralizing Activity Against a Panel of Env Pseudotyped Reference Viruses in TZM-bl Cells for All Participants | 377.v4.c09 (Day-112) | 17.94 Relative luminescence units (RLU) |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Magnitude of Neutralizing Activity Against a Panel of Env Pseudotyped Reference Viruses in TZM-bl Cells for All Participants | 377.v4.c09 (Day-140) | 14.48 Relative luminescence units (RLU) |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Magnitude of Neutralizing Activity Against a Panel of Env Pseudotyped Reference Viruses in TZM-bl Cells for All Participants | 377.v4.c09 (Day-224) | 17.09 Relative luminescence units (RLU) |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Magnitude of Neutralizing Activity Against a Panel of Env Pseudotyped Reference Viruses in TZM-bl Cells for All Participants | AC10.0.29 (Day- 0) | 5.00 Relative luminescence units (RLU) |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Magnitude of Neutralizing Activity Against a Panel of Env Pseudotyped Reference Viruses in TZM-bl Cells for All Participants | AC10.0.29 (Day- 3) | 3854.76 Relative luminescence units (RLU) |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Magnitude of Neutralizing Activity Against a Panel of Env Pseudotyped Reference Viruses in TZM-bl Cells for All Participants | AC10.0.29 (Day- 28) | 1039.01 Relative luminescence units (RLU) |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Magnitude of Neutralizing Activity Against a Panel of Env Pseudotyped Reference Viruses in TZM-bl Cells for All Participants | AC10.0.29 (Day- 56) | 500.07 Relative luminescence units (RLU) |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Magnitude of Neutralizing Activity Against a Panel of Env Pseudotyped Reference Viruses in TZM-bl Cells for All Participants | AC10.0.29 (Day-112) | 85.57 Relative luminescence units (RLU) |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Magnitude of Neutralizing Activity Against a Panel of Env Pseudotyped Reference Viruses in TZM-bl Cells for All Participants | AC10.0.29 (Day-140) | 75.66 Relative luminescence units (RLU) |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Magnitude of Neutralizing Activity Against a Panel of Env Pseudotyped Reference Viruses in TZM-bl Cells for All Participants | AC10.0.29 (Day-224) | 57.51 Relative luminescence units (RLU) |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Magnitude of Neutralizing Activity Against a Panel of Env Pseudotyped Reference Viruses in TZM-bl Cells for All Participants | Ce1176_A3 (Day- 0) | 5.00 Relative luminescence units (RLU) |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Magnitude of Neutralizing Activity Against a Panel of Env Pseudotyped Reference Viruses in TZM-bl Cells for All Participants | Ce1176_A3 (Day- 3) | 8628.18 Relative luminescence units (RLU) |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Magnitude of Neutralizing Activity Against a Panel of Env Pseudotyped Reference Viruses in TZM-bl Cells for All Participants | Ce1176_A3 (Day- 28) | 2081.67 Relative luminescence units (RLU) |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Magnitude of Neutralizing Activity Against a Panel of Env Pseudotyped Reference Viruses in TZM-bl Cells for All Participants | Ce1176_A3 (Day- 56) | 842.00 Relative luminescence units (RLU) |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Magnitude of Neutralizing Activity Against a Panel of Env Pseudotyped Reference Viruses in TZM-bl Cells for All Participants | Ce1176_A3 (Day-112) | 199.63 Relative luminescence units (RLU) |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Magnitude of Neutralizing Activity Against a Panel of Env Pseudotyped Reference Viruses in TZM-bl Cells for All Participants | Ce1176_A3 (Day-140) | 205.80 Relative luminescence units (RLU) |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Magnitude of Neutralizing Activity Against a Panel of Env Pseudotyped Reference Viruses in TZM-bl Cells for All Participants | Ce1176_A3 (Day-224) | 101.07 Relative luminescence units (RLU) |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Magnitude of Neutralizing Activity Against a Panel of Env Pseudotyped Reference Viruses in TZM-bl Cells for All Participants | DU156.12 (Day- 0) | 5.00 Relative luminescence units (RLU) |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Magnitude of Neutralizing Activity Against a Panel of Env Pseudotyped Reference Viruses in TZM-bl Cells for All Participants | DU156.12 (Day- 3) | 84807.92 Relative luminescence units (RLU) |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Magnitude of Neutralizing Activity Against a Panel of Env Pseudotyped Reference Viruses in TZM-bl Cells for All Participants | DU156.12 (Day- 28) | 14630.79 Relative luminescence units (RLU) |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Magnitude of Neutralizing Activity Against a Panel of Env Pseudotyped Reference Viruses in TZM-bl Cells for All Participants | DU156.12 (Day- 56) | 3915.57 Relative luminescence units (RLU) |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Magnitude of Neutralizing Activity Against a Panel of Env Pseudotyped Reference Viruses in TZM-bl Cells for All Participants | DU156.12 (Day-112) | 744.96 Relative luminescence units (RLU) |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Magnitude of Neutralizing Activity Against a Panel of Env Pseudotyped Reference Viruses in TZM-bl Cells for All Participants | DU156.12 (Day-140) | 627.31 Relative luminescence units (RLU) |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Magnitude of Neutralizing Activity Against a Panel of Env Pseudotyped Reference Viruses in TZM-bl Cells for All Participants | DU156.12 (Day-224) | 578.62 Relative luminescence units (RLU) |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Magnitude of Neutralizing Activity Against a Panel of Env Pseudotyped Reference Viruses in TZM-bl Cells for All Participants | DU172.17 (Day- 0) | 5.00 Relative luminescence units (RLU) |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Magnitude of Neutralizing Activity Against a Panel of Env Pseudotyped Reference Viruses in TZM-bl Cells for All Participants | DU172.17 (Day- 3) | 1631.83 Relative luminescence units (RLU) |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Magnitude of Neutralizing Activity Against a Panel of Env Pseudotyped Reference Viruses in TZM-bl Cells for All Participants | T263-8 (Day- 28) | 2076.06 Relative luminescence units (RLU) |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Magnitude of Neutralizing Activity Against a Panel of Env Pseudotyped Reference Viruses in TZM-bl Cells for All Participants | T263-8 (Day- 56) | 789.69 Relative luminescence units (RLU) |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Magnitude of Neutralizing Activity Against a Panel of Env Pseudotyped Reference Viruses in TZM-bl Cells for All Participants | T263-8 (Day-112) | 169.57 Relative luminescence units (RLU) |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Magnitude of Neutralizing Activity Against a Panel of Env Pseudotyped Reference Viruses in TZM-bl Cells for All Participants | T263-8 (Day-140) | 99.18 Relative luminescence units (RLU) |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Magnitude of Neutralizing Activity Against a Panel of Env Pseudotyped Reference Viruses in TZM-bl Cells for All Participants | T263-8 (Day-224) | 130.83 Relative luminescence units (RLU) |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Magnitude of Neutralizing Activity Against a Panel of Env Pseudotyped Reference Viruses in TZM-bl Cells for All Participants | TRO.11 (Day- 0) | 5.00 Relative luminescence units (RLU) |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Magnitude of Neutralizing Activity Against a Panel of Env Pseudotyped Reference Viruses in TZM-bl Cells for All Participants | TRO.11 (Day- 3) | 8880.74 Relative luminescence units (RLU) |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Magnitude of Neutralizing Activity Against a Panel of Env Pseudotyped Reference Viruses in TZM-bl Cells for All Participants | TRO.11 (Day- 28) | 1963.86 Relative luminescence units (RLU) |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Magnitude of Neutralizing Activity Against a Panel of Env Pseudotyped Reference Viruses in TZM-bl Cells for All Participants | TRO.11 (Day- 56) | 1023.42 Relative luminescence units (RLU) |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Magnitude of Neutralizing Activity Against a Panel of Env Pseudotyped Reference Viruses in TZM-bl Cells for All Participants | TRO.11 (Day-112) | 182.49 Relative luminescence units (RLU) |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Magnitude of Neutralizing Activity Against a Panel of Env Pseudotyped Reference Viruses in TZM-bl Cells for All Participants | TRO.11 (Day-140) | 146.55 Relative luminescence units (RLU) |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Magnitude of Neutralizing Activity Against a Panel of Env Pseudotyped Reference Viruses in TZM-bl Cells for All Participants | 3426.v5.c17 (Day- 56) | 24227.08 Relative luminescence units (RLU) |
Secondary
Magnitudes of TZM-bl Cells Responses Against a Panel of Env Pseudotyped Viruses for All Participants
Neutralizing antibodies against HIV-1 were measured as a function of reductions in Tat-regulated luciferase (Luc) reporter gene expression in TZM-bl cells. The assay performed in TZM-bl cells measured neutralization titers against the Env-pseudotyped viruses sensitive to the bnAbs (i.e., bnAb-specific viruses) in each infusion group.
Time frame: Measured during Screening, Days 0, 3, 28, 56, 112, 140*, 168*, 224* Days with * are only available for T4
Population: All participants enrolled with available neutralizing antibody data. Visits with 0 participants are due to: (1) Isolates were mAb-specific and only assayed for the treatment arms that received the specific mAbs. (2) Treatment group T4 had more scheduled sample collection visits than treatment groups T1-T3.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| T1: PGT121 + VRC07-523LS mo 0 | Magnitudes of TZM-bl Cells Responses Against a Panel of Env Pseudotyped Viruses for All Participants | CNE55.N160K (Day- 28) | 259.58 Relative luminescence units (RLU) |
| T1: PGT121 + VRC07-523LS mo 0 | Magnitudes of TZM-bl Cells Responses Against a Panel of Env Pseudotyped Viruses for All Participants | T250-4 (Day-112) | 300.37 Relative luminescence units (RLU) |
| T1: PGT121 + VRC07-523LS mo 0 | Magnitudes of TZM-bl Cells Responses Against a Panel of Env Pseudotyped Viruses for All Participants | T250-4 (Day- 56) | 2016.84 Relative luminescence units (RLU) |
| T1: PGT121 + VRC07-523LS mo 0 | Magnitudes of TZM-bl Cells Responses Against a Panel of Env Pseudotyped Viruses for All Participants | T250-4 (Day- 28) | 6458.16 Relative luminescence units (RLU) |
| T1: PGT121 + VRC07-523LS mo 0 | Magnitudes of TZM-bl Cells Responses Against a Panel of Env Pseudotyped Viruses for All Participants | T250-4 (Day- 3) | 32029.39 Relative luminescence units (RLU) |
| T1: PGT121 + VRC07-523LS mo 0 | Magnitudes of TZM-bl Cells Responses Against a Panel of Env Pseudotyped Viruses for All Participants | T250-4 (Day- 0) | 5.00 Relative luminescence units (RLU) |
| T1: PGT121 + VRC07-523LS mo 0 | Magnitudes of TZM-bl Cells Responses Against a Panel of Env Pseudotyped Viruses for All Participants | CNE55.N160K (Day-112) | 28.65 Relative luminescence units (RLU) |
| T1: PGT121 + VRC07-523LS mo 0 | Magnitudes of TZM-bl Cells Responses Against a Panel of Env Pseudotyped Viruses for All Participants | CNE55.N160K (Day- 56) | 105.02 Relative luminescence units (RLU) |
| T1: PGT121 + VRC07-523LS mo 0 | Magnitudes of TZM-bl Cells Responses Against a Panel of Env Pseudotyped Viruses for All Participants | CNE55.N160K (Day- 0) | 5.00 Relative luminescence units (RLU) |
| T1: PGT121 + VRC07-523LS mo 0 | Magnitudes of TZM-bl Cells Responses Against a Panel of Env Pseudotyped Viruses for All Participants | CNE55.N160K (Day- 3) | 917.25 Relative luminescence units (RLU) |
| T2: PGDM1400 + VRC07-523LS mo 0 | Magnitudes of TZM-bl Cells Responses Against a Panel of Env Pseudotyped Viruses for All Participants | CNE55.N160K (Day- 28) | 188.55 Relative luminescence units (RLU) |
| T2: PGDM1400 + VRC07-523LS mo 0 | Magnitudes of TZM-bl Cells Responses Against a Panel of Env Pseudotyped Viruses for All Participants | CNE55.N160K (Day- 3) | 816.88 Relative luminescence units (RLU) |
| T2: PGDM1400 + VRC07-523LS mo 0 | Magnitudes of TZM-bl Cells Responses Against a Panel of Env Pseudotyped Viruses for All Participants | CNE55.N160K (Day-112) | 10.00 Relative luminescence units (RLU) |
| T2: PGDM1400 + VRC07-523LS mo 0 | Magnitudes of TZM-bl Cells Responses Against a Panel of Env Pseudotyped Viruses for All Participants | T250-4 (Day- 56) | 7523.58 Relative luminescence units (RLU) |
| T2: PGDM1400 + VRC07-523LS mo 0 | Magnitudes of TZM-bl Cells Responses Against a Panel of Env Pseudotyped Viruses for All Participants | T250-4 (Day-112) | 800.00 Relative luminescence units (RLU) |
| T2: PGDM1400 + VRC07-523LS mo 0 | Magnitudes of TZM-bl Cells Responses Against a Panel of Env Pseudotyped Viruses for All Participants | T250-4 (Day- 28) | 27318.99 Relative luminescence units (RLU) |
| T2: PGDM1400 + VRC07-523LS mo 0 | Magnitudes of TZM-bl Cells Responses Against a Panel of Env Pseudotyped Viruses for All Participants | CNE55.N160K (Day- 56) | 91.57 Relative luminescence units (RLU) |
| T2: PGDM1400 + VRC07-523LS mo 0 | Magnitudes of TZM-bl Cells Responses Against a Panel of Env Pseudotyped Viruses for All Participants | T250-4 (Day- 3) | 91301.02 Relative luminescence units (RLU) |
| T2: PGDM1400 + VRC07-523LS mo 0 | Magnitudes of TZM-bl Cells Responses Against a Panel of Env Pseudotyped Viruses for All Participants | CNE55.N160K (Day- 0) | 5.00 Relative luminescence units (RLU) |
| T2: PGDM1400 + VRC07-523LS mo 0 | Magnitudes of TZM-bl Cells Responses Against a Panel of Env Pseudotyped Viruses for All Participants | T250-4 (Day- 0) | 5.00 Relative luminescence units (RLU) |
| T3: 10-1074 + VRC07-523LS | Magnitudes of TZM-bl Cells Responses Against a Panel of Env Pseudotyped Viruses for All Participants | T250-4 (Day-112) | 928.27 Relative luminescence units (RLU) |
| T3: 10-1074 + VRC07-523LS | Magnitudes of TZM-bl Cells Responses Against a Panel of Env Pseudotyped Viruses for All Participants | CNE55.N160K (Day- 0) | 5.00 Relative luminescence units (RLU) |
| T3: 10-1074 + VRC07-523LS | Magnitudes of TZM-bl Cells Responses Against a Panel of Env Pseudotyped Viruses for All Participants | CNE55.N160K (Day- 3) | 438.49 Relative luminescence units (RLU) |
| T3: 10-1074 + VRC07-523LS | Magnitudes of TZM-bl Cells Responses Against a Panel of Env Pseudotyped Viruses for All Participants | CNE55.N160K (Day- 28) | 206.12 Relative luminescence units (RLU) |
| T3: 10-1074 + VRC07-523LS | Magnitudes of TZM-bl Cells Responses Against a Panel of Env Pseudotyped Viruses for All Participants | CNE55.N160K (Day- 56) | 152.21 Relative luminescence units (RLU) |
| T3: 10-1074 + VRC07-523LS | Magnitudes of TZM-bl Cells Responses Against a Panel of Env Pseudotyped Viruses for All Participants | CNE55.N160K (Day-112) | 47.58 Relative luminescence units (RLU) |
| T3: 10-1074 + VRC07-523LS | Magnitudes of TZM-bl Cells Responses Against a Panel of Env Pseudotyped Viruses for All Participants | T250-4 (Day- 0) | 5.00 Relative luminescence units (RLU) |
| T3: 10-1074 + VRC07-523LS | Magnitudes of TZM-bl Cells Responses Against a Panel of Env Pseudotyped Viruses for All Participants | T250-4 (Day- 3) | 35379.15 Relative luminescence units (RLU) |
| T3: 10-1074 + VRC07-523LS | Magnitudes of TZM-bl Cells Responses Against a Panel of Env Pseudotyped Viruses for All Participants | T250-4 (Day- 28) | 13028.85 Relative luminescence units (RLU) |
| T3: 10-1074 + VRC07-523LS | Magnitudes of TZM-bl Cells Responses Against a Panel of Env Pseudotyped Viruses for All Participants | T250-4 (Day- 56) | 6515.27 Relative luminescence units (RLU) |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Magnitudes of TZM-bl Cells Responses Against a Panel of Env Pseudotyped Viruses for All Participants | 6540.v4.c1 (Day- 56) | 774.27 Relative luminescence units (RLU) |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Magnitudes of TZM-bl Cells Responses Against a Panel of Env Pseudotyped Viruses for All Participants | CNE55.N160K (Day- 56) | 131.95 Relative luminescence units (RLU) |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Magnitudes of TZM-bl Cells Responses Against a Panel of Env Pseudotyped Viruses for All Participants | CH505TF.N334S.N160A.N280D.1 (Day- 56) | 1751.70 Relative luminescence units (RLU) |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Magnitudes of TZM-bl Cells Responses Against a Panel of Env Pseudotyped Viruses for All Participants | CH505TF.N334S.N160A.N280D.1 (Day- 28) | 3000.56 Relative luminescence units (RLU) |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Magnitudes of TZM-bl Cells Responses Against a Panel of Env Pseudotyped Viruses for All Participants | 6540.v4.c1 (Day- 28) | 2083.51 Relative luminescence units (RLU) |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Magnitudes of TZM-bl Cells Responses Against a Panel of Env Pseudotyped Viruses for All Participants | CNE55.N160K (Day-112) | 47.57 Relative luminescence units (RLU) |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Magnitudes of TZM-bl Cells Responses Against a Panel of Env Pseudotyped Viruses for All Participants | CNE55.N160K (Day-140) | 18.76 Relative luminescence units (RLU) |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Magnitudes of TZM-bl Cells Responses Against a Panel of Env Pseudotyped Viruses for All Participants | CNE55.N160K (Day-168) | 13.27 Relative luminescence units (RLU) |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Magnitudes of TZM-bl Cells Responses Against a Panel of Env Pseudotyped Viruses for All Participants | CNE55.N160K (Day-224) | 37.80 Relative luminescence units (RLU) |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Magnitudes of TZM-bl Cells Responses Against a Panel of Env Pseudotyped Viruses for All Participants | CH505TF.N334S.N160A.N280D.1 (Day- 3) | 13343.35 Relative luminescence units (RLU) |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Magnitudes of TZM-bl Cells Responses Against a Panel of Env Pseudotyped Viruses for All Participants | CH505TF.N334S.N160A.N280D.1 (Day- 0) | 5.00 Relative luminescence units (RLU) |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Magnitudes of TZM-bl Cells Responses Against a Panel of Env Pseudotyped Viruses for All Participants | CH505TF.N334S.N160A.N280D.1 (Day-224) | 206.62 Relative luminescence units (RLU) |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Magnitudes of TZM-bl Cells Responses Against a Panel of Env Pseudotyped Viruses for All Participants | 6540.v4.c1 (Day-224) | 27.66 Relative luminescence units (RLU) |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Magnitudes of TZM-bl Cells Responses Against a Panel of Env Pseudotyped Viruses for All Participants | 6540.v4.c1 (Day-168) | 14.74 Relative luminescence units (RLU) |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Magnitudes of TZM-bl Cells Responses Against a Panel of Env Pseudotyped Viruses for All Participants | 6540.v4.c1 (Day- 3) | 13187.62 Relative luminescence units (RLU) |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Magnitudes of TZM-bl Cells Responses Against a Panel of Env Pseudotyped Viruses for All Participants | 6540.v4.c1 (Day-140) | 45.07 Relative luminescence units (RLU) |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Magnitudes of TZM-bl Cells Responses Against a Panel of Env Pseudotyped Viruses for All Participants | 6540.v4.c1 (Day-112) | 82.11 Relative luminescence units (RLU) |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Magnitudes of TZM-bl Cells Responses Against a Panel of Env Pseudotyped Viruses for All Participants | CNE55.N160K (Day- 3) | 466.43 Relative luminescence units (RLU) |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Magnitudes of TZM-bl Cells Responses Against a Panel of Env Pseudotyped Viruses for All Participants | CNE55.N160K (Day- 0) | 5.00 Relative luminescence units (RLU) |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Magnitudes of TZM-bl Cells Responses Against a Panel of Env Pseudotyped Viruses for All Participants | CH505TF.N334S.N160A.N280D.1 (Day-168) | 111.35 Relative luminescence units (RLU) |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Magnitudes of TZM-bl Cells Responses Against a Panel of Env Pseudotyped Viruses for All Participants | 6540.v4.c1 (Day- 0) | 5.00 Relative luminescence units (RLU) |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Magnitudes of TZM-bl Cells Responses Against a Panel of Env Pseudotyped Viruses for All Participants | CNE55.N160K (Day- 28) | 158.46 Relative luminescence units (RLU) |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Magnitudes of TZM-bl Cells Responses Against a Panel of Env Pseudotyped Viruses for All Participants | CH505TF.N334S.N160A.N280D.1 (Day-140) | 270.10 Relative luminescence units (RLU) |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Magnitudes of TZM-bl Cells Responses Against a Panel of Env Pseudotyped Viruses for All Participants | CH505TF.N334S.N160A.N280D.1 (Day-112) | 339.83 Relative luminescence units (RLU) |
Secondary
Magnitudes of TZM-bl Cells Responses Against mAb-specific Env-pseudotyped Viruses Among Participants Who Received All Scheduled Product Administrations
Neutralizing antibodies against HIV-1 were measured as a function of reductions in Tat-regulated luciferase (Luc) reporter gene expression in TZM-bl cells. The assay performed in TZM-bl cells measured neutralization titers against the Env-pseudotyped viruses sensitive to the bnAbs (i.e., bnAb-specific viruses) in each infusion group.
Time frame: Measured during Screening, Days 0, 3, 28, 56, 112, 140*, 168*, 224* Days with * are only available for T4
Population: T1-T3 particiants who received infusion at Day 0 and T4 participants who received infusions at Day 0 and 112 with available neutralizing antibody data. Visits with 0 participants are due to: (1) Isolates were mAb-specific and only assayed for the treatment arms that received the specific mAbs. (2) Treatment group T4 had more scheduled sample collection visits than treatment groups T1-T3. (3) Data were excluded if the participant didn't receive all scheduled administrations.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| T1: PGT121 + VRC07-523LS mo 0 | Magnitudes of TZM-bl Cells Responses Against mAb-specific Env-pseudotyped Viruses Among Participants Who Received All Scheduled Product Administrations | CNE55.N160K (Day-112) | 28.65 Relative luminescence units (RLU) |
| T1: PGT121 + VRC07-523LS mo 0 | Magnitudes of TZM-bl Cells Responses Against mAb-specific Env-pseudotyped Viruses Among Participants Who Received All Scheduled Product Administrations | T250-4 (Day-112) | 300.37 Relative luminescence units (RLU) |
| T1: PGT121 + VRC07-523LS mo 0 | Magnitudes of TZM-bl Cells Responses Against mAb-specific Env-pseudotyped Viruses Among Participants Who Received All Scheduled Product Administrations | T250-4 (Day- 28) | 6458.16 Relative luminescence units (RLU) |
| T1: PGT121 + VRC07-523LS mo 0 | Magnitudes of TZM-bl Cells Responses Against mAb-specific Env-pseudotyped Viruses Among Participants Who Received All Scheduled Product Administrations | CNE55.N160K (Day- 56) | 105.02 Relative luminescence units (RLU) |
| T1: PGT121 + VRC07-523LS mo 0 | Magnitudes of TZM-bl Cells Responses Against mAb-specific Env-pseudotyped Viruses Among Participants Who Received All Scheduled Product Administrations | T250-4 (Day- 56) | 2016.84 Relative luminescence units (RLU) |
| T1: PGT121 + VRC07-523LS mo 0 | Magnitudes of TZM-bl Cells Responses Against mAb-specific Env-pseudotyped Viruses Among Participants Who Received All Scheduled Product Administrations | CNE55.N160K (Day- 28) | 259.58 Relative luminescence units (RLU) |
| T1: PGT121 + VRC07-523LS mo 0 | Magnitudes of TZM-bl Cells Responses Against mAb-specific Env-pseudotyped Viruses Among Participants Who Received All Scheduled Product Administrations | CNE55.N160K (Day- 0) | 5.00 Relative luminescence units (RLU) |
| T1: PGT121 + VRC07-523LS mo 0 | Magnitudes of TZM-bl Cells Responses Against mAb-specific Env-pseudotyped Viruses Among Participants Who Received All Scheduled Product Administrations | CNE55.N160K (Day- 3) | 917.25 Relative luminescence units (RLU) |
| T1: PGT121 + VRC07-523LS mo 0 | Magnitudes of TZM-bl Cells Responses Against mAb-specific Env-pseudotyped Viruses Among Participants Who Received All Scheduled Product Administrations | T250-4 (Day- 0) | 5.00 Relative luminescence units (RLU) |
| T1: PGT121 + VRC07-523LS mo 0 | Magnitudes of TZM-bl Cells Responses Against mAb-specific Env-pseudotyped Viruses Among Participants Who Received All Scheduled Product Administrations | T250-4 (Day- 3) | 32029.39 Relative luminescence units (RLU) |
| T2: PGDM1400 + VRC07-523LS mo 0 | Magnitudes of TZM-bl Cells Responses Against mAb-specific Env-pseudotyped Viruses Among Participants Who Received All Scheduled Product Administrations | CNE55.N160K (Day- 56) | 91.57 Relative luminescence units (RLU) |
| T2: PGDM1400 + VRC07-523LS mo 0 | Magnitudes of TZM-bl Cells Responses Against mAb-specific Env-pseudotyped Viruses Among Participants Who Received All Scheduled Product Administrations | T250-4 (Day- 0) | 5.00 Relative luminescence units (RLU) |
| T2: PGDM1400 + VRC07-523LS mo 0 | Magnitudes of TZM-bl Cells Responses Against mAb-specific Env-pseudotyped Viruses Among Participants Who Received All Scheduled Product Administrations | CNE55.N160K (Day-112) | 10.00 Relative luminescence units (RLU) |
| T2: PGDM1400 + VRC07-523LS mo 0 | Magnitudes of TZM-bl Cells Responses Against mAb-specific Env-pseudotyped Viruses Among Participants Who Received All Scheduled Product Administrations | T250-4 (Day- 3) | 91301.02 Relative luminescence units (RLU) |
| T2: PGDM1400 + VRC07-523LS mo 0 | Magnitudes of TZM-bl Cells Responses Against mAb-specific Env-pseudotyped Viruses Among Participants Who Received All Scheduled Product Administrations | T250-4 (Day- 28) | 27318.99 Relative luminescence units (RLU) |
| T2: PGDM1400 + VRC07-523LS mo 0 | Magnitudes of TZM-bl Cells Responses Against mAb-specific Env-pseudotyped Viruses Among Participants Who Received All Scheduled Product Administrations | T250-4 (Day- 56) | 7523.58 Relative luminescence units (RLU) |
| T2: PGDM1400 + VRC07-523LS mo 0 | Magnitudes of TZM-bl Cells Responses Against mAb-specific Env-pseudotyped Viruses Among Participants Who Received All Scheduled Product Administrations | T250-4 (Day-112) | 800.00 Relative luminescence units (RLU) |
| T2: PGDM1400 + VRC07-523LS mo 0 | Magnitudes of TZM-bl Cells Responses Against mAb-specific Env-pseudotyped Viruses Among Participants Who Received All Scheduled Product Administrations | CNE55.N160K (Day- 3) | 816.88 Relative luminescence units (RLU) |
| T2: PGDM1400 + VRC07-523LS mo 0 | Magnitudes of TZM-bl Cells Responses Against mAb-specific Env-pseudotyped Viruses Among Participants Who Received All Scheduled Product Administrations | CNE55.N160K (Day- 28) | 188.55 Relative luminescence units (RLU) |
| T2: PGDM1400 + VRC07-523LS mo 0 | Magnitudes of TZM-bl Cells Responses Against mAb-specific Env-pseudotyped Viruses Among Participants Who Received All Scheduled Product Administrations | CNE55.N160K (Day- 0) | 5.00 Relative luminescence units (RLU) |
| T3: 10-1074 + VRC07-523LS | Magnitudes of TZM-bl Cells Responses Against mAb-specific Env-pseudotyped Viruses Among Participants Who Received All Scheduled Product Administrations | T250-4 (Day-112) | 1189.03 Relative luminescence units (RLU) |
| T3: 10-1074 + VRC07-523LS | Magnitudes of TZM-bl Cells Responses Against mAb-specific Env-pseudotyped Viruses Among Participants Who Received All Scheduled Product Administrations | CNE55.N160K (Day- 56) | 170.55 Relative luminescence units (RLU) |
| T3: 10-1074 + VRC07-523LS | Magnitudes of TZM-bl Cells Responses Against mAb-specific Env-pseudotyped Viruses Among Participants Who Received All Scheduled Product Administrations | CNE55.N160K (Day- 3) | 493.12 Relative luminescence units (RLU) |
| T3: 10-1074 + VRC07-523LS | Magnitudes of TZM-bl Cells Responses Against mAb-specific Env-pseudotyped Viruses Among Participants Who Received All Scheduled Product Administrations | T250-4 (Day- 0) | 5.00 Relative luminescence units (RLU) |
| T3: 10-1074 + VRC07-523LS | Magnitudes of TZM-bl Cells Responses Against mAb-specific Env-pseudotyped Viruses Among Participants Who Received All Scheduled Product Administrations | CNE55.N160K (Day- 0) | 5.00 Relative luminescence units (RLU) |
| T3: 10-1074 + VRC07-523LS | Magnitudes of TZM-bl Cells Responses Against mAb-specific Env-pseudotyped Viruses Among Participants Who Received All Scheduled Product Administrations | T250-4 (Day- 28) | 13028.85 Relative luminescence units (RLU) |
| T3: 10-1074 + VRC07-523LS | Magnitudes of TZM-bl Cells Responses Against mAb-specific Env-pseudotyped Viruses Among Participants Who Received All Scheduled Product Administrations | CNE55.N160K (Day-112) | 53.48 Relative luminescence units (RLU) |
| T3: 10-1074 + VRC07-523LS | Magnitudes of TZM-bl Cells Responses Against mAb-specific Env-pseudotyped Viruses Among Participants Who Received All Scheduled Product Administrations | T250-4 (Day- 56) | 7070.48 Relative luminescence units (RLU) |
| T3: 10-1074 + VRC07-523LS | Magnitudes of TZM-bl Cells Responses Against mAb-specific Env-pseudotyped Viruses Among Participants Who Received All Scheduled Product Administrations | T250-4 (Day- 3) | 39113.31 Relative luminescence units (RLU) |
| T3: 10-1074 + VRC07-523LS | Magnitudes of TZM-bl Cells Responses Against mAb-specific Env-pseudotyped Viruses Among Participants Who Received All Scheduled Product Administrations | CNE55.N160K (Day- 28) | 206.12 Relative luminescence units (RLU) |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Magnitudes of TZM-bl Cells Responses Against mAb-specific Env-pseudotyped Viruses Among Participants Who Received All Scheduled Product Administrations | CNE55.N160K (Day- 56) | 131.99 Relative luminescence units (RLU) |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Magnitudes of TZM-bl Cells Responses Against mAb-specific Env-pseudotyped Viruses Among Participants Who Received All Scheduled Product Administrations | 6540.v4.c1 (Day- 0) | 5.00 Relative luminescence units (RLU) |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Magnitudes of TZM-bl Cells Responses Against mAb-specific Env-pseudotyped Viruses Among Participants Who Received All Scheduled Product Administrations | 6540.v4.c1 (Day- 3) | 12301.30 Relative luminescence units (RLU) |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Magnitudes of TZM-bl Cells Responses Against mAb-specific Env-pseudotyped Viruses Among Participants Who Received All Scheduled Product Administrations | 6540.v4.c1 (Day- 28) | 2365.28 Relative luminescence units (RLU) |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Magnitudes of TZM-bl Cells Responses Against mAb-specific Env-pseudotyped Viruses Among Participants Who Received All Scheduled Product Administrations | 6540.v4.c1 (Day- 56) | 674.62 Relative luminescence units (RLU) |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Magnitudes of TZM-bl Cells Responses Against mAb-specific Env-pseudotyped Viruses Among Participants Who Received All Scheduled Product Administrations | 6540.v4.c1 (Day-112) | 82.11 Relative luminescence units (RLU) |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Magnitudes of TZM-bl Cells Responses Against mAb-specific Env-pseudotyped Viruses Among Participants Who Received All Scheduled Product Administrations | 6540.v4.c1 (Day-140) | 1255.62 Relative luminescence units (RLU) |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Magnitudes of TZM-bl Cells Responses Against mAb-specific Env-pseudotyped Viruses Among Participants Who Received All Scheduled Product Administrations | 6540.v4.c1 (Day-224) | 64.76 Relative luminescence units (RLU) |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Magnitudes of TZM-bl Cells Responses Against mAb-specific Env-pseudotyped Viruses Among Participants Who Received All Scheduled Product Administrations | CH505TF.N334S.N160A.N280D.1 (Day- 0) | 5.00 Relative luminescence units (RLU) |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Magnitudes of TZM-bl Cells Responses Against mAb-specific Env-pseudotyped Viruses Among Participants Who Received All Scheduled Product Administrations | CH505TF.N334S.N160A.N280D.1 (Day- 3) | 13209.26 Relative luminescence units (RLU) |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Magnitudes of TZM-bl Cells Responses Against mAb-specific Env-pseudotyped Viruses Among Participants Who Received All Scheduled Product Administrations | CH505TF.N334S.N160A.N280D.1 (Day- 28) | 3344.91 Relative luminescence units (RLU) |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Magnitudes of TZM-bl Cells Responses Against mAb-specific Env-pseudotyped Viruses Among Participants Who Received All Scheduled Product Administrations | CH505TF.N334S.N160A.N280D.1 (Day- 56) | 1491.45 Relative luminescence units (RLU) |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Magnitudes of TZM-bl Cells Responses Against mAb-specific Env-pseudotyped Viruses Among Participants Who Received All Scheduled Product Administrations | CH505TF.N334S.N160A.N280D.1 (Day-112) | 339.83 Relative luminescence units (RLU) |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Magnitudes of TZM-bl Cells Responses Against mAb-specific Env-pseudotyped Viruses Among Participants Who Received All Scheduled Product Administrations | CH505TF.N334S.N160A.N280D.1 (Day-140) | 2563.08 Relative luminescence units (RLU) |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Magnitudes of TZM-bl Cells Responses Against mAb-specific Env-pseudotyped Viruses Among Participants Who Received All Scheduled Product Administrations | CH505TF.N334S.N160A.N280D.1 (Day-224) | 429.44 Relative luminescence units (RLU) |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Magnitudes of TZM-bl Cells Responses Against mAb-specific Env-pseudotyped Viruses Among Participants Who Received All Scheduled Product Administrations | CNE55.N160K (Day- 0) | 5.00 Relative luminescence units (RLU) |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Magnitudes of TZM-bl Cells Responses Against mAb-specific Env-pseudotyped Viruses Among Participants Who Received All Scheduled Product Administrations | CNE55.N160K (Day- 3) | 469.12 Relative luminescence units (RLU) |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Magnitudes of TZM-bl Cells Responses Against mAb-specific Env-pseudotyped Viruses Among Participants Who Received All Scheduled Product Administrations | CNE55.N160K (Day- 28) | 218.32 Relative luminescence units (RLU) |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Magnitudes of TZM-bl Cells Responses Against mAb-specific Env-pseudotyped Viruses Among Participants Who Received All Scheduled Product Administrations | CNE55.N160K (Day-112) | 47.57 Relative luminescence units (RLU) |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Magnitudes of TZM-bl Cells Responses Against mAb-specific Env-pseudotyped Viruses Among Participants Who Received All Scheduled Product Administrations | CNE55.N160K (Day-140) | 92.76 Relative luminescence units (RLU) |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Magnitudes of TZM-bl Cells Responses Against mAb-specific Env-pseudotyped Viruses Among Participants Who Received All Scheduled Product Administrations | CNE55.N160K (Day-224) | 58.52 Relative luminescence units (RLU) |
Secondary
Serum Concentration Levels of PGT121, PGDM1400, and VRC07-523LS Among Participants Who Received All Scheduled Product Administrations
Serum PGDM1400, PGT121, and VRC07-523LS IgG levels were measured on a Bio-Plex instrument (Bio-Rad) using a validated assay designed to simultaneously measure infused PGDM1400, PGT121, and VRC07-523LS by its ability to bind anti-idiotype antibody captured on fluorescent magnetic beads. This assay was derived from a standardized custom HIV-1 Luminex assay. PGDM1400, PGT121 and VRC07-523LS were titrated and combined to create a standard curve that was used to determine concentration of the diluted samples. The negative controls were CH58 (an irrelevant mAb) and blank beads.Serum 10-1074 level was measured by anti-idotypic ELISA. Participant serum sample was incubated in anti-ID coated micro-plate well. A conjugated secondary antibody was used to detect bound 10-1074. Samples were titrated to ensure positive optical density (O.D.) readouts fall within the linear range of the assay for monoclonal antibody concentration calculations.
Time frame: Measured during Screening, Days 0, 3, 6, 14, 28, 56, 84*, 112, 140*, 168, 224, 280, 336, 392*, and 448* Days with * are only available for T4
Population: T1-T3 particiants who received infusion at Day 0 and T4 participants who received infusions at Day 0 and 112 with available serum concentration data. Visits with 0 participants analyzed are due to: (1) mAbs were only assayed for the treatment arms that received those mAbs. (2) Treatment group T4 had more scheduled sample collection visits than treatment groups T1-T3. (3) Data were excluded if the participant didn't receive all scheduled administrations.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| T1: PGT121 + VRC07-523LS mo 0 | Serum Concentration Levels of PGT121, PGDM1400, and VRC07-523LS Among Participants Who Received All Scheduled Product Administrations | VRC07-523LS (Day- 14) | 134.44 mg/ml |
| T1: PGT121 + VRC07-523LS mo 0 | Serum Concentration Levels of PGT121, PGDM1400, and VRC07-523LS Among Participants Who Received All Scheduled Product Administrations | PGT121 (Day-112) | 4.03 mg/ml |
| T1: PGT121 + VRC07-523LS mo 0 | Serum Concentration Levels of PGT121, PGDM1400, and VRC07-523LS Among Participants Who Received All Scheduled Product Administrations | PGT121 (Day- 14) | 80.12 mg/ml |
| T1: PGT121 + VRC07-523LS mo 0 | Serum Concentration Levels of PGT121, PGDM1400, and VRC07-523LS Among Participants Who Received All Scheduled Product Administrations | VRC07-523LS (Day-224) | 8.47 mg/ml |
| T1: PGT121 + VRC07-523LS mo 0 | Serum Concentration Levels of PGT121, PGDM1400, and VRC07-523LS Among Participants Who Received All Scheduled Product Administrations | VRC07-523LS (Day- 28) | 94.58 mg/ml |
| T1: PGT121 + VRC07-523LS mo 0 | Serum Concentration Levels of PGT121, PGDM1400, and VRC07-523LS Among Participants Who Received All Scheduled Product Administrations | VRC07-523LS (Day- 3) | 265.97 mg/ml |
| T1: PGT121 + VRC07-523LS mo 0 | Serum Concentration Levels of PGT121, PGDM1400, and VRC07-523LS Among Participants Who Received All Scheduled Product Administrations | PGT121 (Day- 6) | 129.35 mg/ml |
| T1: PGT121 + VRC07-523LS mo 0 | Serum Concentration Levels of PGT121, PGDM1400, and VRC07-523LS Among Participants Who Received All Scheduled Product Administrations | PGT121 (Day- 3) | 196.57 mg/ml |
| T1: PGT121 + VRC07-523LS mo 0 | Serum Concentration Levels of PGT121, PGDM1400, and VRC07-523LS Among Participants Who Received All Scheduled Product Administrations | VRC07-523LS (Day- 56) | 60.53 mg/ml |
| T1: PGT121 + VRC07-523LS mo 0 | Serum Concentration Levels of PGT121, PGDM1400, and VRC07-523LS Among Participants Who Received All Scheduled Product Administrations | PGT121 (Day-224) | 0.31 mg/ml |
| T1: PGT121 + VRC07-523LS mo 0 | Serum Concentration Levels of PGT121, PGDM1400, and VRC07-523LS Among Participants Who Received All Scheduled Product Administrations | PGT121 (Day- 0) | 0.05 mg/ml |
| T1: PGT121 + VRC07-523LS mo 0 | Serum Concentration Levels of PGT121, PGDM1400, and VRC07-523LS Among Participants Who Received All Scheduled Product Administrations | VRC07-523LS (Day-168) | 14.45 mg/ml |
| T1: PGT121 + VRC07-523LS mo 0 | Serum Concentration Levels of PGT121, PGDM1400, and VRC07-523LS Among Participants Who Received All Scheduled Product Administrations | PGT121 (Day- 56) | 22.08 mg/ml |
| T1: PGT121 + VRC07-523LS mo 0 | Serum Concentration Levels of PGT121, PGDM1400, and VRC07-523LS Among Participants Who Received All Scheduled Product Administrations | VRC07-523LS (Day-112) | 24.93 mg/ml |
| T1: PGT121 + VRC07-523LS mo 0 | Serum Concentration Levels of PGT121, PGDM1400, and VRC07-523LS Among Participants Who Received All Scheduled Product Administrations | PGT121 (Day-168) | 1.70 mg/ml |
| T1: PGT121 + VRC07-523LS mo 0 | Serum Concentration Levels of PGT121, PGDM1400, and VRC07-523LS Among Participants Who Received All Scheduled Product Administrations | VRC07-523LS (Day-336) | 1.33 mg/ml |
| T1: PGT121 + VRC07-523LS mo 0 | Serum Concentration Levels of PGT121, PGDM1400, and VRC07-523LS Among Participants Who Received All Scheduled Product Administrations | VRC07-523LS (Day- 6) | 171.02 mg/ml |
| T1: PGT121 + VRC07-523LS mo 0 | Serum Concentration Levels of PGT121, PGDM1400, and VRC07-523LS Among Participants Who Received All Scheduled Product Administrations | VRC07-523LS (Day- 0) | 0.01 mg/ml |
| T1: PGT121 + VRC07-523LS mo 0 | Serum Concentration Levels of PGT121, PGDM1400, and VRC07-523LS Among Participants Who Received All Scheduled Product Administrations | PGT121 (Day- 28) | 44.46 mg/ml |
| T1: PGT121 + VRC07-523LS mo 0 | Serum Concentration Levels of PGT121, PGDM1400, and VRC07-523LS Among Participants Who Received All Scheduled Product Administrations | PGT121 (Day-336) | 0.05 mg/ml |
| T2: PGDM1400 + VRC07-523LS mo 0 | Serum Concentration Levels of PGT121, PGDM1400, and VRC07-523LS Among Participants Who Received All Scheduled Product Administrations | PGDM1400 (Day- 3) | 251.54 mg/ml |
| T2: PGDM1400 + VRC07-523LS mo 0 | Serum Concentration Levels of PGT121, PGDM1400, and VRC07-523LS Among Participants Who Received All Scheduled Product Administrations | PGDM1400 (Day- 6) | 182.23 mg/ml |
| T2: PGDM1400 + VRC07-523LS mo 0 | Serum Concentration Levels of PGT121, PGDM1400, and VRC07-523LS Among Participants Who Received All Scheduled Product Administrations | PGDM1400 (Day- 14) | 139.77 mg/ml |
| T2: PGDM1400 + VRC07-523LS mo 0 | Serum Concentration Levels of PGT121, PGDM1400, and VRC07-523LS Among Participants Who Received All Scheduled Product Administrations | VRC07-523LS (Day-224) | 11.24 mg/ml |
| T2: PGDM1400 + VRC07-523LS mo 0 | Serum Concentration Levels of PGT121, PGDM1400, and VRC07-523LS Among Participants Who Received All Scheduled Product Administrations | VRC07-523LS (Day- 0) | 0.01 mg/ml |
| T2: PGDM1400 + VRC07-523LS mo 0 | Serum Concentration Levels of PGT121, PGDM1400, and VRC07-523LS Among Participants Who Received All Scheduled Product Administrations | PGDM1400 (Day- 28) | 70.92 mg/ml |
| T2: PGDM1400 + VRC07-523LS mo 0 | Serum Concentration Levels of PGT121, PGDM1400, and VRC07-523LS Among Participants Who Received All Scheduled Product Administrations | VRC07-523LS (Day- 3) | 239.32 mg/ml |
| T2: PGDM1400 + VRC07-523LS mo 0 | Serum Concentration Levels of PGT121, PGDM1400, and VRC07-523LS Among Participants Who Received All Scheduled Product Administrations | PGDM1400 (Day- 56) | 27.88 mg/ml |
| T2: PGDM1400 + VRC07-523LS mo 0 | Serum Concentration Levels of PGT121, PGDM1400, and VRC07-523LS Among Participants Who Received All Scheduled Product Administrations | VRC07-523LS (Day- 6) | 176.51 mg/ml |
| T2: PGDM1400 + VRC07-523LS mo 0 | Serum Concentration Levels of PGT121, PGDM1400, and VRC07-523LS Among Participants Who Received All Scheduled Product Administrations | VRC07-523LS (Day-280) | 3.88 mg/ml |
| T2: PGDM1400 + VRC07-523LS mo 0 | Serum Concentration Levels of PGT121, PGDM1400, and VRC07-523LS Among Participants Who Received All Scheduled Product Administrations | VRC07-523LS (Day- 14) | 139.18 mg/ml |
| T2: PGDM1400 + VRC07-523LS mo 0 | Serum Concentration Levels of PGT121, PGDM1400, and VRC07-523LS Among Participants Who Received All Scheduled Product Administrations | PGDM1400 (Day-112) | 5.50 mg/ml |
| T2: PGDM1400 + VRC07-523LS mo 0 | Serum Concentration Levels of PGT121, PGDM1400, and VRC07-523LS Among Participants Who Received All Scheduled Product Administrations | VRC07-523LS (Day- 28) | 96.17 mg/ml |
| T2: PGDM1400 + VRC07-523LS mo 0 | Serum Concentration Levels of PGT121, PGDM1400, and VRC07-523LS Among Participants Who Received All Scheduled Product Administrations | VRC07-523LS (Day- 56) | 56.91 mg/ml |
| T2: PGDM1400 + VRC07-523LS mo 0 | Serum Concentration Levels of PGT121, PGDM1400, and VRC07-523LS Among Participants Who Received All Scheduled Product Administrations | PGDM1400 (Day-168) | 1.08 mg/ml |
| T2: PGDM1400 + VRC07-523LS mo 0 | Serum Concentration Levels of PGT121, PGDM1400, and VRC07-523LS Among Participants Who Received All Scheduled Product Administrations | VRC07-523LS (Day-112) | 31.65 mg/ml |
| T2: PGDM1400 + VRC07-523LS mo 0 | Serum Concentration Levels of PGT121, PGDM1400, and VRC07-523LS Among Participants Who Received All Scheduled Product Administrations | PGDM1400 (Day-224) | 0.26 mg/ml |
| T2: PGDM1400 + VRC07-523LS mo 0 | Serum Concentration Levels of PGT121, PGDM1400, and VRC07-523LS Among Participants Who Received All Scheduled Product Administrations | VRC07-523LS (Day-336) | 1.31 mg/ml |
| T2: PGDM1400 + VRC07-523LS mo 0 | Serum Concentration Levels of PGT121, PGDM1400, and VRC07-523LS Among Participants Who Received All Scheduled Product Administrations | PGDM1400 (Day-280) | 0.09 mg/ml |
| T2: PGDM1400 + VRC07-523LS mo 0 | Serum Concentration Levels of PGT121, PGDM1400, and VRC07-523LS Among Participants Who Received All Scheduled Product Administrations | PGDM1400 (Day-336) | 0.02 mg/ml |
| T2: PGDM1400 + VRC07-523LS mo 0 | Serum Concentration Levels of PGT121, PGDM1400, and VRC07-523LS Among Participants Who Received All Scheduled Product Administrations | PGDM1400 (Day- 0) | 0.02 mg/ml |
| T2: PGDM1400 + VRC07-523LS mo 0 | Serum Concentration Levels of PGT121, PGDM1400, and VRC07-523LS Among Participants Who Received All Scheduled Product Administrations | VRC07-523LS (Day-168) | 12.57 mg/ml |
| T3: 10-1074 + VRC07-523LS | Serum Concentration Levels of PGT121, PGDM1400, and VRC07-523LS Among Participants Who Received All Scheduled Product Administrations | 10-1074 (Day- 0) | 0.21 mg/ml |
| T3: 10-1074 + VRC07-523LS | Serum Concentration Levels of PGT121, PGDM1400, and VRC07-523LS Among Participants Who Received All Scheduled Product Administrations | VRC07-523LS (Day-168) | 11.57 mg/ml |
| T3: 10-1074 + VRC07-523LS | Serum Concentration Levels of PGT121, PGDM1400, and VRC07-523LS Among Participants Who Received All Scheduled Product Administrations | 10-1074 (Day- 6) | 453.99 mg/ml |
| T3: 10-1074 + VRC07-523LS | Serum Concentration Levels of PGT121, PGDM1400, and VRC07-523LS Among Participants Who Received All Scheduled Product Administrations | 10-1074 (Day- 14) | 300.15 mg/ml |
| T3: 10-1074 + VRC07-523LS | Serum Concentration Levels of PGT121, PGDM1400, and VRC07-523LS Among Participants Who Received All Scheduled Product Administrations | 10-1074 (Day- 28) | 242.22 mg/ml |
| T3: 10-1074 + VRC07-523LS | Serum Concentration Levels of PGT121, PGDM1400, and VRC07-523LS Among Participants Who Received All Scheduled Product Administrations | VRC07-523LS (Day- 56) | 59.33 mg/ml |
| T3: 10-1074 + VRC07-523LS | Serum Concentration Levels of PGT121, PGDM1400, and VRC07-523LS Among Participants Who Received All Scheduled Product Administrations | 10-1074 (Day- 56) | 111.62 mg/ml |
| T3: 10-1074 + VRC07-523LS | Serum Concentration Levels of PGT121, PGDM1400, and VRC07-523LS Among Participants Who Received All Scheduled Product Administrations | VRC07-523LS (Day-280) | 3.17 mg/ml |
| T3: 10-1074 + VRC07-523LS | Serum Concentration Levels of PGT121, PGDM1400, and VRC07-523LS Among Participants Who Received All Scheduled Product Administrations | 10-1074 (Day-112) | 25.18 mg/ml |
| T3: 10-1074 + VRC07-523LS | Serum Concentration Levels of PGT121, PGDM1400, and VRC07-523LS Among Participants Who Received All Scheduled Product Administrations | VRC07-523LS (Day- 28) | 87.91 mg/ml |
| T3: 10-1074 + VRC07-523LS | Serum Concentration Levels of PGT121, PGDM1400, and VRC07-523LS Among Participants Who Received All Scheduled Product Administrations | 10-1074 (Day-168) | 8.60 mg/ml |
| T3: 10-1074 + VRC07-523LS | Serum Concentration Levels of PGT121, PGDM1400, and VRC07-523LS Among Participants Who Received All Scheduled Product Administrations | VRC07-523LS (Day- 14) | 119.67 mg/ml |
| T3: 10-1074 + VRC07-523LS | Serum Concentration Levels of PGT121, PGDM1400, and VRC07-523LS Among Participants Who Received All Scheduled Product Administrations | 10-1074 (Day-280) | 0.98 mg/ml |
| T3: 10-1074 + VRC07-523LS | Serum Concentration Levels of PGT121, PGDM1400, and VRC07-523LS Among Participants Who Received All Scheduled Product Administrations | VRC07-523LS (Day- 6) | 176.01 mg/ml |
| T3: 10-1074 + VRC07-523LS | Serum Concentration Levels of PGT121, PGDM1400, and VRC07-523LS Among Participants Who Received All Scheduled Product Administrations | 10-1074 (Day-336) | 2.44 mg/ml |
| T3: 10-1074 + VRC07-523LS | Serum Concentration Levels of PGT121, PGDM1400, and VRC07-523LS Among Participants Who Received All Scheduled Product Administrations | VRC07-523LS (Day- 3) | 182.66 mg/ml |
| T3: 10-1074 + VRC07-523LS | Serum Concentration Levels of PGT121, PGDM1400, and VRC07-523LS Among Participants Who Received All Scheduled Product Administrations | VRC07-523LS (Day-336) | 1.48 mg/ml |
| T3: 10-1074 + VRC07-523LS | Serum Concentration Levels of PGT121, PGDM1400, and VRC07-523LS Among Participants Who Received All Scheduled Product Administrations | VRC07-523LS (Day-112) | 29.37 mg/ml |
| T3: 10-1074 + VRC07-523LS | Serum Concentration Levels of PGT121, PGDM1400, and VRC07-523LS Among Participants Who Received All Scheduled Product Administrations | VRC07-523LS (Day- 0) | 0.01 mg/ml |
| T3: 10-1074 + VRC07-523LS | Serum Concentration Levels of PGT121, PGDM1400, and VRC07-523LS Among Participants Who Received All Scheduled Product Administrations | 10-1074 (Day- 3) | 598.55 mg/ml |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Serum Concentration Levels of PGT121, PGDM1400, and VRC07-523LS Among Participants Who Received All Scheduled Product Administrations | VRC07-523LS (Day-448) | 2.16 mg/ml |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Serum Concentration Levels of PGT121, PGDM1400, and VRC07-523LS Among Participants Who Received All Scheduled Product Administrations | PGDM1400 (Day- 56) | 28.38 mg/ml |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Serum Concentration Levels of PGT121, PGDM1400, and VRC07-523LS Among Participants Who Received All Scheduled Product Administrations | PGT121 (Day-224) | 11.28 mg/ml |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Serum Concentration Levels of PGT121, PGDM1400, and VRC07-523LS Among Participants Who Received All Scheduled Product Administrations | VRC07-523LS (Day-140) | 76.03 mg/ml |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Serum Concentration Levels of PGT121, PGDM1400, and VRC07-523LS Among Participants Who Received All Scheduled Product Administrations | VRC07-523LS (Day-224) | 39.86 mg/ml |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Serum Concentration Levels of PGT121, PGDM1400, and VRC07-523LS Among Participants Who Received All Scheduled Product Administrations | VRC07-523LS (Day-280) | 15.13 mg/ml |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Serum Concentration Levels of PGT121, PGDM1400, and VRC07-523LS Among Participants Who Received All Scheduled Product Administrations | PGDM1400 (Day- 0) | 0.02 mg/ml |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Serum Concentration Levels of PGT121, PGDM1400, and VRC07-523LS Among Participants Who Received All Scheduled Product Administrations | PGDM1400 (Day- 3) | 209.25 mg/ml |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Serum Concentration Levels of PGT121, PGDM1400, and VRC07-523LS Among Participants Who Received All Scheduled Product Administrations | PGDM1400 (Day- 6) | 172.18 mg/ml |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Serum Concentration Levels of PGT121, PGDM1400, and VRC07-523LS Among Participants Who Received All Scheduled Product Administrations | PGDM1400 (Day- 14) | 129.97 mg/ml |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Serum Concentration Levels of PGT121, PGDM1400, and VRC07-523LS Among Participants Who Received All Scheduled Product Administrations | PGDM1400 (Day- 28) | 67.59 mg/ml |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Serum Concentration Levels of PGT121, PGDM1400, and VRC07-523LS Among Participants Who Received All Scheduled Product Administrations | PGDM1400 (Day- 84) | 10.93 mg/ml |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Serum Concentration Levels of PGT121, PGDM1400, and VRC07-523LS Among Participants Who Received All Scheduled Product Administrations | PGDM1400 (Day-112) | 4.99 mg/ml |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Serum Concentration Levels of PGT121, PGDM1400, and VRC07-523LS Among Participants Who Received All Scheduled Product Administrations | PGDM1400 (Day-140) | 46.07 mg/ml |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Serum Concentration Levels of PGT121, PGDM1400, and VRC07-523LS Among Participants Who Received All Scheduled Product Administrations | PGDM1400 (Day-224) | 6.24 mg/ml |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Serum Concentration Levels of PGT121, PGDM1400, and VRC07-523LS Among Participants Who Received All Scheduled Product Administrations | PGDM1400 (Day-280) | 1.27 mg/ml |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Serum Concentration Levels of PGT121, PGDM1400, and VRC07-523LS Among Participants Who Received All Scheduled Product Administrations | PGDM1400 (Day-336) | 0.52 mg/ml |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Serum Concentration Levels of PGT121, PGDM1400, and VRC07-523LS Among Participants Who Received All Scheduled Product Administrations | PGDM1400 (Day-392) | 0.11 mg/ml |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Serum Concentration Levels of PGT121, PGDM1400, and VRC07-523LS Among Participants Who Received All Scheduled Product Administrations | PGDM1400 (Day-448) | 0.02 mg/ml |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Serum Concentration Levels of PGT121, PGDM1400, and VRC07-523LS Among Participants Who Received All Scheduled Product Administrations | PGT121 (Day- 0) | 0.05 mg/ml |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Serum Concentration Levels of PGT121, PGDM1400, and VRC07-523LS Among Participants Who Received All Scheduled Product Administrations | PGT121 (Day- 3) | 169.62 mg/ml |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Serum Concentration Levels of PGT121, PGDM1400, and VRC07-523LS Among Participants Who Received All Scheduled Product Administrations | PGT121 (Day- 6) | 130.33 mg/ml |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Serum Concentration Levels of PGT121, PGDM1400, and VRC07-523LS Among Participants Who Received All Scheduled Product Administrations | PGT121 (Day- 14) | 95.54 mg/ml |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Serum Concentration Levels of PGT121, PGDM1400, and VRC07-523LS Among Participants Who Received All Scheduled Product Administrations | PGT121 (Day- 28) | 60.62 mg/ml |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Serum Concentration Levels of PGT121, PGDM1400, and VRC07-523LS Among Participants Who Received All Scheduled Product Administrations | PGT121 (Day- 56) | 25.79 mg/ml |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Serum Concentration Levels of PGT121, PGDM1400, and VRC07-523LS Among Participants Who Received All Scheduled Product Administrations | PGT121 (Day- 84) | 12.42 mg/ml |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Serum Concentration Levels of PGT121, PGDM1400, and VRC07-523LS Among Participants Who Received All Scheduled Product Administrations | PGT121 (Day-112) | 5.82 mg/ml |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Serum Concentration Levels of PGT121, PGDM1400, and VRC07-523LS Among Participants Who Received All Scheduled Product Administrations | PGT121 (Day-140) | 49.17 mg/ml |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Serum Concentration Levels of PGT121, PGDM1400, and VRC07-523LS Among Participants Who Received All Scheduled Product Administrations | PGT121 (Day-280) | 2.36 mg/ml |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Serum Concentration Levels of PGT121, PGDM1400, and VRC07-523LS Among Participants Who Received All Scheduled Product Administrations | PGT121 (Day-336) | 1.05 mg/ml |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Serum Concentration Levels of PGT121, PGDM1400, and VRC07-523LS Among Participants Who Received All Scheduled Product Administrations | PGT121 (Day-392) | 0.33 mg/ml |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Serum Concentration Levels of PGT121, PGDM1400, and VRC07-523LS Among Participants Who Received All Scheduled Product Administrations | PGT121 (Day-448) | 0.10 mg/ml |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Serum Concentration Levels of PGT121, PGDM1400, and VRC07-523LS Among Participants Who Received All Scheduled Product Administrations | VRC07-523LS (Day- 0) | 0.01 mg/ml |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Serum Concentration Levels of PGT121, PGDM1400, and VRC07-523LS Among Participants Who Received All Scheduled Product Administrations | VRC07-523LS (Day- 3) | 212.11 mg/ml |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Serum Concentration Levels of PGT121, PGDM1400, and VRC07-523LS Among Participants Who Received All Scheduled Product Administrations | VRC07-523LS (Day- 6) | 156.15 mg/ml |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Serum Concentration Levels of PGT121, PGDM1400, and VRC07-523LS Among Participants Who Received All Scheduled Product Administrations | VRC07-523LS (Day- 14) | 140.86 mg/ml |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Serum Concentration Levels of PGT121, PGDM1400, and VRC07-523LS Among Participants Who Received All Scheduled Product Administrations | VRC07-523LS (Day- 28) | 101.42 mg/ml |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Serum Concentration Levels of PGT121, PGDM1400, and VRC07-523LS Among Participants Who Received All Scheduled Product Administrations | VRC07-523LS (Day- 56) | 56.94 mg/ml |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Serum Concentration Levels of PGT121, PGDM1400, and VRC07-523LS Among Participants Who Received All Scheduled Product Administrations | VRC07-523LS (Day- 84) | 39.57 mg/ml |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Serum Concentration Levels of PGT121, PGDM1400, and VRC07-523LS Among Participants Who Received All Scheduled Product Administrations | VRC07-523LS (Day-112) | 26.07 mg/ml |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Serum Concentration Levels of PGT121, PGDM1400, and VRC07-523LS Among Participants Who Received All Scheduled Product Administrations | VRC07-523LS (Day-336) | 9.52 mg/ml |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Serum Concentration Levels of PGT121, PGDM1400, and VRC07-523LS Among Participants Who Received All Scheduled Product Administrations | VRC07-523LS (Day-392) | 4.49 mg/ml |
Secondary
Serum Concentrations of PGT121, PGDM1400, 10-1074, and VRC07-523LS for All Participants
Serum PGDM1400, PGT121, and VRC07-523LS IgG levels were measured on a Bio-Plex instrument (Bio-Rad) using a validated assay designed to simultaneously measure infused PGDM1400, PGT121, and VRC07-523LS by its ability to bind anti-idiotype antibody captured on fluorescent magnetic beads. This assay was derived from a standardized custom HIV-1 Luminex assay. PGDM1400, PGT121 and VRC07-523LS were titrated and combined to create a standard curve that was used to determine concentration of the diluted samples. The negative controls were CH58 (an irrelevant mAb) and blank beads.Serum 10-1074 level was measured by anti-idotypic ELISA. Participant serum sample was incubated in anti-ID coated micro-plate well. A conjugated secondary antibody was used to detect bound 10-1074. Samples were titrated to ensure positive optical density (O.D.) readouts fall within the linear range of the assay for monoclonal antibody concentration calculations
Time frame: Measured during Screening, Days 0, 3, 6, 14, 28, 56, 84*, 112, 140*, 168, 224, 280, 336, 392*, and 448* Days with * are only available for T4
Population: All participants enrolled with available serum concentration data. Visits with 0 participants are due to: (1) mAbs were only assayed for the treatment arms that received those mAbs. (2) Treatment group T4 had more scheduled sample collection visits than treatment groups T1-T3.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| T1: PGT121 + VRC07-523LS mo 0 | Serum Concentrations of PGT121, PGDM1400, 10-1074, and VRC07-523LS for All Participants | PGT121 (Day-168) | 1.70 mg/ml |
| T1: PGT121 + VRC07-523LS mo 0 | Serum Concentrations of PGT121, PGDM1400, 10-1074, and VRC07-523LS for All Participants | PGT121 (Day- 14) | 80.12 mg/ml |
| T1: PGT121 + VRC07-523LS mo 0 | Serum Concentrations of PGT121, PGDM1400, 10-1074, and VRC07-523LS for All Participants | VRC07-523LS (Day- 3) | 265.97 mg/ml |
| T1: PGT121 + VRC07-523LS mo 0 | Serum Concentrations of PGT121, PGDM1400, 10-1074, and VRC07-523LS for All Participants | PGT121 (Day- 28) | 44.46 mg/ml |
| T1: PGT121 + VRC07-523LS mo 0 | Serum Concentrations of PGT121, PGDM1400, 10-1074, and VRC07-523LS for All Participants | PGT121 (Day- 56) | 22.08 mg/ml |
| T1: PGT121 + VRC07-523LS mo 0 | Serum Concentrations of PGT121, PGDM1400, 10-1074, and VRC07-523LS for All Participants | VRC07-523LS (Day- 0) | 0.01 mg/ml |
| T1: PGT121 + VRC07-523LS mo 0 | Serum Concentrations of PGT121, PGDM1400, 10-1074, and VRC07-523LS for All Participants | PGT121 (Day-336) | 0.05 mg/ml |
| T1: PGT121 + VRC07-523LS mo 0 | Serum Concentrations of PGT121, PGDM1400, 10-1074, and VRC07-523LS for All Participants | PGT121 (Day-112) | 4.03 mg/ml |
| T1: PGT121 + VRC07-523LS mo 0 | Serum Concentrations of PGT121, PGDM1400, 10-1074, and VRC07-523LS for All Participants | PGT121 (Day-224) | 0.31 mg/ml |
| T1: PGT121 + VRC07-523LS mo 0 | Serum Concentrations of PGT121, PGDM1400, 10-1074, and VRC07-523LS for All Participants | VRC07-523LS (Day-336) | 1.33 mg/ml |
| T1: PGT121 + VRC07-523LS mo 0 | Serum Concentrations of PGT121, PGDM1400, 10-1074, and VRC07-523LS for All Participants | VRC07-523LS (Day-224) | 8.47 mg/ml |
| T1: PGT121 + VRC07-523LS mo 0 | Serum Concentrations of PGT121, PGDM1400, 10-1074, and VRC07-523LS for All Participants | VRC07-523LS (Day-168) | 14.45 mg/ml |
| T1: PGT121 + VRC07-523LS mo 0 | Serum Concentrations of PGT121, PGDM1400, 10-1074, and VRC07-523LS for All Participants | VRC07-523LS (Day-112) | 24.93 mg/ml |
| T1: PGT121 + VRC07-523LS mo 0 | Serum Concentrations of PGT121, PGDM1400, 10-1074, and VRC07-523LS for All Participants | VRC07-523LS (Day- 56) | 60.53 mg/ml |
| T1: PGT121 + VRC07-523LS mo 0 | Serum Concentrations of PGT121, PGDM1400, 10-1074, and VRC07-523LS for All Participants | VRC07-523LS (Day- 28) | 94.58 mg/ml |
| T1: PGT121 + VRC07-523LS mo 0 | Serum Concentrations of PGT121, PGDM1400, 10-1074, and VRC07-523LS for All Participants | VRC07-523LS (Day- 14) | 134.44 mg/ml |
| T1: PGT121 + VRC07-523LS mo 0 | Serum Concentrations of PGT121, PGDM1400, 10-1074, and VRC07-523LS for All Participants | PGT121 (Day- 0) | 0.05 mg/ml |
| T1: PGT121 + VRC07-523LS mo 0 | Serum Concentrations of PGT121, PGDM1400, 10-1074, and VRC07-523LS for All Participants | PGT121 (Day- 3) | 196.57 mg/ml |
| T1: PGT121 + VRC07-523LS mo 0 | Serum Concentrations of PGT121, PGDM1400, 10-1074, and VRC07-523LS for All Participants | VRC07-523LS (Day- 6) | 171.02 mg/ml |
| T1: PGT121 + VRC07-523LS mo 0 | Serum Concentrations of PGT121, PGDM1400, 10-1074, and VRC07-523LS for All Participants | PGT121 (Day- 6) | 129.35 mg/ml |
| T2: PGDM1400 + VRC07-523LS mo 0 | Serum Concentrations of PGT121, PGDM1400, 10-1074, and VRC07-523LS for All Participants | VRC07-523LS (Day- 28) | 96.17 mg/ml |
| T2: PGDM1400 + VRC07-523LS mo 0 | Serum Concentrations of PGT121, PGDM1400, 10-1074, and VRC07-523LS for All Participants | PGDM1400 (Day- 56) | 27.88 mg/ml |
| T2: PGDM1400 + VRC07-523LS mo 0 | Serum Concentrations of PGT121, PGDM1400, 10-1074, and VRC07-523LS for All Participants | VRC07-523LS (Day-168) | 12.57 mg/ml |
| T2: PGDM1400 + VRC07-523LS mo 0 | Serum Concentrations of PGT121, PGDM1400, 10-1074, and VRC07-523LS for All Participants | PGDM1400 (Day-336) | 0.02 mg/ml |
| T2: PGDM1400 + VRC07-523LS mo 0 | Serum Concentrations of PGT121, PGDM1400, 10-1074, and VRC07-523LS for All Participants | PGDM1400 (Day-112) | 5.50 mg/ml |
| T2: PGDM1400 + VRC07-523LS mo 0 | Serum Concentrations of PGT121, PGDM1400, 10-1074, and VRC07-523LS for All Participants | VRC07-523LS (Day-112) | 31.65 mg/ml |
| T2: PGDM1400 + VRC07-523LS mo 0 | Serum Concentrations of PGT121, PGDM1400, 10-1074, and VRC07-523LS for All Participants | VRC07-523LS (Day- 0) | 0.01 mg/ml |
| T2: PGDM1400 + VRC07-523LS mo 0 | Serum Concentrations of PGT121, PGDM1400, 10-1074, and VRC07-523LS for All Participants | VRC07-523LS (Day- 6) | 176.51 mg/ml |
| T2: PGDM1400 + VRC07-523LS mo 0 | Serum Concentrations of PGT121, PGDM1400, 10-1074, and VRC07-523LS for All Participants | PGDM1400 (Day-168) | 1.08 mg/ml |
| T2: PGDM1400 + VRC07-523LS mo 0 | Serum Concentrations of PGT121, PGDM1400, 10-1074, and VRC07-523LS for All Participants | VRC07-523LS (Day- 56) | 56.91 mg/ml |
| T2: PGDM1400 + VRC07-523LS mo 0 | Serum Concentrations of PGT121, PGDM1400, 10-1074, and VRC07-523LS for All Participants | PGDM1400 (Day-224) | 0.26 mg/ml |
| T2: PGDM1400 + VRC07-523LS mo 0 | Serum Concentrations of PGT121, PGDM1400, 10-1074, and VRC07-523LS for All Participants | VRC07-523LS (Day- 14) | 139.18 mg/ml |
| T2: PGDM1400 + VRC07-523LS mo 0 | Serum Concentrations of PGT121, PGDM1400, 10-1074, and VRC07-523LS for All Participants | VRC07-523LS (Day- 3) | 239.32 mg/ml |
| T2: PGDM1400 + VRC07-523LS mo 0 | Serum Concentrations of PGT121, PGDM1400, 10-1074, and VRC07-523LS for All Participants | PGDM1400 (Day- 0) | 0.02 mg/ml |
| T2: PGDM1400 + VRC07-523LS mo 0 | Serum Concentrations of PGT121, PGDM1400, 10-1074, and VRC07-523LS for All Participants | VRC07-523LS (Day-336) | 1.31 mg/ml |
| T2: PGDM1400 + VRC07-523LS mo 0 | Serum Concentrations of PGT121, PGDM1400, 10-1074, and VRC07-523LS for All Participants | PGDM1400 (Day- 3) | 251.54 mg/ml |
| T2: PGDM1400 + VRC07-523LS mo 0 | Serum Concentrations of PGT121, PGDM1400, 10-1074, and VRC07-523LS for All Participants | PGDM1400 (Day-280) | 0.09 mg/ml |
| T2: PGDM1400 + VRC07-523LS mo 0 | Serum Concentrations of PGT121, PGDM1400, 10-1074, and VRC07-523LS for All Participants | PGDM1400 (Day- 6) | 182.23 mg/ml |
| T2: PGDM1400 + VRC07-523LS mo 0 | Serum Concentrations of PGT121, PGDM1400, 10-1074, and VRC07-523LS for All Participants | VRC07-523LS (Day-280) | 3.88 mg/ml |
| T2: PGDM1400 + VRC07-523LS mo 0 | Serum Concentrations of PGT121, PGDM1400, 10-1074, and VRC07-523LS for All Participants | PGDM1400 (Day- 14) | 139.77 mg/ml |
| T2: PGDM1400 + VRC07-523LS mo 0 | Serum Concentrations of PGT121, PGDM1400, 10-1074, and VRC07-523LS for All Participants | VRC07-523LS (Day-224) | 11.24 mg/ml |
| T2: PGDM1400 + VRC07-523LS mo 0 | Serum Concentrations of PGT121, PGDM1400, 10-1074, and VRC07-523LS for All Participants | PGDM1400 (Day- 28) | 70.92 mg/ml |
| T3: 10-1074 + VRC07-523LS | Serum Concentrations of PGT121, PGDM1400, 10-1074, and VRC07-523LS for All Participants | VRC07-523LS (Day- 14) | 105.05 mg/ml |
| T3: 10-1074 + VRC07-523LS | Serum Concentrations of PGT121, PGDM1400, 10-1074, and VRC07-523LS for All Participants | 10-1074 (Day- 0) | 0.21 mg/ml |
| T3: 10-1074 + VRC07-523LS | Serum Concentrations of PGT121, PGDM1400, 10-1074, and VRC07-523LS for All Participants | 10-1074 (Day- 3) | 521.49 mg/ml |
| T3: 10-1074 + VRC07-523LS | Serum Concentrations of PGT121, PGDM1400, 10-1074, and VRC07-523LS for All Participants | 10-1074 (Day- 6) | 416.31 mg/ml |
| T3: 10-1074 + VRC07-523LS | Serum Concentrations of PGT121, PGDM1400, 10-1074, and VRC07-523LS for All Participants | 10-1074 (Day- 14) | 289.86 mg/ml |
| T3: 10-1074 + VRC07-523LS | Serum Concentrations of PGT121, PGDM1400, 10-1074, and VRC07-523LS for All Participants | 10-1074 (Day- 28) | 242.22 mg/ml |
| T3: 10-1074 + VRC07-523LS | Serum Concentrations of PGT121, PGDM1400, 10-1074, and VRC07-523LS for All Participants | 10-1074 (Day- 56) | 98.27 mg/ml |
| T3: 10-1074 + VRC07-523LS | Serum Concentrations of PGT121, PGDM1400, 10-1074, and VRC07-523LS for All Participants | 10-1074 (Day-112) | 23.96 mg/ml |
| T3: 10-1074 + VRC07-523LS | Serum Concentrations of PGT121, PGDM1400, 10-1074, and VRC07-523LS for All Participants | 10-1074 (Day-168) | 8.60 mg/ml |
| T3: 10-1074 + VRC07-523LS | Serum Concentrations of PGT121, PGDM1400, 10-1074, and VRC07-523LS for All Participants | 10-1074 (Day-280) | 0.59 mg/ml |
| T3: 10-1074 + VRC07-523LS | Serum Concentrations of PGT121, PGDM1400, 10-1074, and VRC07-523LS for All Participants | 10-1074 (Day-336) | 2.44 mg/ml |
| T3: 10-1074 + VRC07-523LS | Serum Concentrations of PGT121, PGDM1400, 10-1074, and VRC07-523LS for All Participants | VRC07-523LS (Day- 0) | 0.01 mg/ml |
| T3: 10-1074 + VRC07-523LS | Serum Concentrations of PGT121, PGDM1400, 10-1074, and VRC07-523LS for All Participants | VRC07-523LS (Day- 3) | 173.73 mg/ml |
| T3: 10-1074 + VRC07-523LS | Serum Concentrations of PGT121, PGDM1400, 10-1074, and VRC07-523LS for All Participants | VRC07-523LS (Day- 6) | 171.62 mg/ml |
| T3: 10-1074 + VRC07-523LS | Serum Concentrations of PGT121, PGDM1400, 10-1074, and VRC07-523LS for All Participants | VRC07-523LS (Day- 28) | 87.91 mg/ml |
| T3: 10-1074 + VRC07-523LS | Serum Concentrations of PGT121, PGDM1400, 10-1074, and VRC07-523LS for All Participants | VRC07-523LS (Day- 56) | 56.91 mg/ml |
| T3: 10-1074 + VRC07-523LS | Serum Concentrations of PGT121, PGDM1400, 10-1074, and VRC07-523LS for All Participants | VRC07-523LS (Day-112) | 28.18 mg/ml |
| T3: 10-1074 + VRC07-523LS | Serum Concentrations of PGT121, PGDM1400, 10-1074, and VRC07-523LS for All Participants | VRC07-523LS (Day-168) | 11.57 mg/ml |
| T3: 10-1074 + VRC07-523LS | Serum Concentrations of PGT121, PGDM1400, 10-1074, and VRC07-523LS for All Participants | VRC07-523LS (Day-280) | 1.81 mg/ml |
| T3: 10-1074 + VRC07-523LS | Serum Concentrations of PGT121, PGDM1400, 10-1074, and VRC07-523LS for All Participants | VRC07-523LS (Day-336) | 1.48 mg/ml |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Serum Concentrations of PGT121, PGDM1400, 10-1074, and VRC07-523LS for All Participants | PGT121 (Day- 56) | 29.32 mg/ml |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Serum Concentrations of PGT121, PGDM1400, 10-1074, and VRC07-523LS for All Participants | PGT121 (Day- 28) | 56.75 mg/ml |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Serum Concentrations of PGT121, PGDM1400, 10-1074, and VRC07-523LS for All Participants | PGDM1400 (Day- 6) | 173.81 mg/ml |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Serum Concentrations of PGT121, PGDM1400, 10-1074, and VRC07-523LS for All Participants | VRC07-523LS (Day- 0) | 0.01 mg/ml |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Serum Concentrations of PGT121, PGDM1400, 10-1074, and VRC07-523LS for All Participants | PGT121 (Day- 14) | 90.47 mg/ml |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Serum Concentrations of PGT121, PGDM1400, 10-1074, and VRC07-523LS for All Participants | PGT121 (Day- 6) | 130.98 mg/ml |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Serum Concentrations of PGT121, PGDM1400, 10-1074, and VRC07-523LS for All Participants | VRC07-523LS (Day-392) | 2.73 mg/ml |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Serum Concentrations of PGT121, PGDM1400, 10-1074, and VRC07-523LS for All Participants | VRC07-523LS (Day- 3) | 230.06 mg/ml |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Serum Concentrations of PGT121, PGDM1400, 10-1074, and VRC07-523LS for All Participants | PGT121 (Day- 3) | 181.38 mg/ml |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Serum Concentrations of PGT121, PGDM1400, 10-1074, and VRC07-523LS for All Participants | PGT121 (Day- 0) | 0.05 mg/ml |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Serum Concentrations of PGT121, PGDM1400, 10-1074, and VRC07-523LS for All Participants | VRC07-523LS (Day-280) | 14.85 mg/ml |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Serum Concentrations of PGT121, PGDM1400, 10-1074, and VRC07-523LS for All Participants | VRC07-523LS (Day- 6) | 169.54 mg/ml |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Serum Concentrations of PGT121, PGDM1400, 10-1074, and VRC07-523LS for All Participants | PGDM1400 (Day-448) | 0.02 mg/ml |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Serum Concentrations of PGT121, PGDM1400, 10-1074, and VRC07-523LS for All Participants | PGDM1400 (Day-392) | 0.04 mg/ml |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Serum Concentrations of PGT121, PGDM1400, 10-1074, and VRC07-523LS for All Participants | VRC07-523LS (Day- 14) | 133.03 mg/ml |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Serum Concentrations of PGT121, PGDM1400, 10-1074, and VRC07-523LS for All Participants | PGDM1400 (Day-336) | 0.25 mg/ml |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Serum Concentrations of PGT121, PGDM1400, 10-1074, and VRC07-523LS for All Participants | PGDM1400 (Day-280) | 0.50 mg/ml |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Serum Concentrations of PGT121, PGDM1400, 10-1074, and VRC07-523LS for All Participants | PGDM1400 (Day- 3) | 231.33 mg/ml |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Serum Concentrations of PGT121, PGDM1400, 10-1074, and VRC07-523LS for All Participants | VRC07-523LS (Day- 28) | 96.52 mg/ml |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Serum Concentrations of PGT121, PGDM1400, 10-1074, and VRC07-523LS for All Participants | PGDM1400 (Day-224) | 2.21 mg/ml |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Serum Concentrations of PGT121, PGDM1400, 10-1074, and VRC07-523LS for All Participants | PGDM1400 (Day-168) | 1.51 mg/ml |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Serum Concentrations of PGT121, PGDM1400, 10-1074, and VRC07-523LS for All Participants | PGDM1400 (Day- 0) | 0.02 mg/ml |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Serum Concentrations of PGT121, PGDM1400, 10-1074, and VRC07-523LS for All Participants | VRC07-523LS (Day- 56) | 60.24 mg/ml |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Serum Concentrations of PGT121, PGDM1400, 10-1074, and VRC07-523LS for All Participants | VRC07-523LS (Day- 84) | 41.64 mg/ml |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Serum Concentrations of PGT121, PGDM1400, 10-1074, and VRC07-523LS for All Participants | PGDM1400 (Day-140) | 3.49 mg/ml |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Serum Concentrations of PGT121, PGDM1400, 10-1074, and VRC07-523LS for All Participants | PGDM1400 (Day-112) | 4.99 mg/ml |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Serum Concentrations of PGT121, PGDM1400, 10-1074, and VRC07-523LS for All Participants | VRC07-523LS (Day-448) | 1.10 mg/ml |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Serum Concentrations of PGT121, PGDM1400, 10-1074, and VRC07-523LS for All Participants | VRC07-523LS (Day-112) | 26.07 mg/ml |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Serum Concentrations of PGT121, PGDM1400, 10-1074, and VRC07-523LS for All Participants | VRC07-523LS (Day-140) | 13.94 mg/ml |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Serum Concentrations of PGT121, PGDM1400, 10-1074, and VRC07-523LS for All Participants | PGDM1400 (Day- 84) | 12.26 mg/ml |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Serum Concentrations of PGT121, PGDM1400, 10-1074, and VRC07-523LS for All Participants | PGDM1400 (Day- 56) | 33.70 mg/ml |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Serum Concentrations of PGT121, PGDM1400, 10-1074, and VRC07-523LS for All Participants | VRC07-523LS (Day-336) | 7.49 mg/ml |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Serum Concentrations of PGT121, PGDM1400, 10-1074, and VRC07-523LS for All Participants | VRC07-523LS (Day-168) | 9.98 mg/ml |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Serum Concentrations of PGT121, PGDM1400, 10-1074, and VRC07-523LS for All Participants | PGDM1400 (Day- 28) | 71.60 mg/ml |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Serum Concentrations of PGT121, PGDM1400, 10-1074, and VRC07-523LS for All Participants | PGDM1400 (Day- 14) | 126.56 mg/ml |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Serum Concentrations of PGT121, PGDM1400, 10-1074, and VRC07-523LS for All Participants | VRC07-523LS (Day-224) | 22.66 mg/ml |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Serum Concentrations of PGT121, PGDM1400, 10-1074, and VRC07-523LS for All Participants | PGT121 (Day-140) | 6.08 mg/ml |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Serum Concentrations of PGT121, PGDM1400, 10-1074, and VRC07-523LS for All Participants | PGT121 (Day-168) | 2.72 mg/ml |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Serum Concentrations of PGT121, PGDM1400, 10-1074, and VRC07-523LS for All Participants | PGT121 (Day-112) | 5.82 mg/ml |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Serum Concentrations of PGT121, PGDM1400, 10-1074, and VRC07-523LS for All Participants | PGT121 (Day-224) | 4.16 mg/ml |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Serum Concentrations of PGT121, PGDM1400, 10-1074, and VRC07-523LS for All Participants | PGT121 (Day-280) | 1.46 mg/ml |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Serum Concentrations of PGT121, PGDM1400, 10-1074, and VRC07-523LS for All Participants | PGT121 (Day- 84) | 15.00 mg/ml |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Serum Concentrations of PGT121, PGDM1400, 10-1074, and VRC07-523LS for All Participants | PGT121 (Day-336) | 0.71 mg/ml |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Serum Concentrations of PGT121, PGDM1400, 10-1074, and VRC07-523LS for All Participants | PGT121 (Day-392) | 0.18 mg/ml |
| T4: PGT121 + PGDM1400 + VRC07-523LS mo(0, 4) | Serum Concentrations of PGT121, PGDM1400, 10-1074, and VRC07-523LS for All Participants | PGT121 (Day-448) | 0.05 mg/ml |